[{"title":"Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China","googleId":"rgyxI7N8O5gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363833","googleCitationCount":771,"googleAuthor":"L Xie","doi":"10.1016/j.annonc.2020.03.296","elsevierAuthor":"Zhang L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"452","altmetricAuthors":["L. Zhang","F. Zhu","L. Xie","C. Wang","J. Wang","R. Chen","P. Jia","H.Q. Guan","L. Peng","Y. Chen","P. Peng","P. Zhang","Q. Chu","Q. Shen","Y. Wang","S.Y. Xu","J.P. Zhao","M. Zhou"],"twitterCount":201,"altmetricId":78449276,"statusesArray":["1286354616154824705","1286354614900731905","1266034325012844545","1266033775575814145","1262779860042354689","1262779859102765058","1261096376357789704","1258193331416379394","1255687296227000320","1255369906016735232","1255245549038682113","1255183752449290243","1255155605972500480","1255154915934175233","1255148932071485446","1255143446513246215","1255142220769816585","1255141801993752578","1255140860666081282","1255139758570782720","1255139575678119938","1255139432090333189","1255138633897504768","1255138209261948937","1255126402095108097","1255126230287790085","1255125796131389441","1254364609940795393","1254320135155920899","1251497537992896513","1250867867420987392","1250867852539654144","1250505448215609345","1250504763529146370","1250422308243533825","1250422188219355143","1249559798951088129","1248932796057468930","1246911467313451008","1246908751698776064","1246897832986107907","1246896893973667840","1246287146362814465","1245290323821002753","1245128952240312330","1244981720346214400","1244977351278166016","1244852014460407808","1244750193377107968","1244750013638610944","1244706722045767680","1244638953287888898","1244557708298047488","1244542760683745282","1244509911024840704","1244410629005479936","1244394270926286854","1244393619680878597","1244339500601487370","1244306968501723141","1244302286303748096","1244287278928687106","1244272185650237442","1244252821383524356","1244243122596589573","1244241166956191744","1244231566424858624","1244230455299358721","1244228857114374146","1244206737718161408","1244203881044815873","1244200605813440512","1244079507742613504","1244078451759316993","1244055794187829249","1244038857877839877","1244027304306769920","1244025936338714625","1244016311673466881","1244015506501271552","1244013015990784000","1244005715062161408","1243982853995663360","1243954807360172032","1243947973618384896","1243935420183982080","1243935107301421057","1243928220736655362","1243926728004849666","1243923395999342592","1243919072691134471","1243913641830776832","1243902942949912576","1243902713546637312","1243902111479402496","1243896311537176582","1243894728636149760","1243887586449465344","1243884407649337344","1243882735267086336","1243871881272463361","1243864298935459843","1243864211102601219","1243860139607756800","1243859650295918593","1243859487695548416","1243855182561230848","1243850968674041856","1243838154555248642","1243836306553294850","1243835956148539392","1243835347265556480","1243834781026201601","1243831036028518401","1243829154979753984","1243822763426623490","1243811840355901441","1243805840987107329","1243791516952379392","1243781323447308288","1243776942060552196","1243753619486318592","1243753084179922944","1243750614292664325","1243748996927160320","1243748673999319040","1243745769284304899","1243743572014305280","1243712568612384768","1243706157170114560","1243693360470097921","1243692412624670720","1243692241023049729","1243691361947324416","1243670347179753474","1243670091310358529","1243668508124295170","1243664280672710664","1243663241047310339","1243662837534375937","1243660680579997696","1243658967986905093","1243651614617022464","1243651071794458626","1243650349677846528","1243646123253866496","1243644344718024711","1243643863190966274","1243642690098601988","1243642625976160259","1243642179391815680","1243641607716573188","1243637685861974021","1243632658858401793","1243626909835112449","1243625617905647617","1243625231224393740","1243622678449270784","1243619517118414848","1243617178324271111","1243614928696741888","1243614617391243266","1243604724005429253","1243604653369147395","1243599368273477635","1243588239266627585","1243585196563337218","1243584189523509254","1243582935292411912","1243581597443674113","1243580371570003968","1243580316675162117","1243580242893189124","1243579877598670850","1243578180432285703","1243572505203392512","1243571788174495745","1243571083258847233","1243570518101499904","1243570353324077059","1243569482754383875","1243568767361220614","1243567743590453248","1243566904494743552","1243565335778742273","1243563224726941698","1243562700174753792","1243562161252769799","1243557439468965891","1243555576652627977","1243543742684049408","1243538813479256067","1243537291475398659","1243535297427787777","1243535081655939073","1243533815781285888","1243532660728889344","1243530869471617025","1243530755382312960","1243528357117075457","1243528040493322241","1243527940434022400","1243525123623268355","1243524971504324609","1243524385790668800","1243515742949179393","1243514305330458626","1243511890405400577","1243511331774439428","1243511106741645313","1243511060793090048","1243510268971360256","1243503697201692672","1243503354996756480","1243501941633814528","1243501693930618880","1243501443065282561","1243501415789707264","1243501355588816897","1243500603587940353","1243500584918974464","1243499902925037573","1243499899481620481","1243499217672380416","1243498772111470592","1243495774341775361","1243494041725153280","1243492564117925895","1243492400053604354","1243492339580047362","1243491876793131008","1243489633033388037","1243487224651558915"]},{"title":"Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (n= 4532)","googleId":"6VRrWkF6U90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397970","googleCitationCount":208,"googleAuthor":"M Rugge","doi":"10.1016/j.annonc.2020.04.479","elsevierAuthor":"Montopoli M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"125","altmetricAuthors":["M. Montopoli","S. Zumerle","R. Vettor","M. Rugge","M. Zorzi","C.V. Catapano","G.M. Carbone","A. Cavalli","F. Pagano","E. Ragazzi","T. Prayer-Galetti","A. Alimonti"],"twitterCount":108,"altmetricId":81534028,"statusesArray":["1359930493098094592","1354868886710198275","1338187171036008448","1338180075397767168","1336361036694360065","1332105835892199424","1322563065951342592","1322557584986046464","1303857607992463360","1303708868644663297","1303704211109093379","1303220944480108545","1303053036911296514","1299338025785126912","1296983234174054400","1296720901795438592","1296712770793029633","1296561488736292864","1296556359882878976","1282000082175291392","1281998539787132928","1281069747816161281","1281010902674944006","1280835443270057984","1280827991568809986","1280826997242056705","1280786180779290624","1280785466711818240","1280756295306485765","1280749376231501825","1280746478672084992","1280734692682215426","1280725854025179136","1280722930880528384","1280719676624912386","1280711352638734336","1280701589838106625","1280700604495495168","1280692556905566208","1280691481322442759","1280678668889657346","1280676846753820672","1280669864500367361","1280664066059571202","1280663807472340992","1280662770908893184","1280654495685451777","1280651619252817922","1280646388091510785","1277445805515829248","1275720328350707715","1272639198143668227","1271108905339367424","1268926222597337091","1268894058153476103","1268893718355968001","1265389962792484864","1265382878386573312","1265182970857562114","1265182573556371457","1265177164242128896","1264996882410921992","1264586032521060353","1264534981147312135","1263716256751984640","1263693536756731905","1263677188412497922","1263602879463673860","1263595711779663877","1262455185101684736","1261385305812275201","1260759858732826624","1260596360954482688","1260497178893733888","1260494220974002180","1260409868005015553","1260399381204873222","1260295974557290497","1259933352938868736","1259816678105456645","1259787091442974720","1259568498629582848","1259534261155233792","1259515564395057153","1259462777300803584","1259461599317897216","1259406844679860224","1259355664645787649","1259352773822464000","1259331727484432384","1259329606500392961","1259315421439832065","1259268272341635073","1259251065016463367","1259236971244933122","1259232773430222848","1259232660951629824","1259224309274378242","1259224043888222208","1259217848993538049","1259214006419697664","1259213439404294146","1259211110387003393","1259209717555105793","1259207796798697481","1259207380136603651","1259207344803778560","1259163136516554752","1259095931024216064","1258892807013642243","1258859316322488322","1258776141176987650","1258691987429040128","1258273431956738049"]},{"title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","googleId":"BsHjnbvXKucJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360806","googleCitationCount":124,"googleAuthor":"S Ganatra","doi":"10.1016/j.annonc.2019.10.023","elsevierAuthor":"Curigliano G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"63","altmetricAuthors":["G. Curigliano","D. Lenihan","M. Fradley","S. Ganatra","A. Barac","A. Blaes","J. Herrmann","C. Porter","A.R. Lyon","P. Lancellotti","A. Patel","J. DeCara","J. Mitchell","E. Harrison","J. Moslehi","R. Witteles","M.G. Calabro","R. Orecchia","E. de Azambuja","J.L. Zamorano","R. Krone","Z. Iakobishvili","J. Carver","S. Armenian","B. Ky","D. Cardinale","C.M. Cipolla","S. Dent","K. Jordan"],"twitterCount":89,"altmetricId":74160615,"statusesArray":["1286070814463291397","1285884061244895232","1264079755294519299","1264079676810473479","1228648315186745344","1223308529882357760","1222997414417596417","1222939719400595460","1222896089742708736","1222869320105123842","1222869265130360833","1222868209264742401","1222868118164443136","1222868080411512832","1220732303367864323","1220304271549325316","1219726883392315394","1219672874593636352","1219446391728066560","1219445070497243137","1219444578463469568","1219400021772316673","1219306439497474051","1219208249985196033","1219185815017799680","1219184445103771649","1219172205105483777","1219095957658374144","1219075114110681095","1219074869737844736","1219055530230140931","1218959434812137477","1218959343367921664","1218948154051244033","1218942174211059712","1218920420226797569","1218909155043487745","1218891664540033024","1218890685190897669","1218852326791950336","1218810582889062400","1218763383740215296","1218693969871286273","1218687648837046272","1218687488442519553","1218687448894656517","1218675753593778178","1218663173814980609","1218663090734206977","1218660455775965189","1218656758849249280","1218656675055443978","1218618528640774144","1218579766120501254","1218577053441720321","1218577030360510464","1218573698267074567","1218569007961460737","1218567801989976065","1218566482768076804","1218566452103581696","1218563472310644737","1218563252743036929","1218547052604526592","1218545811732226048","1218533729880236033","1218529179962105856","1218526604525260801","1218520206705860608","1218498951055364097","1218487982333841411","1218485036191821824","1218474692501295104","1218474614810185734","1218458804993560576","1218457844653142018","1218453679860109312","1218447303989702657","1218438958473994240","1218415931933761537","1218414743356088320","1218409978010177536","1218392206861590528","1218387066435842048","1218381236017590272","1218372950484606976","1218368871981289473","1218352744131629061","1218351130792615942","1218348587647754244","1218339901747486728","1218337364193501185","1218334220726231040","1218333592385925126","1218333443173556225","1218333390560284674","1218332344685408257","1218329793344823296","1218327410103476230","1218327174756950017"]},{"title":"Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report","googleId":"Sl5_4RzRQsIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36387-0/pdf","googleCitationCount":221,"googleAuthor":"JM Michot","statusesArray":[]},{"title":"Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic","googleId":"lz277TZzAp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398252","googleCitationCount":149,"googleAuthor":"A Sud","doi":"10.1016/j.annonc.2020.05.009","elsevierAuthor":"Sud A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"80","altmetricAuthors":["A. Sud","M.E. Jones","J. Broggio","C. Loveday","B. Torr","A. Garrett","D.L. Nicol","S. Jhanji","S.A. Boyce","F. Gronthoud","P. Ward","J.M. Handy","N. Yousaf","J. Larkin","Y-E. Suh","S. Scott","P.D.P. Pharoah","C. Swanton","C. Abbosh","M. Williams","G. Lyratzopoulos","R. Houlston","C. Turnbull"],"twitterCount":267,"altmetricId":82375906,"statusesArray":["1349104211821277186","1330670296840491012","1308539426381979648","1306688334438129664","1306684098765664259","1301279221617049600","1300889317095608321","1300886696515506178","1300885812649762816","1300760015729389568","1293868665301950464","1287781178884403201","1283029019483676674","1282820813339734016","1282769286164086789","1268256115436945414","1265882653946978304","1265596506368770054","1265581378416115712","1265535478981410819","1265480326828232704","1265417478257213440","1265285445962924033","1265272599891886088","1265247099710562304","1265230151048142849","1264984200530276357","1264958017524596736","1264936018362413058","1264904555415863296","1264877128857894913","1264803072406159360","1264791284172152836","1264778080729604096","1264723046620966912","1264721860270358528","1264694523717988352","1264679344808562688","1264654432102465537","1264616529884254208","1264603822497968129","1264595990385848320","1264576589200789505","1264563271794692096","1264559186739896330","1264557426646429697","1264553767669764097","1264552216800759813","1264551529765314561","1264546776633270272","1264527979440410626","1264521947775410177","1264513772653289472","1264504794212900870","1264479412097032192","1264475710535712768","1264471976833282053","1264458098716131328","1264455883314077696","1264452113540640769","1264451894791069698","1264447156074582016","1264443074719166469","1264439648337620992","1264429553927290881","1264424251047763969","1264422337614688256","1264422254902943744","1264420850700128256","1264417936552464389","1264415359676923905","1264414724009189377","1264412760017952769","1264408352215490560","1264408029124050944","1264407489329737728","1264405379896786945","1264403362994323459","1264402839088107520","1264402745693335552","1264399865041358848","1264398908618412035","1264397531469021186","1264396858589433857","1264396285437571072","1264396095431544832","1264395893983371266","1264394944967577600","1264394482797199361","1264394168681578496","1264393035271593986","1264392057289875457","1264391051604885505","1264390803327156224","1264390321263333377","1264390022423285760","1264389931700346880","1264389564120080385","1264388801570496512","1264388444886794241","1264387642340319233","1264387140940636163","1264386929124151296","1264386788422017024","1264386375450853376","1264386194542125056","1264386135700025347","1264385913343205377","1264385704500645890","1264385595066814465","1264385560334012417","1264384895628881921","1264384621812252672","1264384574903119872","1264384526379180034","1264384502882762752","1264384204739088384","1264383923049635841","1264383890745176066","1264383802505388033","1264383718522671104","1264383616282435585","1264382862792458240","1264382742948728833","1264382604956090370","1264382542972624898","1264382447845814274","1264382294619553792","1264382291331018753","1264381797229645824","1264381776409092096","1264381664098213896","1264381547349671936","1264381120138874883","1264380856153620480","1264380802118402048","1264380625705930752","1264380376375611392","1264380373116555264","1264380364207697920","1264380254501642241","1264380178823811083","1264380094115729409","1264379961953181697","1264379764749598725","1264379671250194432","1264379648563122176","1264379515662471169","1264379448666673152","1264379353888108545","1264379348406005760","1264379336347529217","1264379270174068738","1264379146760642561","1264378945006383106","1264378837057654784","1264378766370893824","1264378604433158146","1264378603636248577","1264378557729472512","1264378557448536064","1264378555112263680","1264378551278632967","1264378439219511298","1264378408072609792","1264378355815776261","1264378330133991424","1264378237573976064","1264378180560924672","1264378097282895873","1264377990898683906","1264377793623851008","1264377762296586241","1264377725457965057","1264366928958615552","1264358250566352897","1264284393398505472","1264200959749763073","1264182447677333505","1264181673698213889","1264181529070239744","1264163553553952769","1264135367373938689","1263886777812692992","1263863127843766272","1263646913783640064","1263605837412446208","1263594330876305416","1263592382542442499","1263564069006716928","1263559778942492678","1263548077241020416","1263546996075323392","1263542851058745352","1263533196421070850","1263517010052493313","1263514278285451265","1263513002894123009","1263490259825942528","1263489376887222275","1263464162283454470","1263453185835966466","1263444769453334528","1263428044284465152","1263428020389515265","1263424465662349317","1263407965958279174","1263398150070558721","1263395477191569409","1263388234568077312","1263387665271074817","1263380993987293185","1263377699592114176","1263376668384772099","1263376317141135361","1263370856249659393","1263368838235721728","1263361536250335233","1263347025929744384","1263342400493273089","1263341635015806976","1263307229370990595","1263295349797642242","1263289873244532740","1263280484546732033","1263272448788590593","1263269825498935297","1263246511049256965","1263236417053954056","1263234357671518214","1263232109805735936","1263231753537441793","1263230335606755328","1263225038918111235","1263223646463590407","1263223434257072130","1263217061997789184","1263206541571887106","1263206529857191937","1263206352106684419","1263204207592603653","1263200322106855424","1263192028285976576","1263178811480461313","1263165283629510656","1263162302406307841","1263159566533120000","1263158976977534977","1263117795044327424","1263103680703684610","1263103484926103553","1263092512505430016","1263091863881486337","1263087796102639616","1263086378226782208","1263082788246310913","1263080658680926210","1263079517792407554","1263079404181356544","1263075743074041857","1263072944164569088","1263069847241609216","1263067415811948544","1263066838574956549","1263059928886980608","1263057686071070720","1263054724305006593","1263050526410883072","1263049223655829504","1263048684452929542","1263048437932703744","1263047127221055488","1263035887916658688","1263035108824621056","1263033270645788672","1263021475096866816","1263020953589755904","1263018348088090624","1263018034035339264","1263012856309702656","1263012571218673664","1263012070401945600","1263011927439147008","1263010375081037825","1263010054464249859","1263009824708665349"]},{"title":"Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City","googleId":"pmM-tFJQxm4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7172785/","googleCitationCount":179,"googleAuthor":"","doi":"10.1016/j.annonc.2020.04.006","elsevierAuthor":"Miyashita H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"107","altmetricAuthors":["H. Miyashita","T. Mikami","N. Chopra","T. Yamada","S. Chernyavsky","D. Rizk","C. Cruz"],"twitterCount":56,"altmetricId":80343232,"statusesArray":["1255311709243420673","1255245549038682113","1254411507166851072","1254238861649154054","1254193347897356288","1254178723135475712","1254161819226300417","1254160430219628544","1254117486074740737","1254078754525270022","1254064674821279744","1254056610886008832","1254054288533356544","1254033672103030785","1254006132877791233","1253977637074149376","1253947943511642113","1253946224862007296","1253884198936612864","1253803163158749186","1253779122758844416","1253778060064653315","1253775246911569923","1253772579267059713","1253767170703732736","1253766107976159235","1253756781429493760","1253719480934502401","1253709721791586304","1253709717370789889","1253707679962365952","1253697744654544898","1253696645201637377","1253696457355517953","1253695614501740545","1253695298205081603","1253688270095073281","1253687031898738688","1253680786685014020","1253675731374215168","1253672523511840770","1253672482202058760","1253671683396898816","1253671615914823682","1253670860369641473","1253632187792084993","1253629145994547200","1253605661910368258","1253596039585685505","1253592865252360194","1253581326726430720","1253572040004718592","1253570792291434496","1253570406692388865","1253391606721310726","1253373263209775109","1253364307271708673","1253334865954500610","1253048535429382144","1253021177360105505"]},{"title":"Managing COVID-19 in the oncology clinic and avoiding the distraction effect","googleId":"4cTsg-LBZ_oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36373-0/abstract","googleCitationCount":118,"googleAuthor":"M Bartoletti","statusesArray":[]},{"title":"Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA","googleId":"o5vl8moVR8QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360580","googleCitationCount":98,"googleAuthor":"MC Liu","doi":"10.1016/j.annonc.2020.02.011","elsevierAuthor":"Liu M.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"61","altmetricAuthors":["M.C. Liu","G.R. Oxnard","E.A. Klein","C. Swanton","M.V. Seiden","Minetta C. Liu","Geoffrey R. Oxnard","Eric A. Klein","David Smith","Donald Richards","Timothy J. Yeatman","Allen L. Cohn","Rosanna Lapham","Jessica Clement","Alexander S. Parker","Mohan K. Tummala","Kristi McIntyre","Mikkael A. Sekeres","Alan H. Bryce","Robert Siegel","Xuezhong Wang","David P. Cosgrove","Nadeem R. Abu-Rustum","Jonathan Trent","David D. Thiel","Carlos Becerra","Manish Agrawal","Lawrence E. Garbo","Jeffrey K. Giguere","Ross M. Michels","Ronald P. Harris","Stephen L. Richey","Timothy A. McCarthy","David M. Waterhouse","Fergus J. Couch","Sharon T. Wilks","Amy K. Krie","Rama Balaraman","Alvaro Restrepo","Michael W. Meshad","Kimberly Rieger-Christ","Travis Sullivan","Christine M. Lee","Daniel R. Greenwald","William Oh","Che-Kai Tsao","Neil Fleshner","Hagen F. Kennecke","Maged F. Khalil","David R. Spigel","Atisha P. Manhas","Brian K. Ulrich","Philip A. Kovoor","Christopher Stokoe","Jay G. Courtright","Habte A. Yimer","Timothy G. Larson","Charles Swanton","Michael V. Seiden","Steven R. Cummings","Farnaz Absalan","Gregory Alexander","Brian Allen","Hamed Amini","Alexander M. Aravanis","Siddhartha Bagaria","Leila Bazargan","John F. Beausang","Jennifer Berman","Craig Betts","Alexander Blocker","Joerg Bredno","Robert Calef","Gordon Cann","Jeremy Carter","Christopher Chang","Hemanshi Chawla","Xiaoji Chen","Tom C. Chien","Daniel Civello","Konstantin Davydov","Vasiliki Demas","Mohini Desai","Zhao Dong","Saniya Fayzullina","Alexander P. Fields","Darya Filippova","Peter Freese","Eric T. Fung","Sante Gnerre","Samuel Gross","Meredith Halks-Miller","Megan P. Hall","Anne-Renee Hartman","Chenlu Hou","Earl Hubbell","Nathan Hunkapiller","Karthik Jagadeesh","Arash Jamshidi","Roger Jiang","Byoungsok Jung","TaeHyung Kim","Richard D. Klausner","Kathryn N. Kurtzman","Mark Lee","Wendy Lin","Jafi Lipson","Hai Liu","Qinwen Liu","Margarita Lopatin","Tara Maddala","M. Cyrus Maher","Collin Melton","Andrea Mich","Shivani Nautiyal","Jonathan Newman","Joshua Newman","Virgil Nicula","Cosmos Nicolaou","Ongjen Nikolic","Wenying Pan","Shilpen Patel","Sarah A. Prins","Richard Rava","Neda Ronaghi","Onur Sakarya","Ravi Vijaya Satya","Jan Schellenberger","Eric Scott","Amy J. Sehnert","Rita Shaknovich","Avinash Shanmugam","K.C. Shashidhar","Ling Shen","Archana Shenoy","Seyedmehdi Shojaee","Pranav Singh","Kristan K. Steffen","Susan Tang","Jonathan M. Toung","Anton Valouev","Oliver Venn","Richard T. Williams","Tony Wu","Hui H. Xu","Christopher Yakym","Xiao Yang","Jessica Yecies","Alexander S. Yip","Jack Youngren","Jeanne Yue","Jingyang Zhang","Lily Zhang","Lori (Quan) Zhang","Nan Zhang","Christina Curtis","Donald A. Berry"],"twitterCount":315,"altmetricId":78603989,"statusesArray":["1355430624295849985","1355234516831334401","1355173365321850886","1355150967180652545","1355109581932773384","1350338916189044738","1350115909147488259","1334872028004798464","1334818986589106176","1334539440493096969","1333775358638895104","1333548556226093059","1333422671330222086","1333354935287767040","1333232774212427777","1333170705907605505","1333150678206844935","1333136623874269185","1333131019504001035","1333130673587187715","1333126323527675905","1333117543817613312","1333117353111003139","1333116605983813637","1333093214799224835","1333085180861542401","1333082500973924352","1333082378282164228","1333081943907258368","1333001524700717056","1332978905205125122","1332856286019428359","1332795931562045441","1332753389504131073","1332740867237572608","1332735159595126786","1332726131586424834","1332713485340270597","1332708715699392513","1332701629624233985","1332700783339565058","1332696514523705346","1332696421997441028","1332695493072351232","1332685336716173312","1332684853196812295","1332671130293952519","1332665111014682624","1332644498480959495","1332644483431796736","1332638123587670016","1332628899851874305","1332628642174824449","1332622321052495883","1332618465224634369","1332618395783749632","1332615748993363970","1332614334116204544","1332604411147907072","1332600025491394560","1332599482471616513","1332599277709824001","1332599042078109698","1332598424819159040","1332598395568087040","1332597884148199426","1332596015325720582","1332590342768615424","1332586915661455362","1332574394036727813","1332574251430318080","1332573901310676993","1332573324237443072","1332560345152548864","1332491610798649346","1332473633567109120","1332473119576092678","1332461374920937474","1332454165365149696","1332445291157610497","1332440352834416641","1332439343122747394","1332421309066846208","1332398174636568583","1332397549257433093","1332392636515295232","1332391338688589831","1332389472995078146","1332382687944962049","1332379403280666628","1332378640747728897","1332358878575603717","1332351970338803712","1332343985273237504","1332342394155536386","1332341201979273217","1332336310489653248","1332335036662689799","1332334756676177926","1332333835938250756","1332333616601378821","1332333222953414656","1332315289204248576","1332311514854936579","1332303096798732294","1332296957805543425","1332295405275590657","1332294700557078529","1332289878294487040","1332286876238143490","1332285081885536257","1332284080881274880","1332283514587389954","1332282301556912128","1332281709740630017","1332276555024883720","1332269979409002496","1332254229617127424","1332247494747676672","1332241873210118145","1332241713633644546","1332241684571287553","1332241076556541953","1314237211718676482","1307919259826302977","1292719119041802242","1288532989245366273","1284480807671754752","1283095396953337857","1282118574530859008","1282106190705520640","1281837946534940673","1281682384035950593","1281622181357719554","1281581190512697344","1281517331806670849","1281478292617363456","1281468702853074945","1281455360591761409","1281342817693048832","1281341779774562309","1281282960050790400","1281255378383179783","1281245869061308416","1281239275313512450","1281237198533246976","1281212524227002369","1281206795239714816","1281194716671938561","1281167736832512000","1281156860171759616","1281139699541819392","1281135333057363968","1281129460385943552","1281123841796866053","1281088392726487040","1281077210368090112","1281075284482064384","1281073302090342400","1281072900313923584","1281072642980749313","1281062418156793857","1281053267082964992","1281049169034125312","1281038040870408194","1281037357177688064","1281026759815688192","1281020604762767369","1281019486691299328","1281009464376729602","1281006595158106112","1281000532467908608","1280997776919162881","1280995264539627525","1280993258148106240","1280986022248054798","1280985864320028675","1280985140643139585","1280983936697393152","1280982828621144064","1280977149634191360","1280977037214261254","1280973844426231809","1280970343876907010","1280969619780575232","1280969143500648461","1280968398780973057","1280967361819037702","1280965493361426432","1280964748738203648","1280959956762734594","1280954313507057667","1280953521597267968","1280953155665223681","1280942823617986560","1280942779909226497","1280941890960068611","1280940580210642946","1280937270426640387","1280936356999503872","1280935448030871552","1280935225883865100","1280933369740767233","1280933281140297730","1280931897074429955","1280930214034497537","1280930051651964929","1280927159310303232","1280926051015831555","1280925095159042050","1280924989810552832","1280923339318595584","1280920822811631616","1280919905831989249","1280916758258483201","1280914379500851203","1280914345996713984","1280911117074812933","1280911085537812481","1280910951328485378","1280909229210120192","1280904808170434560","1280902956343230465","1280902725778243585","1280902662926598150","1280900125456338944","1280898665742241795","1280898513396805634","1280894475984703489","1280893141604798465","1280891877521317888","1280890759697350656","1280890007851540481","1276449747818119169","1276419879210549248","1273251407148138497","1270528951270719490","1270506823859277836","1270480114787201025","1270472512913186816","1270468475526545410","1270363743621386243","1270282809429630990","1270251055771770881","1270201158074806272","1270169036396118019","1270162183171825666","1270151436593176576","1270115650250264577","1270111661832245249","1270059513752817664","1270049491320811525","1270024619651710977","1269990070356004864","1269979646705065985","1269978193349480455","1269976147326128128","1269975715711258624","1269961343756644354","1269947655926566913","1269945157375479808","1269943158202400769","1269941880881418240","1269941771200593920","1269941320296075265","1269938822290247680","1264618832360091650","1264513908661989382","1264508069565825024","1264327422788452352","1264324791764504578","1262766950050156548","1259877977837506560","1258564829582786561","1258563916709363714","1258489052761817088","1257938663926714369","1255951059698270209","1255935820688764929","1255882588276903938","1255713167688241152","1255713000046157824","1255606826101624832","1255601160141979649","1255446841946181633","1255445338166562817","1255427679794454529","1255419327467212801","1255415064061980680","1255410083007209474","1255406035818422275","1255385086247174145","1255384923835334656","1255379993628225542","1255373825266638848","1255369051301392384","1255291760198266883","1255267160521400321","1255261213048651776","1255257478352326657","1255251889500930048","1255235922842525697","1255233841444409347","1255220403137662978","1255219619985489925","1255219485453287429","1255218626371690504","1255206243955871746","1255203809803960321","1255203527917355009","1255200761438486528","1255200633352830978","1255200234310901766","1255199687059083269","1255199457072820225","1255199353507102720","1255198965903097862","1255198857845248000","1255198764974866434","1255198644732649472","1254517067270819844","1254509290334883841","1252424886871457792","1251517290698485761","1250580301673140225","1249690923400749058","1249578817716277250","1249552398315474944","1249546558908989440","1249544520334577664","1249508480286851073","1249135199251767296","1249135177139466243","1247798769082437637","1247712268772573185","1247617629294116868","1247587023214522371","1247448861196591104","1246899268838883328","1246895639566278656","1246117034007515138","1246097796857573377","1245978846798721024","1245795385051758593","1245669480887394304","1245668500972208128","1245633220592332800","1245304391466352641","1245294503822409730","1245257100718112768","1245221278513909761","1245207618009935874","1245194911663734786","1245116895793217536","1245078204349636608","1245024934335782914","1245018659057217536","1245007248696410113","1245006707383812101","1245005466326859780","1244991906850820096","1244988410365763585","1244975649720328193","1244951202925690880","1244946970998968320","1244939160248561665","1244935237747998720","1244931005712130049","1244923939199102977","1244922660011806723","1244914887731679235","1244910807907008514","1244903995015135232","1244903907198935045","1244903640533360640","1244900889988665351","1244900155914059776","1244899939454529536","1244899429775269888","1244897673007771649","1244896068208394240","1244894622943510528","1244893836532281344","1244892057526730753","1244891902362685441","1244891513814790145","1244890187605442560","1244887033547558912","1244882777595686913","1244851232830885888"]},{"title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"keaXfXE_JPQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36394-8/pdf","googleCitationCount":44,"googleAuthor":"M Falconi","statusesArray":[]},{"title":"COVID-19 in patients with lung cancer","googleId":"lHxSTdF7C0QJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342039894X","googleCitationCount":56,"googleAuthor":"","doi":"10.1016/j.annonc.2020.06.007","elsevierAuthor":"Luo J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"27","altmetricAuthors":["J. Luo","H. Rizvi","I.R. Preeshagul","J.V. Egger","D. Hoyos","C. Bandlamudi","C.G. McCarthy","C.J. Falcon","A.J. Schoenfeld","K.C. Arbour","J.E. Chaft","R.M. Daly","A. Drilon","J. Eng","A. Iqbal","W.V. Lai","B.T. Li","P. Lito","A. Namakydoust","K. Ng","M. Offin","P.K. Paik","G.J. Riely","C.M. Rudin","H.A. Yu","M.G. Zauderer","M.T.A. Donoghue","M. Łuksza","B.D. Greenbaum","M.G. Kris","M.D. Hellmann"],"twitterCount":23,"altmetricId":84239322,"statusesArray":["1313875539468328964","1313698873643339778","1313669012027584513","1313668509055045634","1313655655908204545","1313633128339181569","1313628545705537538","1313622891079053314","1291533165283213312","1291532383049547776","1291531905473503232","1291531853501997057","1291531643367436290","1291531361077981184","1291531218060603392","1291531133042204672","1285452504982081537","1285341876317327360","1285339133389541379","1285260853420462082","1285237837047062529","1285234077713432576","1285233167855611905","1274439451117150208","1273645766075191297","1273580333640953856","1273574464303837185","1273571912095076354"]},{"title":"TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","googleId":"XH4YP-gxFQIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359469","googleCitationCount":49,"googleAuthor":"GR Oxnard","doi":"10.1016/j.annonc.2020.01.013","elsevierAuthor":"Oxnard G.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"36","altmetricAuthors":["G.R. Oxnard","J.C.-H. Yang","H. Yu","S.-W. Kim","H. Saka","L. Horn","K. Goto","Y. Ohe","H. Mann","K.S. Thress","M.M. Frigault","K. Vishwanathan","D. Ghiorghiu","S.S. Ramalingam","M.-J. Ahn"],"twitterCount":26,"altmetricId":75322003,"statusesArray":["1237332907775098884","1237187082604261376","1237152290995396612","1237078172547420163","1237063884617351169","1236923741634015232","1236914661200736256","1236283312588689408","1236239677973241856","1235972619448520704","1235942509672427521","1235851769743175680","1235823454252724224","1235820031767744517","1235813169236303873","1235807855199969282","1235796754785763329","1235724878218747905","1235707276582768640","1235678945644875776","1235623481322147840","1235612649087545345","1235601510693658629","1235567761922891778","1235549946499096576","1235549942258810880","1235546298067140608","1225786341423636481","1225758391492104192","1225752148195074051","1225752115353702406"]},{"title":"Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up✰","googleId":"6sxlIn7jgPMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)35465-1/abstract","googleCitationCount":32,"googleAuthor":"L Arcaini","statusesArray":[]},{"title":"Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort …","googleId":"gbNFMnT5byAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360324","googleCitationCount":46,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.072","elsevierAuthor":"Schmid P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"29","altmetricAuthors":["P. Schmid","R. Salgado","Y.H. Park","E. Muñoz-Couselo","S.B. Kim","J. Sohn","S.-A. Im","T. Foukakis","S. Kuemmel","R. Dent","L. Yin","A. Wang","K. Tryfonidis","V. Karantza","J. Cortés","S. Loi"],"twitterCount":38,"altmetricId":76197297,"statusesArray":["1250386962453860352","1233330477433524225","1230716434969350144","1230419488593473538","1230418755353751552","1229967827333001216","1229824241790570507","1229743993954717696","1229732037587873792","1229662970449408002","1229625306455035904","1229580449263104000","1229500859534450689","1229479214035931139","1229459111055679489","1229451678988062721","1229444713331163141","1229444395046514688","1229430931485843456","1229429757915197441","1229429716018290688","1229414807327182849","1229414391260622848","1229386481464172544","1229372137934381056","1229371160850239489","1229366986091761664","1229366000958787585","1229363192305942528","1229343224973660160","1229329279676272640","1229327967182053377","1229325616580845568","1229324857210556416","1229324793318690816","1229324225145659392","1229322774033731584","1229319767472902144","1229319672211705856","1229319629979471874"]},{"title":"Prevalence and mutational determinants of high tumor mutation burden in breast cancer","googleId":"dEErZ208wSoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419406984","googleCitationCount":37,"googleAuthor":"R Barroso-Sousa","doi":"10.1016/j.annonc.2019.11.010","elsevierAuthor":"Barroso-Sousa R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"28","altmetricAuthors":["R. Barroso-Sousa","E. Jain","O. Cohen","D. Kim","J. Buendia-Buendia","E. Winer","N. Lin","S.M. Tolaney","N. Wagle"],"twitterCount":39,"altmetricId":73852022,"statusesArray":["1272170067627618305","1254893994913550338","1254862318850027524","1254547759522213888","1254541144626728960","1254458282518949888","1254444011370287104","1254435585579601920","1254410743639945219","1254386998078590976","1229415478424166401","1225836082702553089","1225331981556293632","1225320768977895424","1225300466621394944","1225274709387902977","1225240012607938560","1225227685124804608","1216977849082662912","1216951105139113984","1216641776003485696","1216641740494557184","1216105162504392704","1216057246209146880","1216034790492770305","1215998221098659841","1215993900780998657","1215993035521175553","1215988360709275649","1215885380274270208","1215883549989113856","1215882591422730241","1215877962161184769","1215813108498870272","1215787812600942593","1215782529506119681","1215782506819203073","1215774507065073666","1215764769392586753","1215764111172276224","1215764079496908800","1215759884743999491","1215758115607478272","1215755456066543617","1215750054289559552","1215744588146597888","1215730105638641666","1215728838576984064","1215723288694931456","1215706428427657219","1215704516236075010","1215698452522455041","1215689576418856960"]},{"title":"Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019","googleId":"n-YQWNTmXLoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360737","googleCitationCount":37,"googleAuthor":"C Bosetti","doi":"10.1016/j.annonc.2020.02.012","elsevierAuthor":"Bosetti C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"19","altmetricAuthors":["C. Bosetti","C. Santucci","S. Gallus","M. Martinetti","C. La Vecchia"],"twitterCount":19,"altmetricId":79872817,"statusesArray":["1304244324826263554","1261314425560203264","1257515933423239170","1257514326404915201","1253695955238436864","1252915788681375745","1252833916660019200","1252669309031026688","1252644717679927296","1252642705009594368","1252642489690755072","1252634315222999040","1252599408853569539","1252591067842531329","1252576388764200962","1252571062182666240","1252568983653539841","1252507536235696128","1251190869425782784"]},{"title":"Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19","googleId":"DPJ-rk9FW2YJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/PMC7252166","googleCitationCount":48,"googleAuthor":"","doi":"10.1016/j.annonc.2020.04.475","elsevierAuthor":"Solodky M.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"27","altmetricAuthors":["M.L. Solodky","C. Galvez","B. Russias","P. Detourbet","V. N’Guyen-Bonin","A.-L. Herr","P. Zrounba","J.-Y. Blay"],"twitterCount":61,"altmetricId":80990045,"statusesArray":["1262711459815067648","1261348488119549954","1261345381369012230","1261343372037554177","1261199178383966209","1260155345911021570","1259041223668633600","1258793339660500994","1258671980456353797","1258670042650161155","1258661592457248769","1258563562273943554","1258559418414833677","1258558624017891330","1258558500306776064","1258558405796597767","1258285173180968960","1258083760014270464","1258072248214224896","1258050103971110914","1258040934429855747","1258017967280775169","1257998431538352129","1257957434963918848","1257914383277137920","1257890692405354497","1257832470197809153","1257791314860670982","1257790203068133380","1257785367392063488","1257781674861039619","1257458620725428228","1257250330854785024","1257235427477663744","1257214620516958213","1256928322061316096","1256840168117620737","1256813895995580416","1256623394876989441","1256582972783898625","1256547757952827395","1256547352804024325","1256527504967426048","1256525329641943040","1256525040079773698","1256515283377885184","1256441208848728064","1256432945604091904","1256379782016708610","1256340103447736323","1256318880693260288","1256317598087745542","1256317144188375040","1256315492740083712","1256312165067132928","1256277931627814913","1256275679953530882","1256270887361417216","1256242598987137024","1256239760349298691","1256235591013933057","1256235454967545858","1256234168821915653","1256218904709550089","1256180214910062592","1256165661505708032","1256165133585440768"]},{"title":"Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆","googleId":"mtC6fexywf8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43129-1/abstract","googleCitationCount":103,"googleAuthor":"","statusesArray":[]},{"title":"ESO–ESMO 4th International consensus guidelines for breast cancer in young women (BCY4)","googleId":"5OA652yhaLwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363638","googleCitationCount":34,"googleAuthor":"F Cardoso","doi":"10.1016/j.annonc.2020.03.284","elsevierAuthor":"Paluch-Shimon S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"28","altmetricAuthors":["S. Paluch-Shimon","F. Cardoso","A.H. Partridge","O. Abulkhair","H.A. Azim","G. Bianchi-Micheli","M.-J. Cardoso","G. Curigliano","K.A. Gelmon","N. Harbeck","J. Merschdorf","P. Poortmans","G. Pruneri","E. Senkus","T. Spanic","V. Stearns","Y. Wengström","F. Peccatori","O. Pagani"],"twitterCount":10,"altmetricId":77933557,"statusesArray":["1286071626899918848","1286066059754184704","1285990985885863936","1285920435004211201","1285918790488858624","1285918738487926784","1285915246771699714","1285883164804747264","1270935938428858368","1261247302196326401","1242029960031657985","1240971442717691904"]},{"title":"Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"EacC5X8DeNoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39932-4/abstract","googleCitationCount":29,"googleAuthor":"","statusesArray":[]},{"title":"Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","googleId":"3bdR8-4wfLMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342039308X","googleCitationCount":37,"googleAuthor":"TK Choueiri","doi":"10.1016/j.annonc.2020.04.010","elsevierAuthor":"Choueiri T.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"25","altmetricAuthors":["T.K. Choueiri","R.J. Motzer","B.I. Rini","J. Haanen","M.T. Campbell","B. Venugopal","C. Kollmannsberger","G. Gravis-Mescam","M. Uemura","J.L. Lee","M.-O. Grimm","H. Gurney","M. Schmidinger","J. Larkin","M.B. Atkins","S.K. Pal","J. Wang","M. Mariani","S. Krishnaswami","P. Cislo","A. Chudnovsky","C. Fowst","B. Huang","A. di Pietro","L. Albiges"],"twitterCount":74,"altmetricId":80611142,"statusesArray":["1281134939954647043","1258685810498469888","1256511145663496192","1255921868869156865","1254893033339924486","1254807828906246146","1254702558423199745","1254694422140399616","1254692253538418688","1254680471214206976","1254671663372931073","1254638801454084096","1254607750023335937","1254572306157973505","1254560355252162560","1254542956129738753","1254531069174398976","1254530942598885377","1254508231424118784","1254504749732372481","1254502127294009344","1254492975272525828","1254487515764932608","1254485381594013696","1254477607837499392","1254476971775492100","1254474165937209344","1254473841000230916","1254465096237096960","1254464492290953222","1254462460519763975","1254462038174097409","1254459225268461568","1254444757868261376","1254437212537552896","1254436156265160705","1254435769478901760","1254434346972348416","1254432747243724802","1254423842677821447","1254423558744428545","1254418267592065026","1254418113040273408","1254415907721342978","1254415489742393345","1254413104097738752","1254403469131354112","1254399029129207808","1254397756791312384","1254396728578650112","1254391451468922887","1254389201736536064","1254383173347278849","1254377731480936449","1254376184038612992","1254373622560354304","1254373570676916225","1254372105648508931","1254370638350827523","1254368077703254017","1254366202685788162","1254363768257236993","1254363434671583235","1254361509054099456","1254354421397565440","1254348721682370560","1254339558218633221","1254337864290181122","1254329362494763010","1254328259988336640","1254321099996901376","1254321096343662593","1254320416304357376","1254316781264687104","1254315033393324032","1254314797065175040","1254314775024218112","1254314457582444544","1254313726980886528","1254306717778706432","1254305648885587973","1254303535338008576","1254299045025271808","1254298508712083457","1254298369654169600"]},{"title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","googleId":"95DDbU11eX0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399713","googleCitationCount":32,"googleAuthor":"J Remon","doi":"10.1016/j.annonc.2020.07.014","elsevierAuthor":"Mosele F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"8","altmetricAuthors":["F. Mosele","J. Remon","J. Mateo","C.B. Westphalen","F. Barlesi","M.P. Lolkema","N. Normanno","A. Scarpa","M. Robson","F. Meric-Bernstam","N. Wagle","A. Stenzinger","J. Bonastre","A. Bayle","S. Michiels","I. Bièche","E. Rouleau","S. Jezdic","J-Y. Douillard","J.S. Reis-Filho","R. Dienstmann","F. André"],"twitterCount":45,"altmetricId":88850694,"statusesArray":["1358344478210277390","1317603289018605575","1316566875434778625","1316200454141997058","1316174436492402688","1316066147641458692","1316050061311213570","1313750520947851264","1309286946615644160","1307192465686966272","1306876620616224776","1306771260207247361","1306715001240068096","1306700788585189376","1306500475949404160","1306394999089704960","1306352962869043201","1306326581133160449","1306300074985771008","1306292868638744578","1306290517102206978","1302930752385044481","1301518056796106755","1300586601412689925","1300395036450881539","1299285889525272576","1299174529319620609","1299028458731962369","1298958236582846464","1298549461992513536","1298353247141408771","1298311859527798784","1298302232237047811","1298288783406768128","1298288740733878272","1298288317700636672","1298284780077953024","1298276534709620736","1298273683333554178","1298266176271691778","1298262571682693120","1298261975059722248","1298261933485748235","1298261691675770880","1298260659373666305","1298260428628226055","1298247690795376643"]},{"title":"Testing for COVID-19 in lung cancer patients","googleId":"rGnGMrUMu8AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39293-0/pdf","googleCitationCount":39,"googleAuthor":"S Peters","statusesArray":[]},{"title":"Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus","googleId":"gkwEA2X7cC0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399488","googleCitationCount":37,"googleAuthor":"S Banerjee","doi":"10.1016/j.annonc.2020.07.010","elsevierAuthor":"Curigliano G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"20","altmetricAuthors":["G. Curigliano","S. Banerjee","A. Cervantes","M.C. Garassino","P. Garrido","N. Girard","J. Haanen","K. Jordan","F. Lordick","J.P. Machiels","O. Michielin","S. Peters","J. Tabernero","J.Y. Douillard","G. Pentheroudakis","A. Addeo","L. Albiges","P.A. Ascierto","S. Banerjee","F. Barlesi","C. Caldas","F. Cardoso","A. Cervantes","I.F. Chaberny","N.I. Cherny","T.K. Choueiri","M.L.K. Chua","C. Criscitiello","G. Curigliano","E. de Azambuja","D. De Ruysscher","E. de Vries","R. Dent","J.Y. Douillard","D. D’Ugo","R. Dziadziuszko","C. Faivre-Finn","E. Felip","M. Garassino","P. Garrido","N. Girard","R. Glynne-Jones","V. Golfinopoulos","J. Haanen","E. Hamilton","P.A. Jänne","K. Jordan","R. Kanesvaran","S.B. Kim","U.G. Liebert","F. Lordick","J.P. Machiels","O. Michielin","T.S.K. Mok","G. Morgan","R. Obermannova","K. Park","A. Passaro","G. Pentheroudakis","S. Peters","M. Reck","R. Salazar Soler","F. Scotté","S. Senan","C. Sessa","E. Smyth","R. Soo","J.C. Soria","J. Spicer","F. Strasser","J. Tabernero","D.S.W. Tan","D. Trapani","E. Van Cutsem","H. van Halteren","P.E. van Schil","G. Veronesi","J. Yang"],"twitterCount":7,"altmetricId":87054624,"statusesArray":["1319247124320653313","1319227467660394499","1319173228087136257","1319153459518726145","1318981754070368258","1318971626441027589","1297842227566305281"]},{"title":"Eliminating the breast cancer surgery paradigm after neoadjuvant systemic therapy: current evidence and future challenges","googleId":"m-l39GxGlyoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354675","googleCitationCount":24,"googleAuthor":"HM Kuerer","doi":"10.1016/j.annonc.2019.10.012","elsevierAuthor":"Heil J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"16","altmetricAuthors":["J. Heil","H.M. Kuerer","A. Pfob","G. Rauch","H.P. Sinn","M. Golatta","G.J. Liefers","M.J. Vrancken Peeters"],"twitterCount":2,"altmetricId":80938390,"statusesArray":["1357978960769019905","1258411292412518401"]},{"title":"Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE …","googleId":"PfhwiaB7TbAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420364152","googleCitationCount":31,"googleAuthor":"T André","doi":"10.1016/j.annonc.2020.03.310","elsevierAuthor":"Pagès F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"0","altmetricAuthors":["F. Pagès","T. André","J. Taieb","D. Vernerey","J. Henriques","C. Borg","F. Marliot","R. Ben Jannet","C. Louvet","L. Mineur","J. Bennouna","J. Desrame","R. Faroux","A. Kirilovsky","A. Duval","P. Laurent-Puig","M. Svrcek","F. Hermitte","A. Catteau","J. Galon","J.-F. Emile"],"twitterCount":11,"altmetricId":79937886,"statusesArray":["1303474653348810753","1300814076294172672","1300702331990945793","1300465646535352321","1300438190201933824","1300436457170046977","1274777774008471553","1268664974408376322","1266311305067184128","1265583535282425857","1265576809216774151","1250883797979066368"]},{"title":"Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas","googleId":"n1EqoQcwYrQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036018X","googleCitationCount":25,"googleAuthor":"AJ Schoenfeld","doi":"10.1016/j.annonc.2020.01.065","elsevierAuthor":"Schoenfeld A.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"14","altmetricAuthors":["A.J. Schoenfeld","H. Rizvi","C. Bandlamudi","J.L. Sauter","W.D. Travis","N. Rekhtman","A.J. Plodkowski","R. Perez-Johnston","P. Sawan","A. Beras","J.V. Egger","M. Ladanyi","K.C. Arbour","C.M. Rudin","G.J. Riely","B.S. Taylor","M.T.A. Donoghue","M.D. Hellmann"],"twitterCount":74,"altmetricId":75709463,"statusesArray":["1271836733890613248","1271233020842979328","1270603192284459009","1270531389251891203","1270397147683287041","1270393721255628800","1270381669133037569","1270308431476465664","1270251183861620737","1270127828005031936","1270127018466611200","1270086659590193153","1270083027016781825","1270082757809627142","1270075877997662210","1270036499833270273","1270029985764474880","1270024027982233600","1270023938744160258","1270015340995661827","1270006034334179328","1270005191887241216","1269988430265692160","1269975590926520327","1269939030122250240","1269932736749416450","1269931970513035267","1269930302052409346","1269924027990183936","1269892291746988037","1269860801583689732","1269836620871671819","1269828285988507648","1269828019927035909","1269823991172259846","1240307938474037249","1229414994732777472","1227666688163958784","1227500123019599873","1227368493290573825","1227329071203438594","1227305881848762370","1227291469951700992","1227262525730906116","1227247695393361922","1227243789007245313","1227231535411220480","1227220140779089920","1227141947137122304","1227133850775511040","1227133537821704192","1227133494683414530","1227126020441956354","1227104510411264001","1227097089965985797","1227077521268600832","1227065624842522624","1227060453307637760","1227003145605275648","1226990451179192320","1226987902036566018","1226986549490933760","1226979283521933314","1226971181607157761","1226970924567666689","1226943675214725121","1226930334899560448","1226923373583896577","1226922242589720577","1226915363339849728","1226897311910985729","1226873893702553600","1226873647731793921","1226853620206985219","1226852992994988032","1226846908318126081","1226843522369753088","1226837455665541120","1226825118271320065","1226823956910542849","1226823389597306884","1226820432214528000","1226817514094510080","1226817211949633536","1226817195583377408","1226816310769864704"]},{"title":"Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc …","googleId":"KcAJOZ_YqfwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359275","googleCitationCount":32,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.006","elsevierAuthor":"Chalabi M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"23","altmetricAuthors":["M. Chalabi","A. Cardona","D.R. Nagarkar","A. Dhawahir Scala","D.R. Gandara","A. Rittmeyer","M.L. Albert","T. Powles","M. Kok","F.G. Herrera"],"twitterCount":20,"altmetricId":74454706,"statusesArray":["1309485593559068679","1307242670398423041","1265515789614022661","1248245065291411457","1248242520930181120","1240629421909979143","1240592149999165440","1234524030583087109","1232148471471276032","1231975876792684544","1231933480176476161","1231930581354565634","1231927952310337536","1231926888253329408","1225640138652315648","1225505615268777995","1225502670754107393","1225383285477560320","1225364410446860289","1225344217758593025","1220797665740558339","1220752748473409536"]},{"title":"European cancer mortality predictions for the year 2020 with a focus on prostate cancer","googleId":"XzTgOemXGA4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360567","googleCitationCount":23,"googleAuthor":"P Bertuccio","doi":"10.1016/j.annonc.2020.02.009","elsevierAuthor":"Carioli G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"13","altmetricAuthors":["G. Carioli","P. Bertuccio","P. Boffetta","F. Levi","C. La Vecchia","E. Negri","M. Malvezzi"],"twitterCount":1,"altmetricId":80131560,"statusesArray":["1254025370468311041"]},{"title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","googleId":"0OFd8l-6wQQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036364X","googleCitationCount":21,"googleAuthor":"AM Menzies","doi":"10.1016/j.annonc.2020.03.285","elsevierAuthor":"Haanen J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"15","altmetricAuthors":["J. Haanen","M.S. Ernstoff","Y. Wang","A.M. Menzies","I. Puzanov","P. Grivas","J. Larkin","S. Peters","J.A. Thompson","M. Obeid"],"twitterCount":44,"altmetricId":77933863,"statusesArray":["1279306898148397056","1278918520705822720","1278767929597837312","1269999486484582400","1264511869202595841","1264281836596932615","1264242626833899522","1264180062397640710","1264178530243547138","1264139780587225089","1264125578107551746","1264112726151962625","1264111092516761600","1264109548836716544","1264109341344489478","1264108330148126725","1264098758092099584","1264089344857518080","1264087913618423808","1264085503608938496","1264084393011838976","1264082454626926595","1264078602792034306","1264047258322042880","1264045672392806411","1263980897604419587","1263941596283916288","1263916829526970370","1263906504396156932","1263896367589662722","1263895195583680512","1263883246376488960","1263846075351343105","1263841115217833984","1263839119106625537","1263827365106462720","1263804987638980609","1263789364728877057","1263763232675835904","1263761863533363201","1263759938993586176","1263754189525696512","1263753519984771073","1262331622369759232","1241752456612151297","1241563386292436995","1241563257980063744","1240972416672768000"]},{"title":"JSCO—ESMO—ASCO—JSMO—TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with …","googleId":"TpO_JrFmmc8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363869","googleCitationCount":16,"googleAuthor":"G Pentheroudakis","doi":"10.1016/j.annonc.2020.03.299","elsevierAuthor":"Yoshino T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"12","altmetricAuthors":["T. Yoshino","G. Pentheroudakis","S. Mishima","M.J. Overman","K.-H. Yeh","E. Baba","Y. Naito","F. Calvo","A. Saxena","L.-T. Chen","M. Takeda","A. Cervantes","H. Taniguchi","K. Yoshida","Y. Kodera","Y. Kitagawa","J. Tabernero","H. Burris","J.-Y. Douillard"],"twitterCount":35,"altmetricId":79258841,"statusesArray":["1290985679103488001","1290255697427324928","1290253990584705024","1290250678217015297","1290250081162076167","1268329146972766209","1267914279145156608","1254814516531118081","1253673625145704449","1250218540663222272","1250055621837303809","1249985574351626240","1249956825472081921","1249845022930792448","1249837529861365761","1249821194427043840","1249759557670313990","1249738148449382400","1249733830732324868","1249731658791575552","1249731513500999680","1249730442099675139","1249728435657871361","1249715439506161664","1249712722784260098","1249711945323810822","1249678898872430593","1249673460655120384","1249669742153150465","1249655058217738240","1249653426994192384","1249651493357203457","1249649897399152647","1249648354205880320","1249642217037352962","1248942749493145601","1248808453239431169","1248552320595451905","1247463244014456832"]},{"title":"Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized …","googleId":"vdJ68Hd32cgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360788","googleCitationCount":22,"googleAuthor":"AS Mansfield","doi":"10.1016/j.annonc.2019.10.021","elsevierAuthor":"Mansfield A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"13","altmetricAuthors":["A.S. Mansfield","A. Każarnowicz","N. Karaseva","A. Sánchez","R. De Boer","Z. Andric","M. Reck","S. Atagi","J.-S. Lee","M. Garassino","S.V. Liu","L. Horn","X. Wen","C. Quach","W. Yu","F. Kabbinavar","S. Lam","S. Morris","R. Califano"],"twitterCount":39,"altmetricId":74168411,"statusesArray":["1235946060943691782","1224377976801939457","1224356839816679425","1224356778147827719","1224291176733388801","1224271767008632832","1224271324538908672","1220053835219177472","1219360440007958530","1219344395138285568","1219339957778644992","1219316778016354304","1219184428997578754","1219001634031882241","1218976434942697472","1218964619106058240","1218924428018491403","1218919448570028033","1218846117108092928","1218823011270385664","1218768480314576896","1218749334122127361","1218744670165094400","1218687822355296256","1218684180525207553","1218682512299515904","1218679298305024006","1218648040610975744","1218619380717834241","1218619246474907651","1218589949190012928","1218573944875126784","1218572963827605504","1218548783929348097","1218534275630469121","1218510424431386624","1218495811878780928","1218489229090705408","1218480176813703169","1218466680806039552","1218461849722720256","1218458992957186050","1218431229235793920","1218392397056552960","1218382876338638850","1218343043587362817","1218309716570451969"]},{"title":"A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood","googleId":"XJ0zydUFezMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390842","googleCitationCount":19,"googleAuthor":"A Califano","doi":"10.1016/j.annonc.2019.11.003","elsevierAuthor":"Öberg K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"8","altmetricAuthors":["K. Öberg","A. Califano","J.R. Strosberg","S. Ma","U. Pape","L. Bodei","G. Kaltsas","C. Toumpanakis","J.R. Goldenring","A. Frilling","S. Paulson"],"twitterCount":7,"altmetricId":74274383,"statusesArray":["1306986296330518528","1306968168947224576","1306816236613963776","1306755160799145990","1306710101059940352","1306707132620963841","1227277608783618049","1219959530320121857","1219266567915085825"]},{"title":"Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19","googleId":"Wxh0euKHR5oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36080-4/pdf","googleCitationCount":32,"googleAuthor":"","statusesArray":[]},{"title":"Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines","googleId":"Dhb1MBgBk1cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42448-2/abstract","googleCitationCount":16,"googleAuthor":"M Lambertini","statusesArray":[]},{"title":"Acute myeloid leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"vHGSYVVrN1kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36079-8/fulltext","googleCitationCount":14,"googleAuthor":"Y Ofran","statusesArray":[]},{"title":"A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore.","googleId":"_odR_iob2lcJ","googleLink":"https://europepmc.org/article/pmc/pmc7174823","googleCitationCount":34,"googleAuthor":"","statusesArray":[]},{"title":"Man against machine reloaded: performance of a market-approved convolutional neural network in classifying a broad spectrum of skin lesions in comparison …","googleId":"-kDojCbHCYcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354687","googleCitationCount":24,"googleAuthor":"W Stolz","doi":"10.1016/j.annonc.2019.10.013","elsevierAuthor":"Haenssle H.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"20","altmetricAuthors":["H.A. Haenssle","C. Fink","F. Toberer","J. Winkler","W. Stolz","T. Deinlein","R. Hofmann-Wellenhof","A. Lallas","S. Emmert","T. Buhl","M. Zutt","A. Blum","M.S. Abassi","L. Thomas","I. Tromme","P. Tschandl","A. Enk","A. Rosenberger","Christina Alt","Marie Bachelerie","Sonali Bajaj","Alise Balcere","Sophie Baricault","Clément Barthaux","Yvonne Beckenbauer","Ines Bertlich","Andreas Blum","Marie-France Bouthenet","Sophie Brassat","Philipp Marcel Buck","Kristina Buder-Bakhaya","Maria-Letizia Cappelletti","Cécile Chabbert","Julie De Labarthe","Eveline DeCoster","Teresa Deinlein","Michèle Dobler","Daphnée Dumon","Steffen Emmert","Julie Gachon-Buffet","Mikhail Gusarov","Franziska Hartmann","Julia Hartmann","Anke Herrmann","Isabelle Hoorens","Eva Hulstaert","Raimonds Karls","Andreea Kolonte","Christian Kromer","Aimilios Lallas","Céline Le Blanc Vasseux","Annabelle Levy-Roy","Pawel Majenka","Marine Marc","Veronique Martin Bourret","Nadège Michelet-Brunacci","Christina Mitteldorf","Jean Paroissien","Camille Picard","Diana Plise","Valérie Reymann","Fabrice Ribeaudeau","Pauline Richez","Hélène Roche Plaine","Deborah Salik","Elke Sattler","Sarah Schäfer","Roland Schneiderbauer","Thierry Secchi","Karen Talour","Lukas Trennheuser","Alexander Wald","Priscila Wölbing","Pascale Zukervar"],"twitterCount":4,"altmetricId":73785439,"statusesArray":["1218948951333883905","1218913559767396352","1217833803332431873","1215227747162738688"]},{"title":"Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations","googleId":"ugBFpA5s_MgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341936079X","googleCitationCount":23,"googleAuthor":"J Mazieres","doi":"10.1016/j.annonc.2019.10.022","elsevierAuthor":"Mazieres J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"19","altmetricAuthors":["J. Mazieres","C. Cropet","L. Montané","F. Barlesi","P.J. Souquet","X. Quantin","C. Dubos-Arvis","J. Otto","L. Favier","V. Avrillon","J. Cadranel","D. Moro-Sibilot","I. Monnet","V. Westeel","J. Le Treut","E. Brain","J. Trédaniel","M. Jaffro","S. Collot","G.R. Ferretti","C. Tiffon","C. Mahier-Ait Oukhatar","J.Y. Blay"],"twitterCount":49,"altmetricId":73927271,"statusesArray":["1312763773271277568","1233104660547940353","1231228347277041665","1230839743639904256","1227027677728661515","1226081000993636352","1226076480154800134","1225761285872156673","1225678842586525696","1225671576755924993","1225595133195767808","1225589425331027969","1225548765345538048","1225526051549392916","1225519210236915721","1225495320655691779","1225480406352396290","1225410213743714305","1225398048903368704","1225396216839712768","1225382807989608451","1225377505068158976","1225362830989447168","1225359913804877827","1225358491717640192","1224065937969729541","1221454479251427334","1220978873678123009","1220688528608153600","1220097971402039297","1219928657810132992","1219736687183650816","1219707748348317696","1219707719298551808","1219647416040771584","1219620960376172544","1219592506331095041","1219586018036240384","1219579485588283393","1219544783074492416","1219525004850802688","1219522580094365698","1219520596515676160","1219519943818891264","1219509564401471488","1219506929803976705","1219404464135774208","1219380614157230080","1219367290644373505","1219364511746007040","1219358213092585473","1219351422375997441","1219346520740376581","1219329749656440838","1219328141338075136","1219322597705494534","1219322263394230273"]},{"title":"Adverse event profile for immunotherapy agents compared with chemotherapy in solid organ tumors: a systematic review and meta-analysis of randomized …","googleId":"8FF-j098uYEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354638","googleCitationCount":22,"googleAuthor":"DE Magee","doi":"10.1016/j.annonc.2019.10.008","elsevierAuthor":"Magee D.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"13","altmetricAuthors":["D.E. Magee","A.E. Hird","Z. Klaassen","S.S. Sridhar","R.K. Nam","C.J.D. Wallis","G.S. Kulkarni"],"twitterCount":1,"altmetricId":73785625,"statusesArray":["1215228996427730944"]},{"title":"Cancer-related fatigue: ESMO Clinical Practice Guidelines for diagnosis and treatment","googleId":"agJEFPIBxlUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36077-4/pdf","googleCitationCount":16,"googleAuthor":"","statusesArray":[]},{"title":"HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L) 1 blockade in advanced non-small …","googleId":"IiJECdi4WTIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420392954","googleCitationCount":18,"googleAuthor":"HS Kim","doi":"10.1016/j.annonc.2020.04.004","elsevierAuthor":"Shim J.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"16","altmetricAuthors":["J.H. Shim","H.S. Kim","H. Cha","S. Kim","T.M. Kim","V. Anagnostou","Y.-L. Choi","H.A. Jung","J.-M. Sun","J.S. Ahn","M.-J. Ahn","K. Park","W.-Y. Park","S.-H. Lee"],"twitterCount":4,"altmetricId":80386576,"statusesArray":["1275177362464833537","1265542964287283200","1253470213019820033","1253263737722560516"]},{"title":"Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives","googleId":"flJXLGG9SjQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354146","googleCitationCount":20,"googleAuthor":"D Ciardiello","doi":"10.1016/j.annonc.2019.10.007","elsevierAuthor":"Martinelli E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"17","altmetricAuthors":["E. Martinelli","D. Ciardiello","G. Martini","T. Troiani","C. Cardone","P.P. Vitiello","N. Normanno","A.M. Rachiglio","E. Maiello","T. Latiano","F. De Vita","F. Ciardiello"],"twitterCount":3,"altmetricId":75148502,"statusesArray":["1225782653376454656","1225642246562709504","1225508504938713089"]},{"title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","googleId":"vFcPTKK-fD0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363742","googleCitationCount":25,"googleAuthor":"","doi":"10.1016/j.annonc.2020.03.287","elsevierAuthor":"Paz-Ares L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"17","altmetricAuthors":["L. Paz-Ares","A. Spira","D. Raben","D. Planchard","B.C. Cho","M. Özgüroğlu","D. Daniel","A. Villegas","D. Vicente","R. Hui","S. Murakami","D. Spigel","S. Senan","C.J. Langer","B.A. Perez","A-M. Boothman","H. Broadhurst","C. Wadsworth","P.A. Dennis","S.J. Antonia","C. Faivre-Finn"],"twitterCount":2,"altmetricId":79187908,"statusesArray":["1264155318621257728","1264154469106941953","1264147882489282561"]},{"title":"Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression≥ 50%","googleId":"4ppXofhhqZMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419417213","googleCitationCount":19,"googleAuthor":"JF Gainor","doi":"10.1016/j.annonc.2019.11.015","elsevierAuthor":"Gainor J.F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"11","altmetricAuthors":["J.F. Gainor","H. Rizvi","E. Jimenez Aguilar","F. Skoulidis","B.Y. Yeap","J. Naidoo","S. Khosrowjerdi","M. Mooradian","C. Lydon","P. Illei","J. Zhang","R. Peterson","B. Ricciuti","M. Nishino","J. Zhang","J.A. Roth","J. Grishman","D. Anderson","B.P. Little","B.W. Carter","K. Arbour","J.L. Sauter","M. Mino-Kenudson","J.V. Heymach","S. Digumarthy","A.T. Shaw","M.M. Awad","M.D. Hellmann"],"twitterCount":19,"altmetricId":76102028,"statusesArray":["1230113351562223616","1230107355620220929","1229046402707124224","1228767727906643969","1228750144289505281","1228738711782858752","1228737474224148480","1228726858189017091","1228724371600158721","1228715701373931521","1228699259123441664","1228697312127586305","1228685031238971392","1228682524500668416","1228682490690363392","1228607275226607616","1228604976747839489","1228580129061965827","1228556999647993858","1228516370511515650"]},{"title":"COVID-19 infection in cancer patients: early observations and unanswered questions","googleId":"1wS454AcwJMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36384-5/pdf","googleCitationCount":26,"googleAuthor":"","statusesArray":[]},{"title":"Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a phase I trial","googleId":"LIsqyzgs5LIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363808","googleCitationCount":16,"googleAuthor":"R Berardi","doi":"10.1016/j.annonc.2020.03.293","elsevierAuthor":"Schuler M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"9","altmetricAuthors":["M. Schuler","R. Berardi","W.-T. Lim","M. de Jonge","T.M. Bauer","A. Azaro","M. Gottfried","J.-Y. Han","D.H. Lee","M. Wollner","D.S. Hong","A. Vogel","A. Delmonte","M. Akimov","S. Ghebremariam","X. Cui","N. Nwana","M. Giovannini","T.M. Kim"],"twitterCount":2,"altmetricId":78691421,"statusesArray":["1274780465707323396","1244851667960582144"]},{"title":"Ibrutinib in combination with Nab-Paclitaxel and Gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase 3 RESOLVE …","googleId":"UzhCJmhfFp8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753421000983","googleCitationCount":19,"googleAuthor":"M Reni","doi":"10.1016/j.annonc.2021.01.070","elsevierCitationCount":0,"altmetricAuthors":["M. Tempero","D.-Y. Oh","J. Tabernero","M. Reni","E. Van Cutsem","A. Hendifar","D.-T. Waldschmidt","N. Starling","J.-B. Bachet","H.-M. Chang","J. Maurel","R. Garcia-Carbonero","S. Lonardi","L.M. Coussens","L. Fong","L.C. Tsao","G. Cole","D. James","T. Macarulla"],"twitterCount":3,"altmetricId":99272053,"statusesArray":["1357646950292623366","1357585254320492544","1356542444133826562"]},{"title":"Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo","googleId":"UJPt7EO5QPwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398367","googleCitationCount":13,"googleAuthor":"T Karn","doi":"10.1016/j.annonc.2020.05.015","elsevierAuthor":"Karn T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"6","altmetricAuthors":["T. Karn","C. Denkert","K.E. Weber","U. Holtrich","C. Hanusch","B.V. Sinn","B.W. Higgs","P. Jank","H.P. Sinn","J. Huober","C. Becker","J.-U. Blohmer","F. Marmé","W.D. Schmitt","S. Wu","M. van Mackelenbergh","V. Müller","C. Schem","E. Stickeler","P.A. Fasching","C. Jackisch","M. Untch","A. Schneeweiss","S. Loibl"],"twitterCount":17,"altmetricId":82748985,"statusesArray":["1300761062082572290","1300754144496676864","1300752664679067651","1299361818826153987","1299310457900142592","1299310390141165569","1267715358506582016","1265978209209847809","1265727097747714049","1265390916111663106","1265359315147292679","1265327248007065600","1265272630241787905","1265245334621609984","1265226778408185857","1265224289550303233","1265215921146097665","1265210591708434437","1265208152020189185","1265203990750470145","1265203883028201472"]},{"title":"French Sarcoma Group proposals for management of sarcoma patients during the COVID-19 outbreak","googleId":"7KKlQ2brJZ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36413-9/pdf","googleCitationCount":19,"googleAuthor":"S Bonvalot","statusesArray":[]},{"title":"Extrachromosomal DNA–relieving heredity constraints, accelerating tumour evolution","googleId":"hbrHEmWXqcQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363924","googleCitationCount":12,"googleAuthor":"C Bailey","doi":"10.1016/j.annonc.2020.03.303","elsevierAuthor":"Bailey C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"7","altmetricAuthors":["C. Bailey","M.J. Shoura","P.S. Mischel","C. Swanton"],"twitterCount":33,"altmetricId":79343881,"statusesArray":["1347206623631003650","1275800541193482248","1275673014793908224","1275653399128813570","1275609744292675584","1275602663623872512","1275521163276533760","1275515564778283014","1275466507624079366","1275341817752453121","1254950673742876673","1254948479442604033","1254948344889139201","1249478250994135041","1248942505577472001","1248914700110192640","1248277329094283265","1248267064156061699","1248211878397931521","1248169581685772288","1248165806967578624","1248165473771909120","1248150700477071361","1248149674021847040","1248148754999508993","1248148124457144321","1248147001889492992","1248122419719495680","1248119954500657153","1247999195627347971","1247992530991566849","1247949261054119937","1247945381280972800","1247941127421988865","1247939639404609537","1247925820775153671"]},{"title":"Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta …","googleId":"8eJgY7p9cccJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390854","googleCitationCount":14,"googleAuthor":"A Athanasiou","doi":"10.1016/j.annonc.2019.11.004","elsevierAuthor":"Kalliala I.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"10","altmetricAuthors":["I. Kalliala","A. Athanasiou","A.A. Veroniki","G. Salanti","O. Efthimiou","N. Raftis","S. Bowden","M. Paraskevaidi","K. Aro","M. Arbyn","P. Bennett","P. Nieminen","E. Paraskevaidis","M. Kyrgiou"],"twitterCount":11,"altmetricId":73750183,"statusesArray":["1224146109674741764","1220914259896332288","1220861956485255169","1220846150372220928","1220844177740660743","1220241600217075712","1215964634018127873","1215643649427546112","1215399481342152707","1215234239991599105","1214887692246360065"]},{"title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label …","googleId":"lyFoqwPuSNEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420364346","googleCitationCount":17,"googleAuthor":"RL Ferris","doi":"10.1016/j.annonc.2020.04.001","elsevierAuthor":"Ferris R.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"13","altmetricAuthors":["R.L. Ferris","R. Haddad","C. Even","M. Tahara","M. Dvorkin","T.E. Ciuleanu","P.M. Clement","R. Mesia","S. Kutukova","L. Zholudeva","A. Daste","J. Caballero-Daroqui","B. Keam","I. Vynnychenko","C. Lafond","J. Shetty","H. Mann","J. Fan","S. Wildsmith","N. Morsli","J. Fayette","L. Licitra"],"twitterCount":14,"altmetricId":79917415,"statusesArray":["1288822208102567936","1288100762963316736","1288092784336023554","1288087611492507651","1288087172176908288","1274777925011804161","1273271811711602689","1253891781814390789","1252206971664633861","1252144927066079233","1251466169552375808","1251238353124634626","1250906252718325760","1250839628443054080","1250805914346549248"]},{"title":"Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer","googleId":"_enP7C4XwBgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360555","googleCitationCount":18,"googleAuthor":"O Cohen","doi":"10.1016/j.annonc.2020.02.008","elsevierAuthor":"Waks A.G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"13","altmetricAuthors":["A.G. Waks","O. Cohen","B. Kochupurakkal","D. Kim","C.E. Dunn","J. Buendia Buendia","S. Wander","K. Helvie","M.R. Lloyd","L. Marini","M.E. Hughes","S.S. Freeman","S.P. Ivy","J. Geradts","S. Isakoff","P. LoRusso","V.A. Adalsteinsson","S.M. Tolaney","U. Matulonis","I.E. Krop","A.D. D’Andrea","E.P. Winer","N.U. Lin","G.I. Shapiro","N. Wagle"],"twitterCount":57,"altmetricId":76794249,"statusesArray":["1255292465420140545","1246925717268357120","1241133330684313600","1237592935094308865","1237138270590504965","1234345697601781762","1234054794635030528","1233963028212834306","1233890663436914689","1233862789967511561","1233862776805888000","1233860089724882944","1233797697158746113","1233771617681125376","1233768224656850951","1233751318243749889","1233740735905701889","1233730425325080578","1233730346421772294","1233728929778847746","1233728136241713152","1233728099809943553","1233726980996128770","1233716018222190592","1233713097048756225","1233699557747429376","1233685295331041280","1233685023963873281","1233683375489212422","1233682903953027072","1233673570812940288","1233673545177325568","1233668827138973698","1233664599448342528","1233647973847969795","1233643644805992449","1233641334470270976","1233639163678736385","1233639110125867008","1233635512113647616","1233609605017751553","1233599397889560580","1233585876719919104","1233538430493188097","1233532284088832001","1233523488541028354","1233506289025798151","1233494487252570115","1233474896979779586","1233474366144438277","1233458698799996928","1233449278523105280","1233448970317418497","1233437712100646914","1233427765086621698","1233420092127485953","1233408387779584001","1233407212686495745","1233404519330959361","1233393983461695488","1233391701336584193","1233378025368162308","1233376991010787328","1233364975000772608","1233361329609740293","1233358812037382144","1233357052694626306","1233354126534348800","1233351183022116865","1233350947126071298"]},{"title":"Deep learning radiomic nomogram can predict the number of lymph node metastasis in locally advanced gastric cancer: an international multicenter study","googleId":"cc7yeXPHCcUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420392942","googleCitationCount":16,"googleAuthor":"D Dong","doi":"10.1016/j.annonc.2020.04.003","elsevierAuthor":"Dong D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"15","altmetricAuthors":["D. Dong","M.-J. Fang","L. Tang","X.-H. Shan","J.-B. Gao","F. Giganti","R.-P. Wang","X. Chen","X.-X. Wang","D. Palumbo","J. Fu","W.-C. Li","J. Li","L.-Z. Zhong","F. De Cobelli","J.-F. Ji","Z.-Y. Liu","J. Tian"],"twitterCount":15,"altmetricId":80101025,"statusesArray":["1255874113438089216","1252591428871450624","1252571572625260544","1252567354136920064","1252565028202442752","1252563355107131393","1252562209000976384","1252562072409264128","1252562004868386817","1252561334169829377","1252559854134112256","1252559591474266112","1251852563806162944","1251819119420334083","1251818892080668672"]},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS …","googleId":"ABZjXaoc-0gJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419532240","googleCitationCount":13,"googleAuthor":"G Pentheroudakis","doi":"10.1016/j.annonc.2019.12.001","elsevierAuthor":"Chen L.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"9","altmetricAuthors":["L.-T. Chen","E. Martinelli","A.-L. Cheng","G. Pentheroudakis","S. Qin","G.S. Bhattacharyya","M. Ikeda","H.-Y. Lim","G.F. Ho","S.P. Choo","Z. Ren","H. Malhotra","M. Ueno","B.-Y. Ryoo","T.C. Kiang","D. Tai","A. Vogel","A. Cervantes","S.-N. Lu","C.-J. Yen","Y.-H. Huang","S.-C. Chen","C. Hsu","Y.-C. Shen","J. Tabernero","Y. Yen","C.-H. Hsu","T. Yoshino","J.-Y. Douillard"],"twitterCount":2,"altmetricId":73845359,"statusesArray":["1230125891100930049","1215644133735501825"]},{"title":"Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the …","googleId":"cvwh9Cb_5EAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397969","googleCitationCount":24,"googleAuthor":"","doi":"10.1016/j.annonc.2020.04.478","elsevierAuthor":"Mok T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"15","altmetricAuthors":["T. Mok","D.R. Camidge","S.M. Gadgeel","R. Rosell","R. Dziadziuszko","D.-W. Kim","M. Pérol","S.-H.I. Ou","J.S. Ahn","A.T. Shaw","W. Bordogna","V. Smoljanović","M. Hilton","T. Ruf","J. Noé","S. Peters"],"twitterCount":1,"altmetricId":95961777,"statusesArray":["1338489261755158528"]},{"title":"The forefront of ovarian cancer therapy: update on PARP inhibitors","googleId":"A2wPDo9ojcQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398914","googleCitationCount":19,"googleAuthor":"MR Mirza","doi":"10.1016/j.annonc.2020.06.004","elsevierAuthor":"Mirza M.R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"10","altmetricAuthors":["M.R. Mirza","R.L. Coleman","A. González-Martín","K.N. Moore","N. Colombo","I. Ray-Coquard","S. Pignata"],"twitterCount":31,"altmetricId":84387486,"statusesArray":["1304330138675417088","1303355854897532931","1303295002399961094","1303205725662064645","1303184949822980097","1303105588931506176","1303092745427456000","1303077026086047744","1303074501186318336","1303072926527152128","1303070028468756487","1303063043916656640","1303028641694208001","1303013442014580736","1303001390365593602","1302999117795262466","1302987269608034305","1302986610867425283","1302977343154257921","1302975718096338947","1302975606376796162","1302975348385210368","1286346439094829057","1286330967519625216","1275385495086698498","1274466407309348866","1274429645916700674","1274419850652405762","1274389175186403328","1274388269220978689","1274387266975252482","1274386865567793152"]},{"title":"LBA6_PR Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC …","googleId":"w-nteMbYxsQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42378-6/abstract","googleCitationCount":39,"googleAuthor":"K Shitara","statusesArray":[]},{"title":"696O_PR Nivolumab+ cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER …","googleId":"LOeyRQQr1TEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42339-7/abstract","googleCitationCount":37,"googleAuthor":"TK Choueiri","statusesArray":[]},{"title":"Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma","googleId":"2GN65pCEtmUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354067","googleCitationCount":13,"googleAuthor":"S Ugurel","doi":"10.1016/j.annonc.2019.09.005","elsevierAuthor":"Ugurel S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"11","altmetricAuthors":["S. Ugurel","D. Schadendorf","K. Horny","A. Sucker","S. Schramm","J. Utikal","C. Pföhler","R. Herbst","B. Schilling","C. Blank","J.C. Becker","A. Paschen","L. Zimmer","E. Livingstone","P.A. Horn","V. Rebmann"],"twitterCount":5,"altmetricId":73785388,"statusesArray":["1217370757937786881","1215429554740662272","1215368596039307265","1215367022176919552","1215227749004038145"]},{"title":"Management of hepatocellular carcinoma in the time of COVID-19","googleId":"v5bGX8EiKCwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39304-2/abstract","googleCitationCount":17,"googleAuthor":"M Iavarone","statusesArray":[]},{"title":"Epigenetic modulations and lineage plasticity in advanced prostate cancer","googleId":"UZi_jLmBMpwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360348","googleCitationCount":13,"googleAuthor":"R Montironi","doi":"10.1016/j.annonc.2020.02.002","elsevierAuthor":"Ge R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"9","altmetricAuthors":["R. Ge","Z. Wang","R. Montironi","Z. Jiang","M. Cheng","M. Santoni","K. Huang","F. Massari","X. Lu","A. Cimadamore","A. Lopez-Beltran","L. Cheng"],"twitterCount":9,"altmetricId":78094274,"statusesArray":["1275185223873986562","1245721193736482816","1244596380674514944","1244587805436608513","1244587753507033089","1244585417434976257","1244557209188683776","1243155834131152896","1242103340655312896"]},{"title":"Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer","googleId":"F6TcQAXKdLkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390945","googleCitationCount":24,"googleAuthor":"A Lusque","doi":"10.1016/j.annonc.2019.11.006","elsevierAuthor":"Mosele F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"11","altmetricAuthors":["F. Mosele","B. Stefanovska","A. Lusque","A. Tran Dien","I. Garberis","N. Droin","C. Le Tourneau","M.-P. Sablin","L. Lacroix","D. Enrico","I. Miran","C. Jovelet","I. Bièche","J.-C. Soria","F. Bertucci","H. Bonnefoi","M. Campone","F. Dalenc","T. Bachelot","A. Jacquet","M. Jimenez","F. André"],"twitterCount":0,"altmetricId":78607740,"statusesArray":[]},{"title":"Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patients","googleId":"FLQZU05i39wJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398732","googleCitationCount":10,"googleAuthor":"Y Nakamura","doi":"10.1016/j.annonc.2020.05.031","elsevierAuthor":"Nakamura Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"7","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer","googleId":"acxHqv6UDloJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360415","googleCitationCount":16,"googleAuthor":"S Orlov","doi":"10.1016/j.annonc.2020.02.006","elsevierAuthor":"Planchard D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"12","altmetricAuthors":["D. Planchard","N. Reinmuth","S. Orlov","J.R. Fischer","S. Sugawara","S. Mandziuk","D. Marquez-Medina","S. Novello","Y. Takeda","R. Soo","K. Park","M. McCleod","S.L. Geater","M. Powell","R. May","U. Scheuring","P. Stockman","D. Kowalski"],"twitterCount":30,"altmetricId":77044484,"statusesArray":["1258156150580805632","1257200071004901376","1257126277720363009","1257050471849537536","1256956942230192128","1256903137497100288","1256859454492065792","1256841739106758656","1256841521103622144","1256827952886460416","1256700131585515521","1256688557667823623","1256684126998011906","1256660246405185538","1256619000479412226","1256561148901634048","1256530917771878402","1256529400247586817","1256528534908125184","1256521194905440256","1256516927985459200","1256516449432199168","1256513113236451329","1256512885225926657","1256512095736266753","1256512094511529984","1256511962541932545","1256508617462702080","1256501192827469824","1256499750213496832","1256499475654246400"]},{"title":"A randomized phase III trial comparing primary tumor resection plus chemotherapy with chemotherapy alone in incurable stage IV colorectal cancer: Updated results …","googleId":"KI1-fpoSKj8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40538-1/abstract","googleCitationCount":18,"googleAuthor":"K Shitara","statusesArray":[]},{"title":"Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study","googleId":"ouf4Iu9Igh4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419417249","googleCitationCount":9,"googleAuthor":"R Kurzrock","doi":"10.1016/j.annonc.2019.11.018","elsevierAuthor":"Kurzrock R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"9","altmetricAuthors":["R. Kurzrock","D.W. Bowles","H. Kang","F. Meric-Bernstam","J. Hainsworth","D.R. Spigel","R. Bose","H. Burris","C.J. Sweeney","M.S. Beattie","S. Blotner","K. Schulze","V. Cuchelkar","C. Swanton"],"twitterCount":57,"altmetricId":76348180,"statusesArray":["1347206619457671170","1331847912712769536","1331829814723039232","1301054124302139392","1300774829398855681","1300667636187979782","1300638298797346817","1300625426734342145","1300622630001586176","1300615129629827072","1283153184744255491","1283105248756867075","1283082193569329152","1283015973843415041","1282999410704687105","1282924192116006913","1282898397754621958","1282881966300250114","1282876739883020288","1282864700603031553","1234947181792108547","1233288900002668544","1233139706478702595","1233137536215789579","1233088839553617920","1233084302805676033","1233083179701063681","1231963763865051137","1231855243673133057","1231853139181129728","1231796541020569601","1231796464612974594","1231707980099391496","1231701634259931138","1231671874419073024","1231656428844220421","1231612901435301888","1231483324562051073","1231469133520351232","1231430772000772096","1231376416765349888","1231352407713386496","1231344766782255106","1231343623356153857","1231178850735923206","1231171930826432512","1231167824044838912","1231153205851181056","1231150004770934784","1231147033953808384","1231143355163324416","1231141600505540608","1231005537849860096","1230914577589665792","1230913892429090816","1230899985660563457","1230632251240501248","1230454191597944833","1230454011767197696","1230389222411915265","1230378372427124737","1230373507533561857","1230337576281702400","1230335302432149506","1230333880084779009","1230315488686665730","1230315171320492032","1230315113988739072","1230288554271617026","1230283103014309890","1230144390577807361"]},{"title":"Multicenter randomized controlled trial to evaluate the efficacy and tolerability of frozen gloves for the prevention of chemotherapy-induced peripheral …","googleId":"NPgTkgPAclkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354080","googleCitationCount":12,"googleAuthor":"F Mols","doi":"10.1016/j.annonc.2019.09.006","elsevierAuthor":"Beijers A.J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"10","altmetricAuthors":["A.J.M. Beijers","C.S. Bonhof","F. Mols","J. Ophorst","J. de Vos-Geelen","E.M.G. Jacobs","L.V. van de Poll-Franse","G. Vreugdenhil"],"twitterCount":2,"altmetricId":73788502,"statusesArray":["1298237476369133568","1215247383241596929"]},{"title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","googleId":"2c57VdqfLgkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421647","googleCitationCount":7,"googleAuthor":"V Serra","doi":"10.1016/j.annonc.2020.08.2102","elsevierAuthor":"Miller R.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"6","altmetricAuthors":["R.E. Miller","A. Leary","C.L. Scott","V. Serra","C.J. Lord","D. Bowtell","D.K. Chang","D.W. Garsed","J. Jonkers","J.A. Ledermann","S. Nik-Zainal","I. Ray-Coquard","S.P. Shah","X. Matias-Guiu","E.M. Swisher","L.R. Yates"],"twitterCount":14,"altmetricId":91494302,"statusesArray":["1363187757519171589","1362519870462713856","1362478289336606728","1335603850267381766","1328477180280508417","1320987539570716677","1313044922711367681","1312824190802817024","1312823190545207298","1312823161931608066","1312552932567592968","1312535939957186560","1312412141794844681","1312411887217315840","1312411027976278017","1312409975772401665","1312409838090096641"]},{"title":"Differential effects of an electronic symptom monitoring intervention based on the age of patients with advanced cancer","googleId":"NKeaDsv_3u4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354043","googleCitationCount":11,"googleAuthor":"RD Nipp","doi":"10.1016/j.annonc.2019.09.003","elsevierAuthor":"Nipp R.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"5","altmetricAuthors":["R.D. Nipp","N.K. Horick","A.M. Deal","L.J. Rogak","C. Fuh","J.A. Greer","A.C. Dueck","E. Basch","J.S. Temel","A. El-Jawahri"],"twitterCount":47,"altmetricId":73769182,"statusesArray":["1271430454281977856","1236075319079002112","1220456456979472403","1220445318489178112","1219881568740823040","1219472496107442177","1219184456734593024","1218186693343358976","1217280250243158016","1217277859875708928","1217268492598161410","1215909185113726977","1215745052170956805","1215626076090748928","1215622534286184448","1215452671236300801","1215416198537588736","1215400397029945344","1215343983771226112","1215330261941899264","1215326406714019848","1215283850823262209","1215255147342778373","1215242361309147137","1215234952507404288","1215233502423257099","1215214963318513665","1215192212440567809","1215187468217135105","1215174006468419584","1215171594634461184","1215171577010171904","1215170236313288704","1215170202150887427","1215168991506944000","1215161907075780610","1215146542312624128","1215138932406378496","1215134905098809344","1215120042871808000","1215107141603921921","1215102712494333954","1215092536081108992","1215085865350754309","1215085781313699840","1215075232563679232","1215073349564616705","1215070371398942722","1215068085469749254","1215067599412908032","1215065227110289408","1215064086431588354"]},{"title":"Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas","googleId":"tgqXxm9e9RMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420393108","googleCitationCount":7,"googleAuthor":"LK de Klerk","doi":"10.1016/j.annonc.2020.04.011","elsevierAuthor":"Derks S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"5","altmetricAuthors":["S. Derks","L.K. de Klerk","X. Xu","T. Fleitas","K.X. Liu","Y. Liu","F. Dietlein","C. Margolis","A.M. Chiaravalli","A.C. Da Silva","S. Ogino","F.G. Akarca","G.J. Freeman","S.J. Rodig","J.L. Hornick","E. van Allen","B. Li","S.X. Liu","V. Thorsson","A.J. Bass"],"twitterCount":7,"altmetricId":81704783,"statusesArray":["1347409966265556994","1347197437794865152","1294176303797633024","1259786589066018816","1259165118979428353","1259162427754721284","1259151988203405314","1259144869211189254"]},{"title":"Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer","googleId":"2OoMY_m35EEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354092","googleCitationCount":12,"googleAuthor":"D De Ruysscher","doi":"10.1016/j.annonc.2019.10.003","elsevierAuthor":"De Ruysscher D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"9","altmetricAuthors":["D. De Ruysscher","C. Faivre-Finn","K. Nackaerts","K. Jordan","J. Arends","J.Y. Douillard","U. Ricardi","S. Peters"],"twitterCount":1,"altmetricId":73810341,"statusesArray":["1215437732194840578"]},{"title":"LBA43 spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic …","googleId":"7WMCEEMWtEwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42355-5/abstract","googleCitationCount":12,"googleAuthor":"GV Long","statusesArray":[]},{"title":"A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal …","googleId":"rtNp8qsBolcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399270","googleCitationCount":14,"googleAuthor":"S Park","doi":"10.1016/j.annonc.2020.06.017","elsevierAuthor":"Park S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"8","altmetricAuthors":["S. Park","M.-H. Lee","M. Seong","S.T. Kim","J.-H. Kang","B.C. Cho","K.H. Lee","E.K. Cho","J.-M. Sun","S.-H. Lee","J.S. Ahn","K. Park","M.-J. Ahn"],"twitterCount":2,"altmetricId":85416306,"statusesArray":["1349699033736966146","1280805358416523266"]},{"title":"Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind …","googleId":"5IIjn9Orx44J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398392","googleCitationCount":10,"googleAuthor":"I Borbath","doi":"10.1016/j.annonc.2020.05.018","elsevierAuthor":"Demols A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"9","altmetricAuthors":["A. Demols","I. Borbath","M. Van den Eynde","G. Houbiers","M. Peeters","R. Marechal","T. Delaunoit","J.-C. Goemine","S. Laurent","S. Holbrechts","M. Paesmans","J.-L. Van Laethem"],"twitterCount":3,"altmetricId":83005358,"statusesArray":["1266348109765971968","1266344285919739909","1266344160010829825"]},{"title":"Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients","googleId":"oxFPf2cdQdwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359251","googleCitationCount":18,"googleAuthor":"A Algazi","doi":"10.1016/j.annonc.2019.12.008","elsevierAuthor":"Algazi A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"15","altmetricAuthors":["A. Algazi","S. Bhatia","S. Agarwala","M. Molina","K. Lewis","M. Faries","L. Fong","L.P. Levine","M. Franco","A. Oglesby","C. Ballesteros-Merino","C.B. Bifulco","B.A. Fox","D. Bannavong","R. Talia","E. Browning","M.H. Le","R.H. Pierce","S. Gargosky","K.K. Tsai","C. Twitty","A.I. Daud"],"twitterCount":2,"altmetricId":77309255,"statusesArray":["1284042808081301504","1237443312149127168"]},{"title":"Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with∼ …","googleId":"qSPVtGMofikJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360191","googleCitationCount":16,"googleAuthor":"A Knuppel","doi":"10.1016/j.annonc.2020.01.066","elsevierAuthor":"Murphy N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"10","altmetricAuthors":["N. Murphy","A. Knuppel","N. Papadimitriou","R.M. Martin","K.K. Tsilidis","K. Smith-Byrne","G. Fensom","A. Perez-Cornago","R.C. Travis","T.J. Key","M.J. Gunter"],"twitterCount":14,"altmetricId":77320430,"statusesArray":["1239543072217858051","1239250037730926594","1239182948831604738","1239155207575089153","1237712019190689793","1237698636240297986","1237690948328488960","1237683453233172480","1237681272161525760","1237681230319104001","1237680037240938496","1237679852590968832","1237679814854746115","1237679456686419969","1237678994369150977","1237665899592679424","1237665318966788096","1237664546854244352","1237663977955561472"]},{"title":"Prognostic gene expression signature for high-grade serous ovarian cancer","googleId":"A2_DJVg4SMYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398410","googleCitationCount":11,"googleAuthor":"J Millstein","doi":"10.1016/j.annonc.2020.05.019","elsevierAuthor":"Millstein J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"6","altmetricAuthors":["J. Millstein","T. Budden","E.L. Goode","M.S. Anglesio","A. Talhouk","M.P. Intermaggio","H.S. Leong","S. Chen","W. Elatre","B. Gilks","T. Nazeran","M. Volchek","R.C. Bentley","C. Wang","D.S. Chiu","S. Kommoss","S.C.Y. Leung","J. Senz","A. Lum","V. Chow","H. Sudderuddin","R. Mackenzie","J. George","S. Fereday","J. Hendley","N. Traficante","H. Steed","J.M. Koziak","M. Köbel","I.A. McNeish","T. Goranova","D. Ennis","G. Macintyre","D. Silva De Silva","T. Ramón y Cajal","J. García-Donas","S. Hernando Polo","G.C. Rodriguez","K.L. Cushing-Haugen","H.R. Harris","C.S. Greene","R.A. Zelaya","S. Behrens","R.T. Fortner","P. Sinn","E. Herpel","J. Lester","J. Lubiński","O. Oszurek","A. Tołoczko","C. Cybulski","J. Menkiszak","C.L. Pearce","M.C. Pike","C. Tseng","J. Alsop","V. Rhenius","H. Song","M. Jimenez-Linan","A.M. Piskorz","A. Gentry-Maharaj","C. Karpinskyj","M. Widschwendter","N. Singh","C.J. Kennedy","R. Sharma","P.R. Harnett","B. Gao","S.E. Johnatty","R. Sayer","J. Boros","S.J. Winham","G.L. Keeney","S.H. Kaufmann","M.C. Larson","H. Luk","B.Y. Hernandez","P.J. Thompson","L.R. Wilkens","M.E. Carney","B. Trabert","J. Lissowska","L. Brinton","M.E. Sherman","C. Bodelon","S. Hinsley","L.A. Lewsley","R. Glasspool","S.N. Banerjee","E.A. Stronach","P. Haluska","I. Ray-Coquard","S. Mahner","B. Winterhoff","D. Slamon","D.A. Levine","L.E. Kelemen","J. Benitez","J. Chang-Claude","J. Gronwald","A.H. Wu","U. Menon","M.T. Goodman","J.M. Schildkraut","N. Wentzensen","R. Brown","A. Berchuck","G. Chenevix-Trench","A. deFazio","S.A. Gayther","M.J. García","M.J. Henderson","M.A. Rossing","A. Beeghly-Fadiel","P.A. Fasching","S. Orsulic","B.Y. Karlan","G.E. Konecny","D.G. Huntsman","D.D. Bowtell","J.D. Brenton","J.A. Doherty","P.D.P. Pharoah","S.J. Ramus","D. Bowtell","G. Chenevix-Trench","A. Green","P. Webb","A. DeFazio","D. Gertig","N. Traficante","S. Fereday","S. Moore","J. Hung","K. Harrap","T. Sadkowsky","N. Pandeya","M. Malt","A. Mellon","R. Robertson","T. Vanden Bergh","M. Jones","P. Mackenzie","J. Maidens","K. Nattress","Y.E. Chiew","A. Stenlake","H. Sullivan","B. Alexander","P. Ashover","S. Brown","T. Corrish","L. Green","L. Jackman","K. Ferguson","K. Martin","A. Martyn","B. Ranieri","J. White","V. Jayde","P. Mamers","L. Bowes","L. Galletta","D. Giles","J. Hendley","K. Alsop","T. Schmidt","H. Shirley","C. Ball","C. Young","S. Viduka","Hoa Tran","Sanela Bilic","Lydia Glavinas","Julia Brooks","R. Stuart-Harris","F. Kirsten","J. Rutovitz","P. Clingan","A. Glasgow","A. Proietto","S. Braye","G. Otton","J. Shannon","T. Bonaventura","J. Stewart","S. Begbie","M. Friedlander","D. Bell","S. Baron-Hay","A. Ferrier,a","G. Gard","D. Nevell","N. Pavlakis","S. Valmadre","B. Young","C. Camaris","R. Crouch","L. Edwards","N. Hacker","D. Marsden","G. Robertson","P. Beale","J. Beith","J. Carter","C. Dalrymple","R. Houghton","P. Russell","M. Links","J. Grygiel","J. Hill","A. Brand","K. Byth","R. Jaworski","P. Harnett","R. Sharma","G. Wain","B. Ward","D. Papadimos","A. Crandon","M. Cummings","K. Horwood","A. Obermair","L. Perrin","D. Wyld","J. Nicklin","M. Davy","M.K. Oehler","C. Hall","T. Dodd","T. Healy","K. Pittman","D. Henderson","J. Miller","J. Pierdes","P. Blomfield","D. Challis","R. McIntosh","A. Parker","B. Brown","R. Rome","D. Allen","P. Grant","S. Hyde","R. Laurie","M. Robbie","D. Healy","T. Jobling","T. Manolitsas","J. McNealage","P. Rogers","B. Susil","E. Sumithran","I. Simpson","K. Phillips","D. Rischin","S. Fox","D. Johnson","S. Lade","M. Loughrey","N. O’Callaghan","W. Murray","P. Waring","V. Billson","J. Pyman","D. Neesham","M. Quinn","C. Underhill","R. Bell","L.F. Ng","R. Blum","V. Ganju","I. Hammond","Y. Leung","A. McCartney","M. Buck","I. Haviv","D. Purdie","D. Whiteman","N. Zeps"],"twitterCount":20,"altmetricId":83144282,"statusesArray":["1341643169193099265","1321556111850430466","1319007590618222592","1318931572163284998","1318930757092593666","1316144207497756672","1315657610910146563","1315620630331498497","1315597292506759168","1315594308389543936","1313843656047161351","1304326439911583746","1304178045608230912","1297821765721350146","1297790702999482369","1297185913378877441","1295632134116261889","1295572261097807877","1295469948286820352","1295430260821905408","1295427114762551296","1280804693736853504","1270345969289375745","1267034481996652550"]},{"title":"Does androgen deprivation therapy protect against severe complications from COVID-19?","googleId":"R1H_v4qaLfQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39933-6/abstract","googleCitationCount":13,"googleAuthor":"X Zhong","statusesArray":[]},{"title":"The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB)≥ 10: a decision centered on empowering patients and their …","googleId":"D7CdjGBq4Q4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534%2820%2939936-1/fulltext","googleCitationCount":13,"googleAuthor":"V Subbiah","statusesArray":[]},{"title":"Integrating postradiotherapy plasma Epstein–Barr virus DNA and TNM stage for risk stratification of nasopharyngeal carcinoma to adjuvant therapy","googleId":"07zg0H1-SUYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363766","googleCitationCount":10,"googleAuthor":"BB Ma","doi":"10.1016/j.annonc.2020.03.289","elsevierAuthor":"Hui E.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"4","altmetricAuthors":["E.P. Hui","W.F. Li","B.B. Ma","W.K.J. Lam","K.C.A. Chan","F. Mo","Q.Y.H. Ai","A.D. King","C.H. Wong","R. Guo","D.M.C. Poon","M. Tong","L. Li","T.K.H. Lau","K.C.W. Wong","D.C.M. Lam","Y.M.D. Lo","J. Ma","A.T.C. Chan"],"twitterCount":1,"altmetricId":78569388,"statusesArray":["1244333378695880704"]},{"title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","googleId":"FfvSFLjg4xsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424652","googleCitationCount":8,"googleAuthor":"","doi":"10.1016/j.annonc.2020.09.015","elsevierAuthor":"Lin J.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"6","altmetricAuthors":["J.J. Lin","S.V. Liu","C.E. McCoach","V.W. Zhu","A.C. Tan","S. Yoda","J. Peterson","A. Do","K. Prutisto-Chang","I. Dagogo-Jack","L.V. Sequist","L.J. Wirth","J.K. Lennerz","A.N. Hata","M. Mino-Kenudson","V. Nardi","S.-H.I. Ou","D.S.-W. Tan","J.F. Gainor"],"twitterCount":6,"altmetricId":91691228,"statusesArray":["1351294176487383041","1351182044492140549","1351181390495297543","1345386625904373763","1313860251884625920","1312332586111299584"]},{"title":"Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma …","googleId":"9xXOv_5K8hAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354079","googleCitationCount":9,"googleAuthor":"PA Ascierto","doi":"10.1016/j.annonc.2019.10.002","elsevierAuthor":"Ascierto P.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"8","altmetricAuthors":["P.A. Ascierto","K.D. Lewis","A.M. Di Giacomo","L. Demidov","M. Mandalà","I. Bondarenko","C. Herbert","A. Mackiewicz","P. Rutkowski","A. Guminski","B. Simmons","C. Ye","G. Hooper","M.J. Wongchenko","G.R. Goodman","Y. Yan","D. Schadendorf"],"twitterCount":3,"altmetricId":73785490,"statusesArray":["1215332068420390912","1215235024653443073","1215227750652317696"]},{"title":"Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer","googleId":"aLbkOt9viK0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360786","googleCitationCount":12,"googleAuthor":"G Lamberti","doi":"10.1016/j.annonc.2020.02.017","elsevierAuthor":"Lamberti G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"5","altmetricAuthors":["G. Lamberti","L.F. Spurr","Y. Li","B. Ricciuti","G. Recondo","R. Umeton","M. Nishino","L.M. Sholl","M.L. Meyerson","A.D. Cherniack","M.M. Awad"],"twitterCount":41,"altmetricId":80802828,"statusesArray":["1257311709284298755","1256760538211643393","1256604392150536193","1256593453082988545","1256439204034166784","1256063753621307392","1256009044562546688","1255985911399018496","1255877080845373442","1255832542483267584","1255784348453867522","1255756596300460034","1255749292041670656","1255711910412107780","1255695274774839299","1255658292237352961","1255639897832132614","1255634847479074824","1255609009073201161","1255608902017744897","1255607890104246272","1255607866406436870","1255607491330740225","1255587481665273858","1255586209742667779","1255585593280659457","1255575003652935683","1255569700903411713","1255528931668697088","1255527014343327744","1255523699744178179","1255522959483166725","1255517146790219784","1255483758893023234","1255480394046201857","1255470704469979143","1255440104082071553","1255439866952892424","1255429410938896384","1255414237154992128","1255324312258654210","1255323969466630145","1255322600131244033","1255321439328141314"]},{"title":"A systematic review and meta-analysis of the 2007 WCRF/AICR score in relation to cancer-related health outcomes","googleId":"J8z9-MWXHUsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420319219","googleCitationCount":12,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.001","elsevierAuthor":"Solans M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"10","altmetricAuthors":["M. Solans","D.S.M. Chan","P. Mitrou","T. Norat","D. Romaguera"],"twitterCount":4,"altmetricId":76343934,"statusesArray":["1230515432492294145","1230382048747147264","1230346906091565056","1230125392779862016"]},{"title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","googleId":"DiJw6z1VjykJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42460-3/abstract","googleCitationCount":27,"googleAuthor":"F Cardoso","statusesArray":[]},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO …","googleId":"dUGfUJzYiOsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360831","googleCitationCount":7,"googleAuthor":"KH Lee","doi":"10.1016/j.annonc.2019.10.026","elsevierAuthor":"Park K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"7","altmetricAuthors":["K. Park","J. Vansteenkiste","K.H. Lee","G. Pentheroudakis","C. Zhou","K. Prabhash","T. Seto","P.J. Voon","D.S.W. Tan","J.C.H. Yang","J. Wang","K. Govind Babu","Y. Nakayama","A. Alip","K.L.M. Chua","J.C.-H. Cheng","S. Senan","Y.C. Ahn","T.-Y. Kim","H.K. Ahn","S. Peters","T. Yoshino","J.-Y. Douillard"],"twitterCount":35,"altmetricId":73845116,"statusesArray":["1245109419630886922","1233328874802384898","1223249724943355905","1222948302049697792","1222803904326459392","1222468531079520256","1222466997662949376","1222438637981356039","1222422157889806336","1222419296334184448","1222406370252808197","1222385438679347201","1222338181036572672","1222336861168947200","1222311961808994305","1222297848236191744","1222297077809668096","1222284691903901696","1222282238982795267","1222233595227656192","1222230266241900544","1222229577600323586","1222191992605573120","1222176331443724290","1222176316293877765","1222132254203416576","1222127347937112067","1222125337955299328","1222122223114366976","1222120502845530112","1222112123171622912","1222110304307298304","1222110072886693893","1222099103104086016","1222097907358355456","1222097000541364225","1215949437295636480","1215642500439990273"]},{"title":"Bone health in cancer: ESMO clinical practice guidelines","googleId":"yjXVVOyuOQIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39995-6/abstract","googleCitationCount":14,"googleAuthor":"R Coleman","statusesArray":[]},{"title":"Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and …","googleId":"rhmbclHXLbcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39938-5/abstract","googleCitationCount":6,"googleAuthor":"F Cardoso","statusesArray":[]},{"title":"Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival","googleId":"w8N9L-Mu_3EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342043162X","googleCitationCount":6,"googleAuthor":"MJM Magbanua","doi":"10.1016/j.annonc.2020.11.007","elsevierAuthor":"Magbanua M.J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"2","altmetricAuthors":["M.J.M. Magbanua","L.B. Swigart","H.-T. Wu","G.L. Hirst","C. Yau","D.M. Wolf","A. Tin","R. Salari","S. Shchegrova","H. Pawar","A.L. Delson","A. DeMichele","M.C. Liu","A.J. Chien","D. Tripathy","S. Asare","C.-H.J. Lin","P. Billings","A. Aleshin","H. Sethi","M. Louie","B. Zimmermann","L.J. Esserman","L.J. van ‘t Veer"],"twitterCount":23,"altmetricId":94906114,"statusesArray":["1336552245501046785","1336550973767102464","1336505237893353472","1336035643688771584","1335735170721263621","1335703674849529856","1335703443340734471","1335695519696424960","1335691296648933378","1335672364135288835","1335672297429098496","1335668425478320129","1335645294474768384","1335612822055759873","1335610137495695361","1335605325408460800","1335570202927493120","1335508386184650752","1335506214680195072","1335496193451941888","1335489442304372736","1335481794297262080","1331560020597608448"]},{"title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients …","googleId":"rVaraWt_ov4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397982","googleCitationCount":12,"googleAuthor":"F André","doi":"10.1016/j.annonc.2020.05.001","elsevierAuthor":"Rugo H.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"7","altmetricAuthors":["H.S. Rugo","F. André","T. Yamashita","H. Cerda","I. Toledano","S.M. Stemmer","J.C. Jurado","D. Juric","I. Mayer","E.M. Ciruelos","H. Iwata","P. Conte","M. Campone","C. Wilke","D. Mills","A. Lteif","M. Miller","F. Gaudenzi","S. Loibl"],"twitterCount":4,"altmetricId":82212538,"statusesArray":["1262267109515681795","1262122489053761537","1262122028263526400","1262117916805300224"]},{"title":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors","googleId":"NENwnyRoHAoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399282","googleCitationCount":8,"googleAuthor":"F Meric-Bernstam","doi":"10.1016/j.annonc.2020.06.018","elsevierAuthor":"Bahleda R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"6","altmetricAuthors":["R. Bahleda","F. Meric-Bernstam","L. Goyal","B. Tran","Y. He","I. Yamamiya","K.A. Benhadji","I. Matos","H.-T. Arkenau"],"twitterCount":3,"altmetricId":85303123,"statusesArray":["1282524716561924096","1281971787342008320","1280087830375645184"]},{"title":"Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer","googleId":"PwNrlAJv6UUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420363821","googleCitationCount":7,"googleAuthor":"Y Jiang","doi":"10.1016/j.annonc.2020.03.295","elsevierAuthor":"Jiang Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["Y. Jiang","H. Wang","J. Wu","C. Chen","Q. Yuan","W. Huang","T. Li","S. Xi","Y. Hu","Z. Zhou","Y. Xu","G. Li","R. Li"],"twitterCount":5,"altmetricId":78691397,"statusesArray":["1265412007894769664","1263923588555575298","1263922834759442438","1261027138301378562","1244851516969811969"]},{"title":"Measures of body fatness and height in early and mid-to-late adulthood and prostate cancer: risk and mortality in The Pooling Project of Prospective Studies of …","googleId":"kvlFRvbPn1sJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354134","googleCitationCount":8,"googleAuthor":"JM Genkinger","doi":"10.1016/j.annonc.2019.09.007","elsevierAuthor":"Genkinger J.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"4","altmetricAuthors":["J.M. Genkinger","K. Wu","M. Wang","D. Albanes","A. Black","P.A. van den Brandt","K.A. Burke","M.B. Cook","S.M. Gapstur","G.G. Giles","E. Giovannucci","G.G. Goodman","P.J. Goodman","N. Håkansson","T.J. Key","S. Männistö","L. Le Marchand","L.M. Liao","R.J. MacInnis","M.L. Neuhouser","E.A. Platz","N. Sawada","J.M. Schenk","V.L. Stevens","R.C. Travis","S. Tsugane","K. Visvanathan","L.R. Wilkens","A. Wolk","S.A. Smith-Warner"],"twitterCount":10,"altmetricId":73816369,"statusesArray":["1252581214902517760","1237306132475019264","1237037069035122690","1237032540705177601","1237024318107701248","1236988826083643392","1233366750772813826","1231877685804195841","1227603851060006912","1227204242802429953","1215485365169147904"]},{"title":"Clinical development of therapies targeting TGFβ: current knowledge and future perspectives.","googleId":"R1UXAr4PW90J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399464","googleCitationCount":5,"googleAuthor":"D Ciardiello","doi":"10.1016/j.annonc.2020.07.009","elsevierAuthor":"Ciardiello D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"4","altmetricAuthors":["D. Ciardiello","E. Elez","J. Tabernero","J. Seoane"],"twitterCount":1,"altmetricId":86718454,"statusesArray":["1288424235099201539"]},{"title":"Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials","googleId":"Nz2kQiOi_LgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354110","googleCitationCount":10,"googleAuthor":"","doi":"10.1016/j.annonc.2019.10.005","elsevierAuthor":"Yoshino T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"8","altmetricAuthors":["T. Yoshino","J.M. Cleary","E. Van Cutsem","R.J. Mayer","A. Ohtsu","E. Shinozaki","A. Falcone","K. Yamazaki","T. Nishina","R. Garcia-Carbonero","Y. Komatsu","H. Baba","G. Argilés","A. Tsuji","A. Sobrero","K. Yamaguchi","M. Peeters","K. Muro","A. Zaniboni","N. Sugimoto","Y. Shimada","Y. Tsuji","H.S. Hochster","T. Moriwaki","B. Tran","T. Esaki","C. Hamada","T. Tanase","F. Benedetti","L. Makris","F. Yamashita","H.-J. Lenz"],"twitterCount":4,"altmetricId":73787757,"statusesArray":["1258728415928168449","1215678206096769029","1215623084234956807","1215242125241126912"]},{"title":"811MO maintenance olaparib for patients (PTS) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (Y) follow-up (f/u) from …","googleId":"oi9w_cO8PGsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40946-9/abstract","googleCitationCount":11,"googleAuthor":"N Colombo","statusesArray":[]},{"title":"Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the …","googleId":"ZfAaBXFIBvIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421064","googleCitationCount":8,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2098","elsevierAuthor":"Litton J.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"5","altmetricAuthors":["J.K. Litton","S.A. Hurvitz","L.A. Mina","H.S. Rugo","K.-H. Lee","A. Gonçalves","S. Diab","N. Woodward","A. Goodwin","R. Yerushalmi","H. Roché","Y.-H. Im","W. Eiermann","R.G.W. Quek","T. Usari","S. Lanzalone","A. Czibere","J.L. Blum","M. Martin","J. Ettl"],"twitterCount":2,"altmetricId":88982250,"statusesArray":["1299117949836570628","1299026108218830853"]},{"title":"Analysis of tumor microenvironmental features to refine prognosis by T, N risk group in patients with stage III colon cancer (NCCTG N0147)(Alliance)","googleId":"CpTWaK4cMO8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359445","googleCitationCount":7,"googleAuthor":"TC Smyrk","doi":"10.1016/j.annonc.2020.01.011","elsevierAuthor":"Lee H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"6","altmetricAuthors":["H. Lee","D. Sha","N.R. Foster","Q. Shi","S.R. Alberts","T.C. Smyrk","F.A. Sinicrope"],"twitterCount":13,"altmetricId":76689041,"statusesArray":["1283223882883792896","1238760104738140161","1235079524322168833","1234730333943107585","1234699504802291718","1234636952013541377","1234489954270576640","1232925690112151552","1232706798328504320","1232654047238381568","1232626216387084288","1232625371201314817","1232622275679010816","1232621368694407169"]},{"title":"ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee","googleId":"TDALFMKmFZIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399397","googleCitationCount":5,"googleAuthor":"PA Ascierto","doi":"10.1016/j.annonc.2020.07.004","elsevierAuthor":"Keilholz U.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"1","altmetricAuthors":["U. Keilholz","P.A. Ascierto","R. Dummer","C. Robert","P. Lorigan","A. van Akkooi","A. Arance","C.U. Blank","V. Chiarion Sileni","M. Donia","M.B. Faries","C. Gaudy-Marqueste","H. Gogas","J.J. Grob","M. Guckenberger","J. Haanen","A.J. Hayes","C. Hoeller","C. Lebbé","I. Lugowska","M. Mandalà","I. Márquez-Rodas","P. Nathan","B. Neyns","R. Olofsson Bagge","S. Puig","P. Rutkowski","B. Schilling","V.K. Sondak","H. Tawbi","A. Testori","O. Michielin"],"twitterCount":2,"altmetricId":87130048,"statusesArray":["1292090718702522375","1290592615935639552"]},{"title":"Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients","googleId":"FnoShPpOI6MJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420393066","googleCitationCount":5,"googleAuthor":"P Razavi","doi":"10.1016/j.annonc.2020.04.008","elsevierAuthor":"Ross D.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"3","altmetricAuthors":["D.S. Ross","B. Liu","A.M. Schram","P. Razavi","S.M. Lagana","Y. Zhang","M. Scaltriti","J.F. Bromberg","M. Ladanyi","D.M. Hyman","A. Drilon","A. Zehir","R. Benayed","S. Chandarlapaty","J.F. Hechtman"],"twitterCount":32,"altmetricId":80891059,"statusesArray":["1283251197281890304","1265028557035757568","1263251108203503616","1262774136952193029","1262509203022917638","1262410144136204288","1262368610707820544","1262308190106071040","1262305785956184064","1262262867195244549","1262255464915570688","1262254529233530880","1262247061531000836","1262246563973398528","1258679925747453953","1258554762946998278","1258541851344121856","1257644772124168193","1257606835248513024","1257517219258433537","1257503307163189248","1257496162770264069","1257496060873920518","1257491420559994881","1257477583777693698","1257409020953911296","1257367259376504834","1257349512970076172","1257333779884015616","1257320367422468096","1257317317500735490","1255800958115655681"]},{"title":"An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45","googleId":"AbplPkpSoYwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360843","googleCitationCount":8,"googleAuthor":"F Cardoso","doi":"10.1016/j.annonc.2019.10.027","elsevierAuthor":"Bjelic-Radisic V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"0","altmetricAuthors":["V. Bjelic-Radisic","F. Cardoso","D. Cameron","E. Brain","K. Kuljanic","R.A. da Costa","T. Conroy","E.C. Inwald","S. Serpentini","M. Pinto","J. Weis","O. Morag","G. Lindviksmoen Astrup","K.A. Tomaszweksi","K. Pogoda","P. Sinai","M. Sprangers","N. Aaronson","G. Velikova","E. Greimel","J. Arraras","A. Bottomley","Eveline Bleiker","Brigitte Bliem","Weichu Chie","Carien Creutzberg","Valerie Deville","Francois Duhoux","Kirsten Eilf","Sue Hartup","Michael Koller","Eva Nagele","Ourania Nicolatou-Galitis","Anne Oberguggenberger","Claudia Schmalz","Zoe Winters"],"twitterCount":1,"altmetricId":76426645,"statusesArray":["1235629007724572674"]},{"title":"Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline …","googleId":"hWLeihe80qMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397908","googleCitationCount":6,"googleAuthor":"D Dolling","doi":"10.1016/j.annonc.2020.04.473","elsevierAuthor":"Lu C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"4","altmetricAuthors":["C. Lu","A. Terbuch","D. Dolling","J. Yu","H. Wang","Y. Chen","J. Fountain","C. Bertan","A. Sharp","S. Carreira","W.B. Isaacs","E.S. Antonarakis","J.S. De Bono","J. Luo"],"twitterCount":2,"altmetricId":81787574,"statusesArray":["1262455380552101889","1259787090247643136"]},{"title":"Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a …","googleId":"aqixsgI_sh0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354031","googleCitationCount":8,"googleAuthor":"WTA Van Der Graaf","doi":"10.1016/j.annonc.2019.09.002","elsevierAuthor":"Poort H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"3","altmetricAuthors":["H. Poort","M.E.W.J. Peters","W.T.A. van der Graaf","P.T. Nieuwkerk","A.J. van de Wouw","M.W.G. Nijhuis-van der Sanden","G. Bleijenberg","C.A.H.H.V.M. Verhagen","H. Knoop"],"twitterCount":88,"altmetricId":73772928,"statusesArray":["1347202140461281281","1224724651437367297","1224045015258804224","1222131172748267521","1218020755625140225","1216992396581490688","1216977916044677120","1216860217641721856","1216814466400182272","1216667186455924736","1216650753579851776","1216647246533611520","1216641557811679233","1216361693061664768","1216282073067085829","1216274557897707520","1216108313022279681","1216081314857869314","1216060242066206720","1216043876961673216","1216034210298966016","1215808035844771840","1215805560198778880","1215730159216734209","1215724957579259904","1215723747757391872","1215642292360372229","1215624488106242048","1215623519708569600","1215622715270406144","1215622631577346048","1215615394536480768","1215582272188870657","1215516595264507905","1215484779526750208","1215449308952178689","1215409864152731648","1215400865701552128","1215398354047455232","1215373946276777997","1215373931965628416","1215371548799799296","1215364963931430912","1215362284329017344","1215357862345658369","1215357487085281280","1215356622479847424","1215349229364961284","1215349103972044800","1215344617773621248","1215316068211810310","1215296149206249472","1215290243613462531","1215288471666847751","1215287366568382464","1215284731119579136","1215284425761656833","1215282713004953605","1215279164711936003","1215276732397367296","1215275519480074241","1215269955408666625","1215267244885725190","1215260991488962562","1215258508918083584","1215257803738185728","1215257311171751936","1215254156023345153","1215243231933489152","1215242449460834311","1215232841627381760","1215232283768127489","1215231277563109376","1215224223666450432","1215220634902499329","1215212498632298497","1215212452578648064","1215210612856446977","1215205958055530496","1215195880128729088","1215191478659698689","1215190004403769345","1215189186531266560","1215184103072550912","1215182207771447296","1215180863438303232","1215179913965248513","1215170424897769473","1215170255355555840","1215148387810439168","1215146941215997952","1215146370908049409","1215145955873280000","1215144601192931329","1215128131582873600","1215123514115575809","1215119726759874560","1215107637341233153"]},{"title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"F85io6vBVUoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39898-7/abstract","googleCitationCount":30,"googleAuthor":"E Castro","statusesArray":[]},{"title":"LBA-5 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal …","googleId":"lIt1mjYEfB4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39379-0/pdf","googleCitationCount":8,"googleAuthor":"A Grothey","statusesArray":[]},{"title":"Characterization of on-target adverse events caused by TRK inhibitor therapy","googleId":"IMp4OwIpN5UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398203","googleCitationCount":5,"googleAuthor":"","doi":"10.1016/j.annonc.2020.05.006","elsevierAuthor":"Liu D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"4","altmetricAuthors":["D. Liu","J. Flory","A. Lin","M. Offin","C.J. Falcon","Y.R. Murciano-Goroff","E. Rosen","R. Guo","E. Basu","B.T. Li","J.J. Harding","G. Iyer","K. Jhaveri","M.M. Gounder","N.N. Shukla","S.S. Roberts","J. Glade-Bender","L. Kaplanis","A. Schram","D.M. Hyman","A. Drilon"],"twitterCount":33,"altmetricId":82632764,"statusesArray":["1301621239153397760","1301242327613280256","1301168864995221506","1301153092742926336","1301147599521673216","1301127701512814593","1301115131422748674","1301108517353517056","1301093461991419904","1301091329812951047","1301091060807020546","1268584537245790210","1268426124452859904","1268426080857325568","1268426028478857223","1265911475685797888","1265528419825131520","1265527848862912512","1265380811685019648","1265361527185555457","1265360054569644034","1265359262970232834","1265359164307574787","1265301002267299843","1265295350589386752","1265267729407381504","1265253760722284545","1265246915421241344","1265226523570733056","1265223579144278016","1265210648104964096","1265210473512939520","1265202501520961536","1265200344377819136","1265200200240582657","1264720445552701440","1264676260841652224","1264368632244719617"]},{"title":"ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee","googleId":"gC33zBCdAngJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399403","googleCitationCount":8,"googleAuthor":"PA Ascierto","doi":"10.1016/j.annonc.2020.07.005","elsevierAuthor":"Michielin O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"5","altmetricAuthors":["O. Michielin","A. van Akkooi","P. Lorigan","P.A. Ascierto","R. Dummer","C. Robert","A. Arance","C.U. Blank","V. Chiarion Sileni","M. Donia","M.B. Faries","C. Gaudy-Marqueste","H. Gogas","J.J. Grob","M. Guckenberger","J. Haanen","A.J. Hayes","C. Hoeller","C. Lebbé","I. Lugowska","M. Mandalà","I. Márquez-Rodas","P. Nathan","B. Neyns","R. Olofsson Bagge","S. Puig","P. Rutkowski","B. Schilling","V.K. Sondak","H. Tawbi","A. Testori","U. Keilholz"],"twitterCount":5,"altmetricId":87130134,"statusesArray":["1292386933491077121","1292369137021456384","1292131335948165120","1292090691502460929","1290592913639055360"]},{"title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III …","googleId":"X2tuCjW7ZykJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398999","googleCitationCount":5,"googleAuthor":"R Glynne-Jones","doi":"10.1016/j.annonc.2020.06.012","elsevierAuthor":"Glynne-Jones R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"5","altmetricAuthors":["R. Glynne-Jones","H.M. Meadows","A. Lopes","R. Muirhead","D. Sebag-Montefiore","R. Adams"],"twitterCount":6,"altmetricId":85301223,"statusesArray":["1280492896391761925","1280424959421165568","1280265006072938498","1280264918378274817","1280264895364304902","1280090827193188359"]},{"title":"New hints towards a precision medicine strategy for IDH wild-type glioblastoma","googleId":"WRk3KBIrvfQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424287","googleCitationCount":4,"googleAuthor":"BM Murphy","doi":"10.1016/j.annonc.2020.08.2336","elsevierAuthor":"White K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"2","altmetricAuthors":["K. White","K. Connor","J. Clerkin","B.M. Murphy","M. Salvucci","A.C. O'Farrell","M. Rehm","D. O'Brien","J.H.M. Prehn","S.P. Niclou","M.L.M. Lamfers","M. Verreault","A. Idbaih","R. Verhaak","A. Golebiewska","A.T. Byrne"],"twitterCount":8,"altmetricId":89896337,"statusesArray":["1306140963010686976","1305231784939008008","1305046264451661824","1305043324542353409","1304444569233379329","1304438407544868865","1304418005389017088","1304411040231428096"]},{"title":"138O CNS metastases in HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan: DESTINY-Breast01 subgroup analyses","googleId":"ZK5O7LqaH-EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36318-3/abstract","googleCitationCount":14,"googleAuthor":"","statusesArray":[]},{"title":"Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial","googleId":"uQKssSgFJl4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398331","googleCitationCount":9,"googleAuthor":"JA Di Palma","doi":"10.1016/j.annonc.2020.05.012","elsevierAuthor":"Barcenas C.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"4","altmetricAuthors":["C.H. Barcenas","S.A. Hurvitz","J.A. Di Palma","R. Bose","A.J. Chien","N. Iannotti","G. Marx","A. Brufsky","A. Litvak","E. Ibrahim","R.H. Alvarez","M. Ruiz-Borrego","N. Chan","Y. Manalo","A. Kellum","M. Trudeau","M. Thirlwell","J. Garcia Saenz","D. Hunt","R. Bryce","L. McCulloch","H.S. Rugo","D. Tripathy","A. Chan","L. Carcas","A. Castrellon","D. Chan","K. Cheong","B. Choi","M. Coleman","A. Conlin","R. Dichmann","D. Ellison","N. Erickson","I. Gore","V. Hansen","D. Huang","D. Hufnagel","F. Kass","S.D. Kendall","M. Kozloff","W. Lawler","K.D. Nahum","B. Pistilli","E. Reyes","J. Seeger","R. Somer","E. Tan Chiu","G. Thomas","K. Tkaczuk","I. Vaziri","J. Wade","M. Wilkinson"],"twitterCount":4,"altmetricId":82803026,"statusesArray":["1280197411617615876","1273218340077670401","1267581859564830720","1266310093877866499","1265630947267018755","1265435012297605120"]},{"title":"Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR …","googleId":"E4X5KINOBgcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354018","googleCitationCount":7,"googleAuthor":"M Saigi","doi":"10.1016/j.annonc.2019.09.001","elsevierAuthor":"Pros E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"6","altmetricAuthors":["E. Pros","M. Saigi","D. Alameda","G. Gomez-Mariano","B. Martinez-Delgado","J.J. Alburquerque-Bejar","J. Carretero","R. Tonda","A. Esteve-Codina","I. Catala","R. Palmero","M. Jove","C. Lazaro","A. Patiño-Garcia","I. Gil-Bazo","S. Verdura","A. Teulé","J. Torres-Lanzas","D. Sidransky","N. Reguart","R. Pio","O. Juan-Vidal","E. Nadal","E. Felip","L.M. Montuenga","M. Sanchez-Cespedes"],"twitterCount":2,"altmetricId":74353136,"statusesArray":["1220398379399819270","1220017057422594054"]},{"title":"A multicentre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia …","googleId":"sNkXhUwUOCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420392966","googleCitationCount":9,"googleAuthor":"M Clemons","doi":"10.1016/j.annonc.2020.04.005","elsevierAuthor":"Clemons M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"4","altmetricAuthors":["M. Clemons","D. Fergusson","D. Simos","M. Mates","A. Robinson","N. Califaretti","L. Zibdawi","M. Bahl","J. Raphael","M.F.K. Ibrahim","R. Fernandes","L. Pitre","O. Aseyev","C. Stober","L. Vandermeer","D. Saunders","B. Hutton","R. Mallick","G.R. Pond","A. Awan","J. Hilton"],"twitterCount":53,"altmetricId":80464234,"statusesArray":["1347268284169682949","1288840761258246151","1281198288256077825","1281178365689561088","1279383238797152257","1277938938229993472","1277703188603375619","1277683269094572034","1277655262791372805","1277628127322177537","1277604843230822400","1277576214862061573","1277576064240402433","1277562467149918210","1277560600416129025","1277543088785895426","1277502071957336065","1277498846637993985","1277493558463868933","1277490420344373249","1277485819268411396","1277463790284492800","1277458552748154884","1277443194242752512","1277441118750244864","1277392088577880064","1277375361010016259","1277372391002431489","1277365916607676417","1277364929155252226","1277353460292296705","1277353018154012672","1277350863288389635","1277347425351589888","1277346008964509697","1277341860005117953","1277334682825195520","1277334418797899776","1277333663915683841","1274778265463463939","1273001668603514880","1272992824053641217","1272900487725977600","1260012013327015936","1259968271186571265","1259911407304413194","1259851167129092097","1259834287148290050","1259831809615040512","1259779899944042497","1259747374462730240","1259744645547991041","1259742187413213185","1259732741152800769","1259730960192544768","1259715568686567425","1259705135846043649","1259705009396203521","1253625244188696577"]},{"title":"A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the …","googleId":"LIavQYLN_vsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424597","googleCitationCount":7,"googleAuthor":"U Dafni","doi":"10.1016/j.annonc.2020.09.009","elsevierAuthor":"Popat S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"8","altmetricAuthors":["S. Popat","A. Curioni-Fontecedro","U. Dafni","R. Shah","M. O'Brien","A. Pope","P. Fisher","J. Spicer","A. Roy","D. Gilligan","O. Gautschi","E. Nadal","W.D. Janthur","R. López Castro","R. García Campelo","S. Rusakiewicz","I. Letovanec","V. Polydoropoulou","H. Roschitzki-Voser","B. Ruepp","A. Gasca-Ruchti","S. Peters","R.A. Stahel"],"twitterCount":2,"altmetricId":91714901,"statusesArray":["1363990970723950592","1363927837342916615"]},{"title":"A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma","googleId":"GKMTYTq4hXYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342043131X","googleCitationCount":3,"googleAuthor":"R Nicolle","doi":"10.1016/j.annonc.2020.10.601","elsevierAuthor":"Nicolle R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"2","altmetricAuthors":["R. Nicolle","O. Gayet","P. Duconseil","C. Vanbrugghe","J. Roques","M. Bigonnet","Y. Blum","N. Elarouci","L. Armenoult","M. Ayadi","A. de Reyniès","F. Puleo","J. Augustin","J.F. Emile","M. Svrcek","T. Arsenijevic","P. Hammel","M. Giovannini","P. Grandval","L. Dahan","V. Moutardier","M. Gilabert","J.L. Van Laethem","J.B. Bachet","J. Cros","J. Iovanna","N.J. Dusetti"],"twitterCount":1,"altmetricId":94418395,"statusesArray":["1328503020699615232"]},{"title":"Financial toxicity in lung cancer: an assessment of magnitude, perception, and impact on quality of life","googleId":"GVryPl7ojioJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354122","googleCitationCount":8,"googleAuthor":"W Fu","doi":"10.1016/j.annonc.2019.10.006","elsevierAuthor":"Hazell S.Z.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"7","altmetricAuthors":["S.Z. Hazell","W. Fu","C. Hu","K.R. Voong","B. Lee","V. Peterson","J.L. Feliciano","L.H. Nicholas","T.R. McNutt","P. Han","R.K. Hales"],"twitterCount":32,"altmetricId":73863216,"statusesArray":["1262727241676529664","1256916931082424320","1232055958051991554","1225253500000624640","1218947376163041280","1218293139879931904","1218170408496701440","1218169663139516417","1218129378225348608","1217475736346546177","1216672044714057728","1216642021303209986","1216585288337805313","1216423145785167873","1216371362647945218","1216357218792001536","1216291906654740482","1216234601804443648","1216073429171896321","1216039709132173312","1216019961291755522","1216017875590209536","1215989381351313408","1215988960566169600","1215980571727474689","1215977719453962240","1215968233347584001","1215932738705948672","1215898445971513344","1215895086095130625","1215876502501384193","1215869845008461827","1215802855228985345","1215799356801970176","1215794918007832576","1215794500192415744","1215794347146465281"]},{"title":"Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the …","googleId":"hCOYkeBwsM8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431242","googleCitationCount":4,"googleAuthor":"","doi":"10.1016/j.annonc.2020.10.596","elsevierAuthor":"Dent S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"3","altmetricAuthors":["S. Dent","J. Cortés","Y.-H. Im","V. Diéras","N. Harbeck","I.E. Krop","T.R. Wilson","N. Cui","F. Schimmoller","J.Y. Hsu","J. He","M. De Laurentiis","S. Sousa","P. Drullinsky","W. Jacot"],"twitterCount":1,"altmetricId":99268804,"statusesArray":["1356174751182565376"]},{"title":"A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant …","googleId":"NTcg08-mTIIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360373","googleCitationCount":10,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.074","elsevierAuthor":"Kolinsky M.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"2","altmetricAuthors":["M.P. Kolinsky","P. Rescigno","D. Bianchini","Z. Zafeiriou","N. Mehra","J. Mateo","V. Michalarea","R. Riisnaes","M. Crespo","I. Figueiredo","S. Miranda","D. Nava Rodrigues","P. Flohr","N. Tunariu","U. Banerji","R. Ruddle","A. Sharp","J. Welti","M. Lambros","S. Carreira","F.I. Raynaud","K.E. Swales","S. Plymate","J. Luo","H. Tovey","N. Porta","R. Slade","L. Leonard","E. Hall","J.S. de Bono"],"twitterCount":15,"altmetricId":78655049,"statusesArray":["1348562935124258816","1344676327002169344","1264891302111588352","1260996027408101377","1260690175165968389","1260683956695052293","1260679187955888129","1260626017389088768","1260620141513097219","1260594968550400002","1260589424943026177","1260587425975472129","1244714938553315332","1244675101825609730","1244675014399528960","1244654773892263945","1244643064179757057","1244625355299786755"]},{"title":"The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer","googleId":"gCdulKRKST0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398690","googleCitationCount":5,"googleAuthor":"G Mauri","doi":"10.1016/j.annonc.2020.05.027","elsevierAuthor":"Mauri G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"5","altmetricAuthors":["G. Mauri","S. Arena","S. Siena","A. Bardelli","A. Sartore-Bianchi"],"twitterCount":1,"altmetricId":94760798,"statusesArray":["1330599034311028737"]},{"title":"Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy☆","googleId":"J6RlTDboOUIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342039788X","googleCitationCount":5,"googleAuthor":"","doi":"10.1016/j.annonc.2020.04.471","elsevierAuthor":"Owen C.N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"5","altmetricAuthors":["C.N. Owen","A.N. Shoushtari","D. Chauhan","D.J. Palmieri","B. Lee","M.W. Rohaan","J. Mangana","V. Atkinson","F. Zaman","A. Young","C. Hoeller","P. Hersey","R. Dummer","M.A. Khattak","M. Millward","S.P. Patel","A. Haydon","D.B. Johnson","S. Lo","C.U. Blank","S. Sandhu","M.S. Carlino","J.M.G. Larkin","A.M. Menzies","G.V. Long"],"twitterCount":2,"altmetricId":81787525,"statusesArray":["1260162354106466304","1259786838643863552"]},{"title":"Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma","googleId":"fSxC-lbZ3fYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359470","googleCitationCount":5,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.014","elsevierAuthor":"Lin G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"4","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases","googleId":"1LpLr0Wqv9IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398355","googleCitationCount":5,"googleAuthor":"O Metzger Filho","doi":"10.1016/j.annonc.2020.05.014","elsevierAuthor":"Metzger Filho O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"4","altmetricAuthors":["O. Metzger Filho","J.P. Leone","T. Li","Z. Tan-Wasielewski","L. Trippa","W.T. Barry","J. Younger","E. Lawler","L. Walker","R.A. Freedman","S.M. Tolaney","I. Krop","E.P. Winer","N.U. Lin"],"twitterCount":36,"altmetricId":83393029,"statusesArray":["1296609324333228034","1296537493697900544","1296450730748936192","1296436409893519360","1271432632623140867","1269256089159077894","1269217173051867136","1268857780984832007","1268804461440491521","1268755595823325185","1268700481741885440","1268689341129375749","1268639969788284928","1268634183976574976","1268617271783677952","1268613291128942593","1268611845155426305","1268602266816315392","1268599328190365696","1268594071154700289","1268593488003768321","1268592957613096961","1268590452929892356","1268587092180897792","1268578900445147147","1268553145111793665","1268550150106071044","1268546473177894912","1268543166833209345","1268526890563878912","1268526679355527170","1268526358180900864","1268517187616210944","1268504048795254784","1268497060690567168","1268487683569070080","1268484427660668928","1268482514546569218","1268480127500984320"]},{"title":"Cisplatin and 5-fluorouracil with or without epidermal growth factor receptor inhibition panitumumab for patients with non-resectable, advanced or metastatic …","googleId":"VF5Q4gDycQIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360740","googleCitationCount":9,"googleAuthor":"","doi":"10.1016/j.annonc.2019.10.018","elsevierAuthor":"Moehler M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"8","altmetricAuthors":["M. Moehler","A. Maderer","P.C. Thuss-Patience","B. Brenner","J. Meiler","T.J. Ettrich","R.-D. Hofheinz","S.E. Al-Batran","A. Vogel","L. Mueller","M.P. Lutz","F. Lordick","M. Alsina","K. Borchert","R. Greil","W. Eisterer","A. Schad","J. Slotta-Huspenina","E. Van Cutsem","S. Lorenzen"],"twitterCount":10,"altmetricId":74361831,"statusesArray":["1223249753783312385","1221544203592916993","1221438829061705728","1221333913077014528","1221327390930034689","1221298416317353986","1221022636546850816","1221015920879030272","1221009833987596288","1220018300522041346"]},{"title":"On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2","googleId":"kB5DSvDfPcAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39892-6/abstract","googleCitationCount":7,"googleAuthor":"","statusesArray":[]},{"title":"First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer","googleId":"8f7oF_DdXqoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35923-8/abstract","googleCitationCount":9,"googleAuthor":"","statusesArray":[]},{"title":"LBA75 Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)","googleId":"bOP91W2he0cJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7506419/","googleCitationCount":6,"googleAuthor":"FR Hirsch","doi":"10.1016/j.annonc.2020.08.2316","elsevierCitationCount":0,"altmetricAuthors":["J. Baena Espinar","V. Torri","J. Whisenant","F.R. Hirsch","J. Rogado","J. de Castro Carpeño","B. Halmos","G.L. Ceresoli","A. Gomez Rueda","M. Tiseo","E. Felip","M. Majem Tarruella","I. Monnet","U. Tapan","H. Wakelee","L-C. Huang","M.C. Garassino","S. Peters","L. Horn","M. Hellmann"],"twitterCount":0,"altmetricId":93976201,"statusesArray":[]},{"title":"KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden","googleId":"xtbxe2Q-DBcJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421702","googleCitationCount":4,"googleAuthor":"D Marinelli","doi":"10.1016/j.annonc.2020.08.2105","elsevierAuthor":"Marinelli D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"2","altmetricAuthors":["D. Marinelli","M. Mazzotta","S. Scalera","I. Terrenato","F. Sperati","L. D'Ambrosio","M. Pallocca","G. Corleone","E. Krasniqi","L. Pizzuti","M. Barba","S. Carpano","P. Vici","M. Filetti","R. Giusti","A. Vecchione","M. Occhipinti","A. Gelibter","A. Botticelli","F. De Nicola","L. Ciuffreda","F. Goeman","E. Gallo","P. Visca","E. Pescarmona","M. Fanciulli","R. De Maria","P. Marchetti","G. Ciliberto","M. Maugeri-Saccà"],"twitterCount":18,"altmetricId":89111944,"statusesArray":["1358954593472958465","1303304523293896705","1300757301666541570","1300737219380916226","1299778809282138112","1299771564905373701","1299766159156416512","1299661073176498176","1299655530307350529","1299655507620311041","1299648639413948416","1299648018044551169","1299636504587841539","1299623632168198144","1299622617993957377","1299601942663041026","1299596735451455488","1299596237705039872"]},{"title":"Germline and sporadic cancers driven by the RAS pathway: parallels and contrasts","googleId":"YVYtYKIrbOsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036378X","googleCitationCount":6,"googleAuthor":"E Burkitt-Wright","doi":"10.1016/j.annonc.2020.03.291","elsevierAuthor":"Dunnett-Kane V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"3","altmetricAuthors":["V. Dunnett-Kane","E. Burkitt-Wright","F.H. Blackhall","A. Malliri","D.G. Evans","C.R. Lindsay"],"twitterCount":6,"altmetricId":79070003,"statusesArray":["1272611049729134595","1272424531815260160","1272271263227154434","1257704862760009728","1257190378924630019","1257078752594604035","1246457338850131973","1246439327179169793"]},{"title":"Deep androgen receptor suppression in prostate cancer exploits sexually dimorphic renal expression for systemic glucocorticoid exposure","googleId":"91b7HY1ETPYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419532252","googleCitationCount":6,"googleAuthor":"M Alyamani","doi":"10.1016/j.annonc.2019.12.002","elsevierAuthor":"Alyamani M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"3","altmetricAuthors":["M. Alyamani","J. Li","M. Patel","S. Taylor","F. Nakamura","M. Berk","C. Przybycin","E.M. Posadas","R.A. Madan","J.L. Gulley","B. Rini","J.A. Garcia","E.A. Klein","N. Sharifi"],"twitterCount":29,"altmetricId":75950997,"statusesArray":["1255042100724367361","1254887227680854018","1254866841455022080","1254863458635354112","1254863021567959040","1254859703269507072","1254065013922377730","1236415542107549696","1230616762087018501","1229485793518989318","1229414926197936128","1228672065042911234","1228641446317547520","1228637354753085441","1228473908032090117","1228361904340557825","1228358996916101121","1228358924249763841","1228349679282376704","1228319707905875976","1228318601188446213","1228314705741041664","1228312579744915456","1228311436423843842","1228311426160353280","1228311378697555968","1228073680552378368","1228038145029156866","1227975002097479688","1227972408205815810","1227965628675264513","1227953786578063360","1227833967589707776","1227791197197832192","1227733051062575104","1227726420442583040","1227720322952114177","1227707587665309702","1227705210027507712"]},{"title":"Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and …","googleId":"isIGEcf3ApYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43146-1/abstract","googleCitationCount":3,"googleAuthor":"C Ay","statusesArray":[]},{"title":"Supporting clinical decision making in advanced melanoma by preclinical testing in personalized immune-humanized xenograft mouse models","googleId":"yA3kiA1zyioJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419390830","googleCitationCount":5,"googleAuthor":"H Jespersen","doi":"10.1016/j.annonc.2019.11.002","elsevierAuthor":"Ny L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"0","altmetricAuthors":["L. Ny","L.Y. Rizzo","V. Belgrano","J. Karlsson","H. Jespersen","L. Carstam","R.O. Bagge","L.M. Nilsson","J.A. Nilsson"],"twitterCount":8,"altmetricId":73711313,"statusesArray":["1358094350157287432","1252997051220099072","1215066306329772032","1214832825188274181","1214828922602500096","1214678248485007360","1214615842899595264","1214552972664946688","1214547227554844672"]},{"title":"Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and …","googleId":"oV6uMfar37cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419354055","googleCitationCount":7,"googleAuthor":"","doi":"10.1016/j.annonc.2019.09.004","elsevierAuthor":"Kundranda M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0","altmetricAuthors":["M. Kundranda","A.C. Gracian","S.F. Zafar","E. Meiri","J. Bendell","H. Algül","F. Rivera","E.R. Ahn","D. Watkins","U. Pelzer","V. Charu","A. Zalutskaya","G. Kuesters","J.M. Pipas","S. Santillana","V. Askoxylakis","A.H. Ko"],"twitterCount":1,"altmetricId":73785684,"statusesArray":["1215229244529422337"]},{"title":"Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types","googleId":"vIN32Nud6uEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360703","googleCitationCount":5,"googleAuthor":"V Ivaturi","doi":"10.1016/j.annonc.2019.10.015","elsevierAuthor":"Zhao X.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"2","altmetricAuthors":["X. Zhao","J. Shen","V. Ivaturi","M. Gopalakrishnan","Y. Feng","B.J. Schmidt","P. Statkevich","V. Goodman","J. Gobburu","A. Bello","A. Roy","S. Agrawal"],"twitterCount":12,"altmetricId":74351416,"statusesArray":["1227993445781864450","1227930797786763264","1227895574038536193","1227840901650829312","1227837252568526849","1227821184638750720","1227819965388075011","1227796794169602048","1227791763135270913","1223823364961132545","1223823238687363074","1219948372808949760"]},{"title":"Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer","googleId":"QHmAlpzWXncJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420364140","googleCitationCount":3,"googleAuthor":"S Dutta","doi":"10.1016/j.annonc.2020.03.309","elsevierAuthor":"Halabi S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-07-01","elsevierCoverDisplayDate":"July 2020","elsevierCitationCount":"2","altmetricAuthors":["S. Halabi","S. Dutta","C.M. Tangen","M. Rosenthal","D.P. Petrylak","I.M. Thompson","K.N. Chi","J.S. De Bono","J.C. Araujo","C. Logothetis","M.A. Eisenberger","D.I. Quinn","K. Fizazi","M.J. Morris","C.S. Higano","I.F. Tannock","E.J. Small","W.K. Kelly"],"twitterCount":11,"altmetricId":79834251,"statusesArray":["1276183374319804416","1256213091672559617","1256049656389349377","1255944525085802497","1255944321376927744","1253680305409527808","1250961032215818240","1250866873970950144","1250789631395868672","1250786364322246657","1250785123903197185","1250364257402630145"]},{"title":"Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: Pooled analysis of 6501 patients treated with fluorouracil …","googleId":"u1LOP2qmqCEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342035924X","googleCitationCount":5,"googleAuthor":"J Yin","doi":"10.1016/j.annonc.2019.12.007","elsevierAuthor":"Salem M.E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"5","altmetricAuthors":["M.E. Salem","J. Yin","R.M. Goldberg","L.D. Pederson","N. Wolmark","S.R. Alberts","J. Taieb","J.L. Marshall","S. Lonardi","T. Yoshino","R.S. Kerr","G. Yothers","A. Grothey","T. Andre","A. De Gramont","Q. Shi"],"twitterCount":5,"altmetricId":76551115,"statusesArray":["1259494676551303169","1249810797401911305","1244317981447835648","1244254578260000768","1244254545208840193","1244254241612607490","1244252481057705984","1231502281176166404"]},{"title":"Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer","googleId":"XU9SkaKn8nwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398902","googleCitationCount":5,"googleAuthor":"F Ruiz-Pace","doi":"10.1016/j.annonc.2020.06.003","elsevierAuthor":"Serna G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"4","altmetricAuthors":["G. Serna","F. Ruiz-Pace","J. Hernando","L. Alonso","R. Fasani","S. Landolfi","R. Comas","J. Jimenez","E. Elez","S. Bullman","J. Tabernero","J. Capdevila","R. Dienstmann","P. Nuciforo"],"twitterCount":30,"altmetricId":84535116,"statusesArray":["1290682414562385921","1290681332742279168","1284783366869590016","1277554258884415490","1276560991229100035","1276075050261712896","1276033460801540096","1275841842815414272","1275829173848809473","1275799890577240065","1275799325235392512","1275797229979283456","1275648406053101568","1275646767451734023","1275617446091608065","1275575463860150272","1275573481690685440","1275563139694841860","1275559230116937729","1275443722885328896","1275427152255541248","1275426045198512129","1275422843069743106","1275418112939241473","1275418028931457024","1275412423533449217","1275394309903114240","1275368656751357952","1275368035684020224","1275338266858999810"]},{"title":"LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC)±atezolizumab (atezo) for …","googleId":"0EHi1GzH994J","googleLink":"https://www.researchgate.net/profile/Margarita_Donica/publication/345371639_LBA15_Primary_results_from_IMpassion131_a_double-blind_placebo-controlled_randomised_phase_III_trial_of_first-line_paclitaxel_PAC_atezolizumab_atezo_for_unresectable_locally_advancedmetastatic_triple-/links/5fd27161299bf188d40afe50/LBA15-Primary-results-from-IMpassion131-a-double-blind-placebo-controlled-randomised-phase-III-trial-of-first-line-paclitaxel-PAC-atezolizumab-atezo-for-unresectable-locally-advanced-metastatic-trip.pdf","googleCitationCount":6,"googleAuthor":"F André","statusesArray":[]},{"title":"Phase I study of CC-90010, a reversible, oral BET inhibitor in patients with advanced solid tumors and relapsed/refractory non-Hodgkin's lymphoma","googleId":"3_YgXegM5ekJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342036381X","googleCitationCount":5,"googleAuthor":"V Moreno","doi":"10.1016/j.annonc.2020.03.294","elsevierAuthor":"Moreno V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"4","altmetricAuthors":["V. Moreno","J.M. Sepulveda","M. Vieito","T. Hernández-Guerrero","B. Doger","O. Saavedra","O. Ferrero","R. Sarmiento","M. Arias","J. De Alvaro","J. Di Martino","M. Zuraek","T. Sanchez-Pérez","I. Aronchik","E.H. Filvaroff","M. Lamba","B. Hanna","Z. Nikolova","I. Braña"],"twitterCount":4,"altmetricId":78957917,"statusesArray":["1282162180033359873","1247106340050423808","1247104277941751809","1246015476066484224"]},{"title":"LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)","googleId":"kAcGkVgOBLYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42357-9/abstract","googleCitationCount":5,"googleAuthor":"PA Ascierto","statusesArray":[]},{"title":"Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase …","googleId":"I3igMxL0WfMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420432211","googleCitationCount":2,"googleAuthor":"","doi":"10.1016/j.annonc.2020.12.013","elsevierAuthor":"Martin M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["M. Martin","C. Zielinski","M. Ruiz-Borrego","E. Carrasco","N. Turner","E.M. Ciruelos","M. Muñoz","B. Bermejo","M. Margeli","A. Anton","Z. Kahan","T. Csöszi","M.I. Casas","L. Murillo","S. Morales","E. Alba","E. Gal-Yam","A. Guerrero-Zotano","L. Calvo","J. de la Haba-Rodriguez","M. Ramos","I. Alvarez","A. Garcia-Palomo","C. Huang Bartlett","M. Koehler","R. Caballero","M. Corsaro","X. Huang","J.A. Garcia-Sáenz","J.I. Chacón","C. Swift","C. Thallinger","M. Gil-Gil"],"twitterCount":24,"altmetricId":96844915,"statusesArray":["1351206546647220231","1351131832327266314","1351104417676861443","1349808513640488962","1345670747746922496","1345521124528984065","1345439249118576641","1345422348263034886","1345383067402326016","1345381012675715072","1345369529241763842","1345328399380692996","1345324620837056512","1345098986856841216","1344409364627644418","1344370588534640643","1344345824101191682","1344342041245986819","1344341559270113292","1344338978502225921","1344316083780644865","1344308886082301953","1344307720325918720","1344306892097552389","1344276062855974913","1344243463143960578","1344242489046097921"]},{"title":"LBA17 ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated …","googleId":"6OIi3uM_3HcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42327-0/abstract","googleCitationCount":16,"googleAuthor":"K Punie","statusesArray":[]},{"title":"NRG1 fusion-driven tumors: biology, detection and the therapeutic role of afatinib and other ErbB-targeting agents","googleId":"wFZhWfqIjIAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424275","googleCitationCount":2,"googleAuthor":"K Tolba","doi":"10.1016/j.annonc.2020.08.2335","elsevierAuthor":"Laskin J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1","altmetricAuthors":["J. Laskin","S.V. Liu","K. Tolba","C. Heining","R.F. Schlenk","P. Cheema","J. Cadranel","M.R. Jones","A. Drilon","A. Cseh","S. Gyorffy","F. Solca","M. Duruisseaux"],"twitterCount":3,"altmetricId":89960698,"statusesArray":["1363551265230376975","1304932914178797573","1304756571717726208"]},{"title":"Relation of cetuximab-induced skin toxicity and early tumor shrinkage in metastatic colorectal cancer patients: results of the randomized phase 3 trial FIRE-3 …","googleId":"XV2yr0JKKhsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341935402X","googleCitationCount":9,"googleAuthor":"","doi":"10.1016/j.annonc.2019.10.001","elsevierAuthor":"Holch J.W.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"January 2020","elsevierCitationCount":"4","altmetricAuthors":["J.W. Holch","S. Held","S. Stintzing","L. Fischer von Weikersthal","T. Decker","A. Kiani","F. Kaiser","T. Heintges","C. Kahl","F. Kullmann","W. Scheithauer","M. Moehler","J.C. von Einem","M. Michl","V. Heinemann"],"twitterCount":3,"altmetricId":73786751,"statusesArray":["1347202142793302018","1215331998757216258","1215235026670899202"]},{"title":"A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance","googleId":"zmKRxmlIizEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342042962X","googleCitationCount":1,"googleAuthor":"J Armenia","doi":"10.1016/j.annonc.2020.10.470","elsevierAuthor":"Tobalina L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["L. Tobalina","J. Armenia","E. Irving","M.J. O'Connor","J.V. Forment"],"twitterCount":5,"altmetricId":92791470,"statusesArray":["1352152878736052225","1352084109993111553","1352082626488659970","1320103367616716806","1319579466515894272","1318821935648833537"]},{"title":"SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients","googleId":"Zqj5W-2vcvcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39340-6/pdf","googleCitationCount":6,"googleAuthor":"","statusesArray":[]},{"title":"LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis","googleId":"EZWUlpk9zG4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42394-4/abstract","googleCitationCount":6,"googleAuthor":"A Desai","statusesArray":[]},{"title":"LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab+ nab-paclitaxel vs placebo+ nab-paclitaxel in previously untreated …","googleId":"pGEc_Be6CZoJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506448/","googleCitationCount":7,"googleAuthor":"LA Emens","doi":"10.1016/j.annonc.2020.08.2244","elsevierCitationCount":0,"altmetricAuthors":["L.A. Emens","S. Adams","C.H. Barrios","V.C. Dieras","H. Iwata","S. Loi","H.S. Rugo","A. Schneeweiss","E.P. Winer","S. Patel","V. Henschel","A. Swat","M. Kaul","L. Molinero","S.Y. Chui","P. Schmid"],"twitterCount":0,"altmetricId":96978182,"statusesArray":[]},{"title":"Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study☆","googleId":"IyIuWeNxY80J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424615","googleCitationCount":4,"googleAuthor":"M Bandini","doi":"10.1016/j.annonc.2020.09.011","elsevierAuthor":"Bandini M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","googleId":"pm3rPH33oj0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431278","googleCitationCount":2,"googleAuthor":"V Subbiah","doi":"10.1016/j.annonc.2020.10.599","elsevierAuthor":"Subbiah V.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial …","googleId":"BcY_nKhaYsAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419406996","googleCitationCount":9,"googleAuthor":"","doi":"10.1016/j.annonc.2019.11.011","elsevierAuthor":"Berthold F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"8","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency …","googleId":"eB5pYc9dvNoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420429631","googleCitationCount":2,"googleAuthor":"","doi":"10.1016/j.annonc.2020.10.471","elsevierAuthor":"Fasching P.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"1","altmetricAuthors":["P.A. Fasching","T. Link","J. Hauke","F. Seither","C. Jackisch","P. Klare","S. Schmatloch","C. Hanusch","J. Huober","A. Stefek","S. Seiler","W.D. Schmitt","C. Uleer","G. Doering","K. Rhiem","A. Schneeweiss","K. Engels","C. Denkert","R.K. Schmutzler","E. Hahnen","M. Untch","N. Burchardi","J.-U. Blohmer","S. Loibl"],"twitterCount":1,"altmetricId":93594015,"statusesArray":["1323209662079160320"]},{"title":"Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2","googleId":"OGdnRJIW5yQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420429655","googleCitationCount":2,"googleAuthor":"A Marra","doi":"10.1016/j.annonc.2020.10.473","elsevierAuthor":"Marra A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["A. Marra","D. Generali","P. Zagami","V. Cervoni","S. Gandini","S. Venturini","S. Morganti","R. Passerini","R. Orecchia","G. Curigliano"],"twitterCount":2,"altmetricId":93193138,"statusesArray":["1321051217192075264","1320969259338493952"]},{"title":"Using methylation signatures on cell-free DNA for early cancer detection: a new era in liquid biopsy?","googleId":"3NGeYrZpslsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36411-5/pdf","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3–5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK …","googleId":"i0zThZVYZvUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398379","googleCitationCount":2,"googleAuthor":"","doi":"10.1016/j.annonc.2020.05.016","elsevierAuthor":"McMillan A.K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"1","altmetricAuthors":["A.K. McMillan","E.H. Phillips","A.A. Kirkwood","S. Barrans","C. Burton","S. Rule","R. Patmore","R. Pettengell","K.M. Ardeshna","A. Lawrie","S. Montoto","S. Paneesha","L. Clifton-Hadley","D.C. Linch"],"twitterCount":3,"altmetricId":82998103,"statusesArray":["1266630572295716864","1266346056377237505","1266310075171233792"]},{"title":"Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal …","googleId":"UlM1IW-p1Y4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360764","googleCitationCount":7,"googleAuthor":"","doi":"10.1016/j.annonc.2019.10.019","elsevierAuthor":"Barbour A.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"6","altmetricAuthors":["A.P. Barbour","E.T. Walpole","G.T. Mai","E.H. Barnes","D.I. Watson","S.P. Ackland","J.M. Martin","M. Burge","R. Finch","C.S. Karapetis","J. Shannon","L.M. Nott","S. Varma","G. Marx","G.L. Falk","V. Gebski","M. Oostendorp","K. Wilson","J. Thomas","G. Lampe","J.R. Zalcberg","J. Simes","B.M. Smithers","A. Barbour","J. Simes","E. Walpole","T. Mai","D. Watson","C. Karapetis","V. Gebski","L. Barnes","M. Oostendorp","K. Wilson"],"twitterCount":7,"altmetricId":74373005,"statusesArray":["1234267533689024512","1222773387199533056","1222463416838680578","1222297036369719296","1222295998233399298","1222273413571432448","1220136326000832512","1220113799694340096"]},{"title":"A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland","googleId":"v3_4HwlBkOgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359287","googleCitationCount":4,"googleAuthor":"","doi":"10.1016/j.annonc.2020.01.007","elsevierAuthor":"Panje C.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"3","altmetricAuthors":["C.M. Panje","J.E. Lupatsch","M. Barbier","E. Pardo","M. Lorez","K.J. Dedes","D.M. Aebersold","L. Plasswilm","O. Gautschi","M. Schwenkglenks"],"twitterCount":26,"altmetricId":74897915,"statusesArray":["1224536862334824449","1224422893200855041","1224413068593111041","1224402526113542144","1224394187094876161","1224347874730766338","1224298968282214400","1224219810445303808","1224192787895201793","1224183173459791872","1224140473637359616","1224116149358682112","1224099275740712964","1224080949559939072","1224051978239647745","1224051416764944387","1224051032474284032","1224050500703870977","1224034499547320320","1224030813278416896","1224000480269013000","1223997307152162817","1223994984090808320","1223989327538966528","1223912576029011968","1223902412957614081","1223878777387802630"]},{"title":"Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm …","googleId":"iZS6BqeHw0oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424457","googleCitationCount":5,"googleAuthor":"","doi":"10.1016/j.annonc.2020.09.004","elsevierAuthor":"Kalinsky K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"3","altmetricAuthors":["K. Kalinsky","J.R. Diamond","L.T. Vahdat","S.M. Tolaney","D. Juric","J. O'Shaughnessy","R.L. Moroose","I.A. Mayer","V.G. Abramson","D.M. Goldenberg","R.M. Sharkey","P. Maliakal","Q. Hong","T. Goswami","W.A. Wegener","A. Bardia"],"twitterCount":11,"altmetricId":92299517,"statusesArray":["1334030893883781120","1333753147127455744","1333712053303988226","1333678582204420096","1333640861352161280","1333580483209342976","1333517883880554496","1333472403108880386","1333464638952968193","1333426349051174912","1333378037421903877"]},{"title":"Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma Network","googleId":"ovIZTPCnhxIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420422975","googleCitationCount":6,"googleAuthor":"B Bjerkehagen","doi":"10.1016/j.annonc.2020.08.2232","elsevierAuthor":"Demetri G.D.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"1","altmetricAuthors":["G.D. Demetri","C.R. Antonescu","B. Bjerkehagen","J.V.M.G. Bovée","K. Boye","M. Chacón","A.P. Dei Tos","J. Desai","J.A. Fletcher","H. Gelderblom","S. George","A. Gronchi","R.L. Haas","N. Hindi","P. Hohenberger","H. Joensuu","R.L. Jones","I. Judson","Y.-K. Kang","A. Kawai","A.J. Lazar","A. Le Cesne","R. Maestro","R.G. Maki","J. Martín","S. Patel","F. Penault-Llorca","C. Premanand Raut","P. Rutkowski","A. Safwat","M. Sbaraglia","I.-M. Schaefer","L. Shen","C. Serrano","P. Schöffski","S. Stacchiotti","K. Sundby Hall","W.D. Tap","D.M. Thomas","J. Trent","C. Valverde","W.T.A. van der Graaf","M. von Mehren","A. Wagner","E. Wardelmann","Y. Naito","J. Zalcberg","J.-Y. Blay"],"twitterCount":7,"altmetricId":89644708,"statusesArray":["1319936319297040384","1319387436494053376","1319230892846600193","1318869284660137985","1303304394830688258","1303277003941072896","1303242307869704192"]},{"title":"610O Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration …","googleId":"xKUe8dng_18J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40866-X/abstract","googleCitationCount":7,"googleAuthor":"JS De Bono","statusesArray":[]},{"title":"1670O Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international …","googleId":"6nXSg6NqKoEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41731-4/abstract","googleCitationCount":5,"googleAuthor":"L Turtle","statusesArray":[]},{"title":"LBA33 Maintenance olaparib plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced high‐grade ovarian carcinoma (HGOC): Final analysis …","googleId":"kq7OkdAsJe4J","googleLink":"https://www.clearityfoundation.org/wp-content/uploads/2020/10/PAOLA-ESMO-2020-PFS2-abstract.pdf","googleCitationCount":4,"googleAuthor":"F Heitz","statusesArray":[]},{"title":"Circulating breast-derived DNA allows universal detection and monitoring of localized breast cancer","googleId":"l1i8PadHgp0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419417201","googleCitationCount":10,"googleAuthor":"J Moss","doi":"10.1016/j.annonc.2019.11.014","elsevierAuthor":"Moss J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-03-01","elsevierCoverDisplayDate":"March 2020","elsevierCitationCount":"6","altmetricAuthors":["J. Moss","A. Zick","A. Grinshpun","E. Carmon","M. Maoz","B.L. Ochana","O. Abraham","O. Arieli","L. Germansky","K. Meir","B. Glaser","R. Shemer","B. Uziely","Y. Dor"],"twitterCount":1,"altmetricId":76222604,"statusesArray":["1229476880962793474"]},{"title":"COVID-19-associated pancytopenia can be self-limiting and does not necessarily warrant bone marrow biopsy for the purposes of SARS-CoV-2 diagnostics","googleId":"MQdfYqHRA2cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42470-6/abstract","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label …","googleId":"q1UetUI2wV8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424627","googleCitationCount":2,"googleAuthor":"L Marandino","doi":"10.1016/j.annonc.2020.09.012","elsevierAuthor":"Giannatempo P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis","googleId":"c05vsIrp3r4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39819-7/abstract","googleCitationCount":5,"googleAuthor":"JO Prior","statusesArray":[]},{"title":"LBA-3 CheckMate 459: Long-term (minimum follow-up 33.6 months) survival outcomes with nivolumab versus sorafenib as first-line treatment in patients with …","googleId":"-v0Tk5oGjH0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39377-7/pdf","googleCitationCount":4,"googleAuthor":"B Sangro","statusesArray":[]},{"title":"First case of persistent pancytopenia associated with SARS-CoV-2 bone marrow infiltration in an immunocompromised patient","googleId":"tIxXVvHlttgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39926-9/abstract","googleCitationCount":7,"googleAuthor":"","statusesArray":[]},{"title":"807O Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label …","googleId":"TRWintnmUhMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40942-1/abstract","googleCitationCount":6,"googleAuthor":"J Hamanishi","statusesArray":[]},{"title":"Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high …","googleId":"8DPJXcTZz80J","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/health-related-quality-of-life-hrqol-in-patients-pts-treated-with","googleCitationCount":4,"googleAuthor":"T André","doi":"10.1016/j.annonc.2020.08.507","elsevierAuthor":"van Oorschot B.","publicationName":"Onkologe","elsevierCoverDate":"2020-01-01","elsevierCoverDisplayDate":"2020","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort","googleId":"TfnNe6HwQuwJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399701","googleCitationCount":3,"googleAuthor":"T Becker","doi":"10.1016/j.annonc.2020.07.013","elsevierAuthor":"Becker T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"2","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Choice of control tissue impacts designation of germline variants in a cohort of papillary thyroid carcinoma patients","googleId":"_e6JKDqnzZEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360749","googleCitationCount":3,"googleAuthor":"JC Rubinstein","doi":"10.1016/j.annonc.2020.02.013","elsevierAuthor":"Rubinstein J.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-06-01","elsevierCoverDisplayDate":"June 2020","elsevierCitationCount":"2","altmetricAuthors":["J.C. Rubinstein","N.G. Nicolson","D. Rottmann","R. Morotti","R. Korah","T. Carling","E.R. Christison-Lagay"],"twitterCount":1,"altmetricId":77499686,"statusesArray":["1239337614164946944"]},{"title":"Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group","googleId":"iCJbfUNKaOAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398240","googleCitationCount":2,"googleAuthor":"M Vazquez","doi":"10.1016/j.annonc.2020.05.008","elsevierAuthor":"De Mattos-Arruda L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"0","altmetricAuthors":["L. De Mattos-Arruda","M. Vazquez","F. Finotello","R. Lepore","E. Porta","J. Hundal","P. Amengual-Rigo","C.K.Y. Ng","A. Valencia","J. Carrillo","T.A. Chan","V. Guallar","N. McGranahan","J. Blanco","M. Griffith"],"twitterCount":15,"altmetricId":84898338,"statusesArray":["1306247772207800322","1278631405258301440","1278286987783520259","1277613121847386114","1277602904514363393","1277565826934112256","1277558811272847361","1277546992332345344","1277542536333099008","1277542346465427456","1277541732717117443","1277541545927946240","1277539688132345857","1277528842186481665","1277527447475572736","1277526268922204160","1277526052546523137","1277523140621582336"]},{"title":"Patient-reported outcomes from the phase III IMpassion130 trial of atezolizumab plus nab-paclitaxel in metastatic triple-negative breast cancer","googleId":"0vkxjvhVkyQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360385","googleCitationCount":4,"googleAuthor":"CH Barrios","doi":"10.1016/j.annonc.2020.02.003","elsevierAuthor":"Adams S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"2","altmetricAuthors":["S. Adams","V. Diéras","C.H. Barrios","E.P. Winer","A. Schneeweiss","H. Iwata","S. Loi","S. Patel","V. Henschel","S.Y. Chui","H.S. Rugo","L.A. Emens","P. Schmid"],"twitterCount":53,"altmetricId":76565337,"statusesArray":["1263822080291647490","1256132699170893825","1253255719152955393","1253213380350967810","1253128374022737924","1253110208890417152","1253104033407160321","1253082591273660419","1253070076829487111","1253063767002361858","1253050305907953677","1253046459311759360","1253031887137898498","1253031456974176259","1253024498753966087","1253001422695735297","1252998219912695808","1252998053994381314","1252996577498628099","1252973079921332226","1252968668331417601","1252968192760152072","1252965681164886016","1252955573420687360","1252952167268249600","1252951813218852865","1252951106898079744","1252949508016803841","1252945910759374848","1252942794332700672","1252942425464672256","1252941250476552193","1252940906526883840","1252939864645013506","1252938315717844992","1252937425418178562","1252936689355546625","1234377747968991233","1233330946834944000","1232670508182888448","1232670466411827200","1231838216635977730","1231837336012410880","1231804568679350273","1231796726866030592","1231747211828105216","1231720998476619777","1231720093710766081","1231705606983057408","1231699997734785024","1231690147931938816","1231671756429123584","1231665247825645569","1231663209976696832","1231659415746596864","1231656240125747203","1231655879969267714","1231655741016154112","1231654390722891776","1231650601727119360","1231650046975905792"]},{"title":"Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1","googleId":"B2CW9FEl4vAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36377-8/pdf","googleCitationCount":8,"googleAuthor":"M Khettab","statusesArray":[]},{"title":"Lurbinectedin as second-or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16)","googleId":"-1v6hkpFctIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359263","googleCitationCount":5,"googleAuthor":"M Pless","doi":"10.1016/j.annonc.2019.12.009","elsevierAuthor":"Metaxas Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"4","altmetricAuthors":["Y. Metaxas","M. Früh","E.I. Eboulet","F. Grosso","M. Pless","P.A. Zucali","G.L. Ceresoli","M. Mark","M. Schneider","A. Maconi","M. Perrino","C. Biaggi-Rudolf","P. Froesch","S. Schmid","C. Waibel","C. Appenzeller","D. Rauch","R. von Moos"],"twitterCount":1,"altmetricId":74764232,"statusesArray":["1347202146253598720"]},{"title":"LBA49 Durvalumab after chemoradiotherapy in stage III NSCLC: 4-year survival update from the phase III PACIFIC trial","googleId":"Dvs8Q7w8S3kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42363-4/abstract","googleCitationCount":8,"googleAuthor":"C Faivre-Finn","statusesArray":[]},{"title":"Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial","googleId":"8vr7af3IUgUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420429795","googleCitationCount":2,"googleAuthor":"S Lonardi","doi":"10.1016/j.annonc.2020.10.477","elsevierAuthor":"Petrelli F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"1","altmetricAuthors":["F. Petrelli","E. Rulli","R. Labianca","S. Lonardi","G. Rosati","K. Dotti","M. Ronzoni","N. Pella","V. Pusceddu","M. Banzi","M.G. Zampino","M. Yasmina","P. Marchetti","M. Cantore","A. Zaniboni","L. Rimassa","L. Ciuffreda","D. Ferrari","V. Zagonel","E. Maiello","A. Sobrero"],"twitterCount":2,"altmetricId":94437415,"statusesArray":["1344998302295552000","1328576664889151488"]},{"title":"LBA86 Durvalumab (D)±tremelimumab (T)+ platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden …","googleId":"TM6Pc7WbER0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42419-6/abstract","googleCitationCount":3,"googleAuthor":"MC Garassino","statusesArray":[]},{"title":"Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"GxLLSD4jr_0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42107-6/abstract","googleCitationCount":5,"googleAuthor":"M Fassnacht","statusesArray":[]},{"title":"Oral THC: CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial","googleId":"jN_4phlgsKIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399968","googleCitationCount":4,"googleAuthor":"N Lintzeris","doi":"10.1016/j.annonc.2020.07.020","elsevierAuthor":"Grimison P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"2","altmetricAuthors":["P. Grimison","A. Mersiades","A. Kirby","N. Lintzeris","R. Morton","P. Haber","I. Olver","A. Walsh","I. McGregor","Y. Cheung","A. Tognela","C. Hahn","K. Briscoe","M. Aghmesheh","P. Fox","E. Abdi","S. Clarke","S. Della-Fiorentina","J. Shannon","C. Gedye","S. Begbie","J. Simes","M. Stockler"],"twitterCount":53,"altmetricId":88279557,"statusesArray":["1355467886584860673","1303068894488399873","1303068881867636738","1302532824315113477","1302364157128445953","1301288789499883521","1300457185500188674","1299240514076762112","1298418796114448385","1298372341508972546","1298370057886556161","1298311274737086472","1298205668550348800","1298092326267412480","1298035084524691456","1298023708158656513","1298023506198724609","1298022027123658754","1298021092561432583","1297971652584710145","1297944303675809794","1297939069469679629","1297898700912693248","1297871753406971906","1297869843325235201","1297837765758001152","1297836560562388994","1297833424745529344","1297476886897942529","1297474358818955266","1297473954118959106","1296791363636416513","1296732346469752832","1296455686746931202","1296434731815444481","1296409859727020033","1296406922749517824","1296406738627960833","1296375061264441345","1296353389748449280","1296346959653900288","1296338656890953731","1296312854769885184","1296310453103030272","1296220419381317633","1296218110559580161","1296213039633633280","1296211838959382528","1295672104952766466","1295273007590649857","1295248812487966720","1294764506598510593","1294763378171416577","1294550518321168386","1294530291722145792","1294529684294623232","1294495500775743493","1294409036259930112","1294397395791425536"]},{"title":"711P Nivolumab+ ipilimumab (N+ I) vs sunitinib (S) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214: 4-year follow-up and …","googleId":"aOAvqOoWvWwJ","googleLink":"https://www.researchgate.net/profile/Shruti_Saggi3/publication/345365652_711P_Nivolumab_ipilimumab_NI_vs_sunitinib_S_for_first-line_treatment_of_advanced_renal_cell_carcinoma_aRCC_in_CheckMate_214_4-year_follow-up_and_subgroup_analysis_of_patients_pts_without_nephrectomy/links/5fd7f6ad299bf140880f5a58/711P-Nivolumab-ipilimumab-N-I-vs-sunitinib-S-for-first-line-treatment-of-advanced-renal-cell-carcinoma-aRCC-in-CheckMate-214-4-year-follow-up-and-subgroup-analysis-of-patients-pts-without-nephrectom.pdf","googleCitationCount":5,"googleAuthor":"","statusesArray":[]},{"title":"LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration","googleId":"fQ1BwQoC3VMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506393/","googleCitationCount":2,"googleAuthor":"S Banerjee","doi":"10.1016/j.annonc.2020.08.2311","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study","googleId":"QkknrtoEKU8J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342043203X","googleCitationCount":1,"googleAuthor":"H Gogas","doi":"10.1016/j.annonc.2020.12.004","elsevierAuthor":"Gogas H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Height as a mediator of sex differences in cancer risk","googleId":"ksLu85g_VUQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360579","googleCitationCount":1,"googleAuthor":"BC Fu","doi":"10.1016/j.annonc.2020.02.010","elsevierAuthor":"Fu B.C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"1","altmetricAuthors":["B.C. Fu","M. Song","X. Li","J. Han","H.O. Adami","E.L. Giovannucci","L.A. Mucci"],"twitterCount":3,"altmetricId":78552317,"statusesArray":["1244461858498592770","1244461731599933441","1244180822288224256"]},{"title":"Defining COVID-19 outcomes in thoracic cancer patients: TERAVOLT (Thoracic cancERs international coVid 19 cOLlaboraTion)","googleId":"DUSRbOqE4pcJ","googleLink":"https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-804086","googleCitationCount":3,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2316","elsevierCitationCount":0,"altmetricAuthors":["J. Baena Espinar","V. Torri","J. Whisenant","F.R. Hirsch","J. Rogado","J. de Castro Carpeño","B. Halmos","G.L. Ceresoli","A. Gomez Rueda","M. Tiseo","E. Felip","M. Majem Tarruella","I. Monnet","U. Tapan","H. Wakelee","L-C. Huang","M.C. Garassino","S. Peters","L. Horn","M. Hellmann"],"twitterCount":0,"altmetricId":93976201,"statusesArray":[]},{"title":"Safety and Efficacy of Quavonlimab, a Novel Anti–CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non–Small Cell …","googleId":"EMt4b0AZKioJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431758","googleCitationCount":1,"googleAuthor":"J Bar","doi":"10.1016/j.annonc.2020.11.020","elsevierAuthor":"Perets R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"1","altmetricAuthors":["R. Perets","J. Bar","D.W. Rasco","M.-J. Ahn","K. Yoh","D.-W. Kim","A. Nagrial","M. Satouchi","D.H. Lee","D.R. Spigel","D. Kotasek","M. Gutierrez","J. Niu","S. Siddiqi","X. Li","J. Cyrus","A. Chackerian","A. Chain","R.A. Altura","B.C. Cho"],"twitterCount":3,"altmetricId":95487764,"statusesArray":["1336077658380177409","1335222779386314753","1335178111168565248"]},{"title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS–ESMO–ESTRO Clinical Practice Guidelines for diagnosis, treatment and …","googleId":"btiWx0H14-kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39949-X/abstract","googleCitationCount":3,"googleAuthor":"JP Machiels","statusesArray":[]},{"title":"Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from …","googleId":"hSYq1dqDOMAJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399300","googleCitationCount":17,"googleAuthor":"F Montemurro","doi":"10.1016/j.annonc.2020.06.020","elsevierAuthor":"Montemurro F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"7","altmetricAuthors":["F. Montemurro","S. Delaloge","C.H. Barrios","R. Wuerstlein","A. Anton","E. Brain","T. Hatschek","C.M. Kelly","C. Peña-Murillo","M. Yilmaz","M. Donica","P. Ellis"],"twitterCount":33,"altmetricId":85266009,"statusesArray":["1313793759142834184","1293688863836315648","1285706719952343040","1280821649965830144","1280767865616883712","1280626938936254467","1280591828266422274","1280527893274247168","1280483291246858240","1280481270061907970","1280470354935365633","1280466456535318530","1280426451674845186","1280418818662293504","1280415535117803520","1280409720424140800","1280402612718886914","1280302668213338112","1280283117497077761","1280250815740076032","1280182868564639744","1280177198163529731","1280176124031569925","1280168217709854720","1280162092822257664","1280144503668707331","1280144230913056768","1280128111015866368","1280103474475094016","1280096990215446529","1280074729974530048","1280065706244157442","1280064790149431296","1279821370608816128"]},{"title":"The FDA approval of pembrolizumab for patients with TMB> 10 mut/Mb: was it a wise decision? No","googleId":"5auEc2zWw9YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534%2820%2939935-X/fulltext","googleCitationCount":5,"googleAuthor":"V Prasad","statusesArray":[]},{"title":"HSD3B1 (1245A> C) germline variant and clinical outcomes in metastatic castration-resistant prostate cancer patients treated with abiraterone and enzalutamide …","googleId":"5sMQNP-womEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398938","googleCitationCount":3,"googleAuthor":"","doi":"10.1016/j.annonc.2020.06.006","elsevierAuthor":"Khalaf D.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"2","altmetricAuthors":["D.J. Khalaf","I.M. Aragón","M. Annala","R. Lozano","S. Taavitsainen","D. Lorente","D.L. Finch","N. Romero-Laorden","J. Vergidis","Y. Cendón","C. Oja","M.I. Pacheco","M. Zulfiqar","M.E. Gleave","A.W. Wyatt","D. Olmos","K.N. Chi","E. Castro","E. Almagro","J.Á. Arranz","E.G. Billalabeitia","P. Borrega","E. Castro","J.A. Contreras","M. Domenech","R. Escribano","E. Fernández-Parra","E. Gallardo","I. García-Carbonero","R. García","J. Garde","A. González del Alba","B. González","A. Hernández","S. Hernando","P. Jiménez","N. Laínez","D. Lorente","R. Luque","E. Martínez","A. Medina","M.J. Méndez-Vidal","A. Montesa","R. Morales","Olmos David","J.L. Pérez-Gracia","B. Pérez-Valderrama","Á. Pinto","J. Piulats","J. Puente","R. Querol","A. Rodríguez-Vida","N. Romero-Laorden","M.I. Sáez","S. Vázquez","E. Vélez","J.C. Villa-Guzmán","R. Villatoro","C. Zambrana"],"twitterCount":2,"altmetricId":84599307,"statusesArray":["1276160279118823426","1275731437619163150"]},{"title":"TBCRC 030: a phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: evaluating the homologous recombination deficiency (HRD) …","googleId":"7qknh2GRQdEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420420617","googleCitationCount":3,"googleAuthor":"R Jankowitz","doi":"10.1016/j.annonc.2020.08.2064","elsevierAuthor":"Mayer E.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["E.L. Mayer","V. Abramson","R. Jankowitz","C. Falkson","P.K. Marcom","T. Traina","L. Carey","M. Rimawi","J. Specht","K. Miller","V. Stearns","N. Tung","C. Perou","A.L. Richardson","K. Componeschi","L. Trippa","Z. Tan-Wasielewski","K. Timms","I. Krop","A.C. Wolff","E.P. Winer"],"twitterCount":11,"altmetricId":88510493,"statusesArray":["1348626051656802307","1348239739594432513","1348215315621171200","1348052452680073219","1347957296295510018","1328853506330038272","1296129788755705858","1296127238027513858","1296083618230566912","1296082398455595009","1296081978085855233"]},{"title":"Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final …","googleId":"mBcPlvx_WswJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431667","googleCitationCount":2,"googleAuthor":"F André","doi":"10.1016/j.annonc.2020.11.011","elsevierAuthor":"André F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"1","altmetricAuthors":["F. André","E.M. Ciruelos","D. Juric","S. Loibl","M. Campone","I.A. Mayer","G. Rubovszky","T. Yamashita","B. Kaufman","Y.-S. Lu","K. Inoue","Z. Pápai","M. Takahashi","F. Ghaznawi","D. Mills","M. Kaper","M. Miller","P.F. Conte","H. Iwata","H.S. Rugo"],"twitterCount":2,"altmetricId":95437612,"statusesArray":["1362826114612273156","1356174751182565376"]},{"title":"The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence and mortality","googleId":"AMtRNMqPWowJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42104-0/abstract","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"High-risk neuroblastoma: where do we go?","googleId":"rivzS4g5HZ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)53226-4/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) …","googleId":"ZqggrHkLv20J","googleLink":"https://vbn.aau.dk/en/publications/a-randomised-double-blind-placebo-controlled-phase-ii-trial-of-pa","googleCitationCount":2,"googleAuthor":"MR Mirza","doi":"10.1016/j.annonc.2020.08.2258","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)","googleId":"QS1ZZ_zaKpIJ","googleLink":"https://elibrary.ru/item.asp?id=43977890","googleCitationCount":3,"googleAuthor":"JS de Bono","statusesArray":[]},{"title":"POD1UM-202: phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based …","googleId":"OpsBNuMSgF4J","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/pod1um-202-phase-ii-study-of-retifanlimab-in-patients-pts-with-sq","googleCitationCount":2,"googleAuthor":"D Gilbert","doi":"10.1016/j.annonc.2020.08.2272","elsevierCitationCount":0,"altmetricAuthors":["S. Rao","J. Capdevila","D. Gilbert","S. Kim","L. Dahan","T. Kayyal","M. Fakih","A. Demols","L.H. Jensen","K-L.G. Spindler","D. Arnold","S. Tamberi","M.G. Guren","M. Cornfeld","M. Jones","C. Tian","M. Catlett","J-P. Spano"],"twitterCount":0,"altmetricId":98651286,"statusesArray":[]},{"title":"Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of …","googleId":"wa8O-X7nfCUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420397945","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.04.476","elsevierAuthor":"Seligmann J.F.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"1","altmetricAuthors":["J.F. Seligmann","F. Elliott","S. Richman","G. Hemmings","S. Brown","B. Jacobs","C. Williams","S. Tejpar","J.H. Barrett","P. Quirke","M. Seymour"],"twitterCount":8,"altmetricId":81784703,"statusesArray":["1327294939168993282","1327287761716580353","1295102575352709122","1260161946013351936","1259825977544388610","1259786094188482561","1259780037835993088","1259765456854028288"]},{"title":"Unintended on-target chromosomal instability following CRISPR/Cas9 single gene targeting","googleId":"9Q3W2gWG6YAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39799-4/fulltext","googleCitationCount":3,"googleAuthor":"J Przewrocka","statusesArray":[]},{"title":"A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients …","googleId":"AtSmHrOqayEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431722","googleCitationCount":2,"googleAuthor":"","doi":"10.1016/j.annonc.2020.11.017","elsevierAuthor":"Park S.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"1","altmetricAuthors":["S.H. Park","D.H. Lim","T.S. Sohn","J. Lee","D.Y. Zang","S.T. Kim","J.H. Kang","S.Y. Oh","I.G. Hwang","J.H. Ji","D.B. Shin","J.I. Yu","K.-M. Kim","J.Y. An","M.G. Choi","J.H. Lee","S. Kim","J.Y. Hong","J.O. Park","Y.S. Park","H.Y. Lim","J.M. Bae","W.K. Kang"],"twitterCount":1,"altmetricId":95522970,"statusesArray":["1335540762725896193"]},{"title":"Antitumor activity of ipatasertib combined with chemotherapy: results from a phase Ib study in solid tumors","googleId":"AU74g6Q3CxIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420360543","googleCitationCount":2,"googleAuthor":"JC Soria","doi":"10.1016/j.annonc.2020.02.007","elsevierAuthor":"Isakoff S.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"1","altmetricAuthors":["S.J. Isakoff","J. Tabernero","L.R. Molife","J.-C. Soria","A. Cervantes","N.J. Vogelzang","M.R. Patel","M. Hussain","A. Baron","G. Argilés","P.R. Conkling","D. Sampath","D. Maslyar","P. Patel","W. Chan","S. Gendreau","L. Musib","N. Xu","H. Ma","K. Lin","J. Bendell"],"twitterCount":16,"altmetricId":76993442,"statusesArray":["1255479186917072896","1255389043124248577","1255110075942920192","1235185089593724928","1235146489472716800","1235105630144229381","1235097522214821888","1235082560260042753","1235062762121752577","1234923500814639114","1234887092318154754","1234877031759765504","1234877012369477632","1234872652461989889","1234866902167629824","1234866412667232256","1234853425810112513","1234853295568625665"]},{"title":"Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors","googleId":"NpLNUrSU99cJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420424664","googleCitationCount":1,"googleAuthor":"N Shaverdian","doi":"10.1016/j.annonc.2020.09.016","elsevierAuthor":"Shaverdian N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1","altmetricAuthors":["N. Shaverdian","J. Beattie","M. Thor","M. Offin","A.F. Shepherd","D.Y. Gelblum","A.J. Wu","C.B. Simone","M.D. Hellmann","J.E. Chaft","A. Rimner","D.R. Gomez"],"twitterCount":9,"altmetricId":91734130,"statusesArray":["1316019662392451072","1315827819302313985","1315666046712504320","1315662086601670657","1314882104996638722","1314712671200194560","1313901632556539905","1313897908404658184","1312694984563290112"]},{"title":"Response to WC Taylor, and C. Fiala and EP Diamandis","googleId":"9_bm5usvF2sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39895-1/abstract","googleCitationCount":2,"googleAuthor":"MC Liu","statusesArray":[]},{"title":"Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast …","googleId":"3bfWBaA1ZLQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399348","googleCitationCount":1,"googleAuthor":"SJ Luen","doi":"10.1016/j.annonc.2020.06.024","elsevierAuthor":"Luen S.J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"0","altmetricAuthors":["S.J. Luen","R. Asher","C.K. Lee","P. Savas","R. Kammler","P. Dell’Orto","O.M. Biasi","D. Demanse","W. Hackl","B. Thuerlimann","G. Viale","A. Di Leo","M. Colleoni","M.M. Regan","S. Loi"],"twitterCount":4,"altmetricId":85649524,"statusesArray":["1295687716659658754","1282893683608547333","1282825796982202369","1282219328872603649"]},{"title":"A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer","googleId":"o40t9GGSxQ4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341936082X","googleCitationCount":5,"googleAuthor":"F Saad","doi":"10.1016/j.annonc.2019.10.025","elsevierAuthor":"Sternberg C.N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"3","altmetricAuthors":["C.N. Sternberg","F. Saad","J.N. Graff","A. Peer","U.N. Vaishampayan","E. Leung","E. Rosenbaum","H. Gurney","R.J. Epstein","I.D. Davis","B. Wu","L. Trandafir","V.J. Wagner","M. Hussain"],"twitterCount":13,"altmetricId":74058894,"statusesArray":["1238169739874140162","1238057148837318657","1226269564750659584","1220846190536937473","1218002915253682176","1217970393727848448","1217756362245099520","1217629529155436544","1217623548895907840","1217525338521010178","1217496299303587841","1217492982087266304","1217477225328586753","1217470732684447744"]},{"title":"INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with …","googleId":"JRvuNa6PKCMJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/inovatyon-study-randomized-phase-iii-international-study-comparin","googleCitationCount":3,"googleAuthor":"N Colombo","doi":"10.1016/j.annonc.2020.08.2260","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1581O Estimation of European cancer burden for the year 2020","googleId":"QPFKKZvC4ZoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42388-9/abstract","googleCitationCount":1,"googleAuthor":"G Randi","statusesArray":[]},{"title":"611O Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised …","googleId":"onqsdk_zovkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40867-1/abstract","googleCitationCount":2,"googleAuthor":"N James","statusesArray":[]},{"title":"746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD …","googleId":"f1ZtrVyNfxEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40814-2/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"LBA18 Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP)+ fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth …","googleId":"yNQmpMwzDnQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42328-2/abstract","googleCitationCount":5,"googleAuthor":"F André","statusesArray":[]},{"title":"1421MO Final results and subgroup analysis of the PETRARCA randomized phase II AIO trial: Perioperative trastuzumab and pertuzumab in combination with …","googleId":"ema9cK71UC4J","googleLink":"https://www.researchgate.net/profile/Manfred_Welslau2/publication/345365307_1421MO_Final_results_and_subgroup_analysis_of_the_PETRARCA_randomized_phase_II_AIO_trial_Perioperative_trastuzumab_and_pertuzumab_in_combination_with_FLOT_versus_FLOT_alone_for_HER2_positive_resectabl/links/5ff454db92851c13feebb30e/1421MO-Final-results-and-subgroup-analysis-of-the-PETRARCA-randomized-phase-II-AIO-trial-Perioperative-trastuzumab-and-pertuzumab-in-combination-with-FLOT-versus-FLOT-alone-for-HER2-positive-resectabl.pdf","googleCitationCount":2,"googleAuthor":"SE Al-Batran","statusesArray":[]},{"title":"Disparities in access to oncology clinical trials in Europe in the period 2009-2019","googleId":"GfvWIbZZlTcJ","googleLink":"https://orbi.uliege.be/handle/2268/253768","googleCitationCount":2,"googleAuthor":"M Scheffler","statusesArray":[]},{"title":"Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial","googleId":"Rb9APBwvGqwJ","googleLink":"https://www.researchgate.net/profile/Gerardo_Rosati/publication/344414424_399O_Oxaliplatin_plus_fluoropyrimidines_as_adjuvant_therapy_for_colon_cancer_in_elderly_patients_A_subgroup_analysis_from_TOSCA_trial/links/5f730c5f92851c14bc9d0b0c/399O-Oxaliplatin-plus-fluoropyrimidines-as-adjuvant-therapy-for-colon-cancer-in-elderly-patients-A-subgroup-analysis-from-TOSCA-trial.pdf","googleCitationCount":2,"googleAuthor":"S Lonardi","statusesArray":[]},{"title":"Access to essential anticancer medicines for children and adolescents in Europe","googleId":"HziMoWMSivoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420432235","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.12.015","elsevierAuthor":"Vassal G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["G. Vassal","O. Kozhaeva","S. Griskjane","F. Arnold","K. Nysom","L. Basset","L. Kameric","A. Kienesberger","S. Kamal","N. Cherny","G. Bricalli","N. Latino","P. Kearns"],"twitterCount":1,"altmetricId":97074349,"statusesArray":["1346060655435124736"]},{"title":"BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma","googleId":"OtEn42R-2PMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40645-3/abstract","googleCitationCount":2,"googleAuthor":"V Moreno","statusesArray":[]},{"title":"Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC)","googleId":"dPfXRf0XN6IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39865-3/pdf","googleCitationCount":1,"googleAuthor":"G Pentheroudakis","statusesArray":[]},{"title":"O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced …","googleId":"1JZSKItw8z0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39358-3/pdf","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"861P Limited implementation of the ESMO-ESGO (European Society of Gynaecological Oncology)-ESTRO (European Society for Radiotherapy and Oncology) …","googleId":"DQjMiB7syhcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40996-2/abstract","googleCitationCount":1,"googleAuthor":"N Colombo","statusesArray":[]},{"title":"Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open …","googleId":"a65Afc_uIVMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420429825","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.10.479","elsevierAuthor":"Shi M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"1","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III …","googleId":"Sy5NDsMVpmQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420393133","googleCitationCount":2,"googleAuthor":"M Van der Meulen","doi":"10.1016/j.annonc.2020.04.014","elsevierAuthor":"van der Meulen M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-08-01","elsevierCoverDisplayDate":"August 2020","elsevierCitationCount":"1","altmetricAuthors":["M. van der Meulen","K. Bakunina","M. Nijland","M.C. Minnema","G. Cull","W.B.C. Stevens","J.W. Baars","K.D. Mason","A. Beeker","M. Beijert","M.J.B. Taphoorn","M.J. van den Bent","S. Issa","J.K. Doorduijn","J.E.C. Bromberg","L. Dirven"],"twitterCount":1,"altmetricId":81562246,"statusesArray":["1258341138391609345"]},{"title":"O-3 Efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers: Updated integrated analysis of three clinical trials (STARTRK-2 …","googleId":"2o_TzVK1LlMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39355-8/pdf","googleCitationCount":2,"googleAuthor":"S Siena","statusesArray":[]},{"title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO …","googleId":"E-bxMnWwjMQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420359299","googleCitationCount":4,"googleAuthor":"E Senkus-Konefka","doi":"10.1016/j.annonc.2020.01.008","elsevierAuthor":"Park Y.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-04-01","elsevierCoverDisplayDate":"April 2020","elsevierCitationCount":"3","altmetricAuthors":["Y.H. Park","E. Senkus-Konefka","S.-A. Im","G. Pentheroudakis","S. Saji","S. Gupta","H. Iwata","M.Y. Mastura","R. Dent","Y.-S. Lu","Y. Yin","B.K. Smruti","T. Toyama","S. Malwinder","S.C. Lee","L.-M. Tseng","J.H. Kim","T.-Y. Kim","K.J. Suh","F. Cardoso","T. Yoshino","J.-Y. Douillard"],"twitterCount":2,"altmetricId":78574677,"statusesArray":["1244399552154628096","1244392522375446529"]},{"title":"LBA11 IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab+ chemotherapy in early triple-negative breast cancer (TNBC)","googleId":"LpSzIDhlyR4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42321-X/abstract","googleCitationCount":3,"googleAuthor":"CH Barrios","statusesArray":[]},{"title":"TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma","googleId":"l9-P1qlTW0oJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342042472X","googleCitationCount":1,"googleAuthor":"S Negrier","doi":"10.1016/j.annonc.2020.09.021","elsevierAuthor":"Albiges L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"1","altmetricAuthors":["L. Albiges","P. Barthélémy","M. Gross-Goupil","S. Negrier","M.N. Needle","B. Escudier"],"twitterCount":4,"altmetricId":91750530,"statusesArray":["1351949570872381446","1348105679312048128","1314938577822810113","1312799150006624256"]},{"title":"LBA65 The Canadian Cancer Trials Group PA. 7 trial: Results of a randomized phase II study of gemcitabine (GEM) and nab-paclitaxel (Nab-P) vs GEM, nab-P …","googleId":"7sahSUxK7gUJ","googleLink":"https://www.researchgate.net/profile/Duan_Tu2/publication/345371394_LBA65_The_Canadian_Cancer_Trials_Group_PA7_trial_Results_of_a_randomized_phase_II_study_of_gemcitabine_GEM_and_nab-paclitaxel_Nab-P_vs_GEM_nab-P_durvalumab_D_and_tremelimumab_T_as_first_line_therapy_i/links/5ffbd5a5299bf14088886586/LBA65-The-Canadian-Cancer-Trials-Group-PA7-trial-Results-of-a-randomized-phase-II-study-of-gemcitabine-GEM-and-nab-paclitaxel-Nab-P-vs-GEM-nab-P-durvalumab-D-and-tremelimumab-T-as-first-line-therapy.pdf","googleCitationCount":2,"googleAuthor":"DJ Renouf","statusesArray":[]},{"title":"Olaparib monotherapy as primary treatment in unselected triple negative breast cancer","googleId":"WctsfTsnYgYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431643","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.11.009","elsevierAuthor":"Eikesdal H.P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"1","altmetricAuthors":["H.P. Eikesdal","S. Yndestad","A. Elzawahry","A. Llop-Guevara","B. Gilje","E.S. Blix","H. Espelid","S. Lundgren","J. Geisler","G. Vagstad","A. Venizelos","L. Minsaas","B. Leirvaag","E.G. Gudlaugsson","O.K. Vintermyr","H.S. Aase","T. Aas","J. Balmaña","V. Serra","E.A.M. Janssen","S. Knappskog","P.E. Lønning"],"twitterCount":16,"altmetricId":94847198,"statusesArray":["1335025299571011584","1335018338272096259","1334948517845065729","1334916499262226432","1334911866271715330","1334903139607212033","1334857255167070208","1334828668103831554","1334776413447196674","1334770004684922880","1332829205336244226","1332633843682033665","1332302579007709186","1332278635961544706","1331944070030082048","1331202785786867715"]},{"title":"O-4 NTRK gene fusions in bilio-pancreatic cancers","googleId":"jpa8tI09ZSgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39356-X/pdf","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall …","googleId":"2ZDUJiGd-XEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421556","googleCitationCount":6,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2100","elsevierAuthor":"Papadimitrakopoulou V.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"3","altmetricAuthors":["V.A. Papadimitrakopoulou","T.S. Mok","J.-Y. Han","M.-J. Ahn","A. Delmonte","S.S. Ramalingam","S.W. Kim","F.A. Shepherd","J. Laskin","Y. He","H. Akamatsu","W.S.M.E. Theelen","W.-C. Su","T. John","M. Sebastian","H. Mann","M. Miranda","G. Laus","Y. Rukazenkov","Y.-L. Wu"],"twitterCount":2,"altmetricId":89498619,"statusesArray":["1302043508732235782","1302040332809449472"]},{"title":"Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline-and taxane-refractory metastatic breast cancer: final analysis of …","googleId":"QRVWhbib-mkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431308","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.10.600","elsevierAuthor":"Xu B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["B. Xu","T. Sun","Q. Zhang","P. Zhang","Z. Yuan","Z. Jiang","X. Wang","S. Cui","Y. Teng","X.-C. Hu","J. Yang","H. Pan","Z. Tong","H. Li","Q. Yao","Y. Wang","Y. Yin","P. Sun","H. Zheng","J. Cheng","J. Lu","B. Zhang","C. Geng","J. Liu","K. Shen","S. Yu","H. Li","L. Tang","R. Qiu"],"twitterCount":0,"altmetricId":94484434,"statusesArray":[]},{"title":"1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center","googleId":"UDbt7KJmrIcJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506356/","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1752","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA50 ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non …","googleId":"aTmp9NJ8vX4J","googleLink":"https://www.researchgate.net/profile/Delvys_Rodriguez-Abreu/publication/345365073_LBA51_KEYNOTE-024_5-year_OS_update_First-line_1L_pembrolizumab_pembro_vs_platinum-based_chemotherapy_chemo_in_patients_pts_with_metastatic_NSCLC_and_PD-L1_tumour_proportion_score_TPS_50/links/5fe9ed4292851c13fecfa64a/LBA51-KEYNOTE-024-5-year-OS-update-First-line-1L-pembrolizumab-pembro-vs-platinum-based-chemotherapy-chemo-in-patients-pts-with-metastatic-NSCLC-and-PD-L1-tumour-proportion-score-TPS-50.pdf","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"LBA74 Disparities in cancer during the COVID-19 pandemic: COVID-19 and cancer outcomes study (CCOS)","googleId":"1nHwoT-ld-MJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506490/","googleCitationCount":1,"googleAuthor":"D Doroshow","doi":"10.1016/j.annonc.2020.08.2315","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA72 Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium …","googleId":"Jgu3FxhZB0gJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506465/","googleCitationCount":2,"googleAuthor":"J Warner","doi":"10.1016/j.annonc.2020.08.2313","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Inconsistencies in currently used definitions of sarcopenia in oncology","googleId":"9btYyxZDs9sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)36077-6/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Interpreting the impact of apalutamide on overall survival among patients with non-metastatic castration-resistant prostate cancer","googleId":"Pu7Dv8snPvcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43226-2/abstract","googleCitationCount":2,"googleAuthor":"ZR McCaw","statusesArray":[]},{"title":"Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling","googleId":"clf2XzMQV_EJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420432168","googleCitationCount":1,"googleAuthor":"AM Frankell","doi":"10.1016/j.annonc.2020.12.010","elsevierAuthor":"Ococks E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A case treated with Crizotinib after secondary MET amplification of a double rare L747S and G719S EGFR mutation pulmonary sarcomatoid carcinoma","googleId":"y3r_y9oSAGMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35942-1/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Androgen deprivation therapy may constitute a more effective COVID-19 prophylactic than therapeutic strategy","googleId":"LA6rI0swtecJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42103-9/abstract","googleCitationCount":2,"googleAuthor":"IM Bennani-Baiti","statusesArray":[]},{"title":"1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer","googleId":"JD7DrLjBn8MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41400-0/abstract","googleCitationCount":3,"googleAuthor":"A Drilon","statusesArray":[]},{"title":"1294P RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type","googleId":"mIsXPR15CTYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41604-7/abstract","googleCitationCount":2,"googleAuthor":"E Nadal","statusesArray":[]},{"title":"Tucatinib vs placebo added to trastuzumab and capecitabine in previously treated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB)","googleId":"H7qFJpIuA94J","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/tucatinib-vs-placebo-added-to-trastuzumab-and-capecitabine-in-pre","googleCitationCount":1,"googleAuthor":"S Loi","doi":"10.1016/j.annonc.2020.03.238","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Homozygous HSD3B1 (1245C) inheritance and poor outcomes in metastatic castration-resistant prostate cancer with abiraterone or enzalutamide: what does it mean …","googleId":"nA72TrqVfTIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39896-3/abstract","googleCitationCount":2,"googleAuthor":"N Sharifi","statusesArray":[]},{"title":"1676MO Prevalence and clinical impact of asymptomatic or mildly symptomatic SARSCoV-2 infection among actively treated cancer patients during COVID-19 …","googleId":"AI38wiGVXOsJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/pmc7506461/","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1741","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Exosome-based Liquid Biopsies in Cancer: Opportunities and Challenges","googleId":"54I7jvduNaQJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753421001034","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2021.01.074","elsevierCitationCount":0,"altmetricAuthors":["W. Yu","J. Hurley","D. Roberts","S. Chakrabortty","D. Enderle","M. Noerholm","X.O. Breakefield","J. Skog"],"twitterCount":6,"altmetricId":99669486,"statusesArray":["1361366458736005124","1359955368604934148","1358576973618974727","1358478520574349312","1358379158779400193","1358371312419278850"]},{"title":"The effect of age on the acquisition and selection of cancer driver mutations in sun-exposed normal skin","googleId":"ZNCZq1BgD60J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431990","googleCitationCount":0,"googleAuthor":"B Hernando","doi":"10.1016/j.annonc.2020.11.023","elsevierAuthor":"Hernando B.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"0","altmetricAuthors":["B. Hernando","M. Dietzen","G. Parra","M. Gil-Barrachina","G. Pitarch","L. Mahiques","F. Valcuende-Cavero","N. McGranahan","C. Martinez-Cadenas"],"twitterCount":12,"altmetricId":95871795,"statusesArray":["1352897945612509184","1339342331800064005","1339227021520609281","1339225141490888705","1339222825488551936","1339208602905677831","1339208198004355072","1339207774551633921","1339188722282221569","1339187328514883586","1339184972079443968","1339183374846619650","1337715341279936513"]},{"title":"1410P Safety and efficacy of vibostolimab, an anti-TIGIT antibody, plus pembrolizumab in patients with anti-PD-1/PD-L1-naive NSCLC","googleId":"jGq6KQxpLx8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41720-X/abstract","googleCitationCount":2,"googleAuthor":"A Nagrial","statusesArray":[]},{"title":"A prospective study of type 2 diabetes, metformin use, and risk of breast cancer","googleId":"kgZKawCDuNsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420432144","googleCitationCount":1,"googleAuthor":"KM O'Brien","doi":"10.1016/j.annonc.2020.12.008","elsevierAuthor":"Park Y.M.M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"0","altmetricAuthors":["Y.-M.M. Park","D.B. Bookwalter","K.M. O'Brien","C.L. Jackson","C.R. Weinberg","D.P. Sandler"],"twitterCount":3,"altmetricId":99003273,"statusesArray":["1361390928997531651","1361388509597163521","1354969759104847873"]},{"title":"Androgen deprivation and SARS-CoV-2 in men with prostate cancer","googleId":"fWeuxuYYrWYJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7323668/","googleCitationCount":2,"googleAuthor":"M Koskinen","doi":"10.1016/j.annonc.2020.06.015","elsevierAuthor":"Koskinen M.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"0","altmetricAuthors":["M. Koskinen","O. Carpen","V. Honkanen","M.R.J. Seppänen","P.J. Miettinen","J.A. Tuominen","T. Raivio"],"twitterCount":2,"altmetricId":85165519,"statusesArray":["1281114603854929920","1278993047884165121"]},{"title":"A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical …","googleId":"0DGABh4XKK4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420421714","googleCitationCount":2,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2106","elsevierAuthor":"Amiri-Kordestani L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-12-01","elsevierCoverDisplayDate":"December 2020","elsevierCitationCount":"1","altmetricAuthors":["L. Amiri-Kordestani","D. Xie","S.M. Tolaney","E. Bloomquist","S. Tang","A. Ibrahim","K.B. Goldberg","M.R. Theoret","R. Pazdur","R. Sridhara","E.P. Winer","J.A. Beaver"],"twitterCount":25,"altmetricId":89259831,"statusesArray":["1306386793407811585","1306341525912276995","1306233060229292033","1306231619561365506","1306212796472860675","1306077735870226436","1306075330512257024","1306067809022009345","1306064503998541824","1306057767472463873","1306029390464258050","1306027813246504960","1305985758357065729","1305965361146331139","1305958379265970177","1305923924581126145","1305919036929331206","1305893830277947392","1305887550058364929","1305885178590621697","1305876036324855808","1305854383771602944","1305854287667437569","1302605951523008513","1302597688651919361","1302555678570156033","1300736441371095040"]},{"title":"A meta-analysis of efficacy and safety of cetuximab with biweekly vs. weekly dosing","googleId":"QaM3tlOhPAAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40562-9/abstract","googleCitationCount":1,"googleAuthor":"A Parikh","statusesArray":[]},{"title":"685P A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer …","googleId":"c2htdNIdOQgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42076-9/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours","googleId":"AfUTAaXE7fAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42353-1/abstract","googleCitationCount":2,"googleAuthor":"Z Lwin","statusesArray":[]},{"title":"Important considerations prior to elimination of breast cancer surgery after neoadjuvant systemic therapy: Listening to what our patients want","googleId":"jd_s87TWJ-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39307-8/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"1400P Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC","googleId":"b939U1-GnKgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41710-7/abstract","googleCitationCount":2,"googleAuthor":"DW Kim","statusesArray":[]},{"title":"Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"mtH_jUY2hl0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42469-X/abstract","googleCitationCount":9,"googleAuthor":"","statusesArray":[]},{"title":"1675MO Screening of COVID-19 disease based on chest CT and PCR for cancer patients undergoing radiotherapy in a French coronavirus hotspot","googleId":"bCf50oQfxm4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506406/","googleCitationCount":1,"googleAuthor":"R Sun","doi":"10.1016/j.annonc.2020.08.1740","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Personalized cancer supportive care in COVID-19 era","googleId":"xCatCs0USeYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39817-3/pdf","googleCitationCount":2,"googleAuthor":"GH Lyman","statusesArray":[]},{"title":"P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013)+/-chemotherapy in first-line therapy of advanced/metastatic HER2+ …","googleId":"iIoVroCLPRQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39723-4/pdf","googleCitationCount":1,"googleAuthor":"D Catenacci","statusesArray":[]},{"title":"Successful pregnancy in a cancer patient previously cured of a gestational trophoblastic tumor by immunotherapy","googleId":"jL-uesfRr6YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36076-2/pdf","googleCitationCount":2,"googleAuthor":"PA Bolze","statusesArray":[]},{"title":"1736P Elevated AXL expression following SARS-CoV-2 infection in non-small cell lung cancer","googleId":"rmAOvs9ZKqYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41796-X/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study","googleId":"Tsu3sX5eSsYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420398665","googleCitationCount":3,"googleAuthor":"","doi":"10.1016/j.annonc.2020.05.024","elsevierAuthor":"Van Cutsem E.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-09-01","elsevierCoverDisplayDate":"September 2020","elsevierCitationCount":"2","altmetricAuthors":["E. Van Cutsem","I. Danielewicz","M.P. Saunders","P. Pfeiffer","G. Argilés","C. Borg","R. Glynne-Jones","C.J.A. Punt","A.J. Van de Wouw","M. Fedyanin","D. Stroyakovskiy","H. Kroening","P. Garcia-Alfonso","H. Wasan","A. Falcone","A. Kanehisa","A. Egorov","P. Aubel","N. Amellal","V. Moiseenko"],"twitterCount":13,"altmetricId":83301942,"statusesArray":["1268856718013992961","1268846179720105986","1268501258295533568","1268172768786464768","1268019239669112832","1267993043077967873","1267949800646901760","1267944566231105537","1267922103266934784","1267917594843058178","1267895651280584705","1267880218863243264","1267866998287073280"]},{"title":"Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases","googleId":"KgiU8DlZtzIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40469-7/abstract","googleCitationCount":1,"googleAuthor":"M Fakih","statusesArray":[]},{"title":"1731P Molecular diagnostics for cancer patients and high-risk individuals during the SARS-CoV-2 pandemic at the Institute for Oncology and Radiology of Serbia","googleId":"rCzAkN1XBz8J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506399/","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1795","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA47 Primary analysis of phase II results for cemiplimab in patients (pts) with locally advanced basal cell carcinoma (laBCC) who progress on or are intolerant to …","googleId":"5aUqOdWE4MsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42359-2/abstract","googleCitationCount":1,"googleAuthor":"AJ Stratigos","statusesArray":[]},{"title":"Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group","googleId":"XscrBF8ltDgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375341953229X","googleCitationCount":7,"googleAuthor":"T André","doi":"10.1016/j.annonc.2019.12.006","elsevierAuthor":"André T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"2","altmetricAuthors":["T. André","D. Vernerey","S.A. Im","G. Bodoky","R. Buzzoni","S. Reingold","F. Rivera","J. McKendrick","W. Scheithauer","G. Ravit","G. Fountzilas","W.P. Yong","R. Isaacs","P. Österlund","J.T. Liang","G.J. Creemers","M. Rakez","E. Van Cutsem","D. Cunningham","J. Tabernero","A. de Gramont"],"twitterCount":1,"altmetricId":74361623,"statusesArray":["1220017044600606721"]},{"title":"LBA77 Anti-SARS-CoV-2 antibody response in patients with cancer and oncology healthcare workers: A multicenter, prospective study","googleId":"K8jhajoEZD8J","googleLink":"https://www.researchgate.net/profile/Antonio_Marra2/publication/345371398_LBA77_Anti-SARS-CoV-2_antibody_response_in_patients_with_cancer_and_oncology_healthcare_workers_A_multicenter_prospective_study/links/5faa9f42299bf15bae0638e6/LBA77-Anti-SARS-CoV-2-antibody-response-in-patients-with-cancer-and-oncology-healthcare-workers-A-multicenter-prospective-study.pdf","googleCitationCount":1,"googleAuthor":"A Marra","statusesArray":[]},{"title":"1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)","googleId":"SIrJm2zEaAoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41571-6/abstract","googleCitationCount":1,"googleAuthor":"GJ Riely","statusesArray":[]},{"title":"Immunotherapy for early breast cancer: too soon, too superficial, or just right?","googleId":"sYebn7048YoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431989","googleCitationCount":0,"googleAuthor":"MA Franzoi","doi":"10.1016/j.annonc.2020.11.022","elsevierAuthor":"Franzoi M.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"0","altmetricAuthors":["M.A. Franzoi","E. Romano","M. Piccart"],"twitterCount":3,"altmetricId":95817630,"statusesArray":["1338778013337530371","1338224685205450752","1337350925095198721"]},{"title":"Impact of tucatinib on progression free survival in patients with HER2+ metastatic breast cancer and stable or active brain metastases","googleId":"WOqWRwvqpl8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40391-6/abstract","googleCitationCount":1,"googleAuthor":"NU Lin","statusesArray":[]},{"title":"CN14 The utility of a brief clinical frailty scale (CFS) in predicting prognosis and discharge destination in oncology inpatients","googleId":"2HGbUOJMhjsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42184-2/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer","googleId":"stf_1Rbb89sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40510-1/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"PD-1 Systematic review and meta-analysis of the efficacy of chemotherapeutic regimens in advanced gallbladder cancer: Assessing current practice and …","googleId":"FUMHmJ5sa2EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39756-8/pdf","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) …","googleId":"o5v912RcMqUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40670-2/abstract","googleCitationCount":1,"googleAuthor":"V Moreno","statusesArray":[]},{"title":"833P Mirvetuximab soravtansine (MIRV), a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin (CARBO) and …","googleId":"O2tHeIifR0IJ","googleLink":"https://www.clearityfoundation.org/wp-content/uploads/2020/10/Mirv-and-CarboPt-and-Bev-ESMO-2020-abstract.pdf","googleCitationCount":1,"googleAuthor":"IB Vergote","statusesArray":[]},{"title":"633P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III …","googleId":"uG0jYDN-dI8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40888-9/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"375O Final efficacy results from IMpower132: First-line atezolizumab+ chemotherapy in patients with stage IV non-squamous NSCLC","googleId":"ARmSy5Aheq4J","googleLink":"https://digitalcommons.psjhealth.org/publications/4179/","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"1922P Exploratory patient-reported outcomes among patients with RET-mutant medullary thyroid cancer in LIBRETTO-001: A phase I/II trial of selpercatinib (LOXO …","googleId":"IewcorYOaKoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41406-1/abstract","googleCitationCount":1,"googleAuthor":"DSW Tan","statusesArray":[]},{"title":"1255TiP CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO±ipilimumab (IPI) versus CCRT …","googleId":"HzqNwfiVwEoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40124-3/abstract","googleCitationCount":1,"googleAuthor":"D De Ruysscher","statusesArray":[]},{"title":"735P Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: A multicentric retrospective study","googleId":"LF5K4uty_74J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40803-8/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"1620O Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma","googleId":"QL1UTYzSdDMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41842-3/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"1256TiP Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT …","googleId":"_keJheLVu6QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40147-4/abstract","googleCitationCount":2,"googleAuthor":"T Kato","statusesArray":[]},{"title":"1914MO Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912","googleId":"akhEJ0vvpTcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41398-5/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"LBA48 Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial","googleId":"qgqqPxUMuT8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42360-9/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"810MO Patient-reported outcomes (PROs) in patients (pts) receiving niraparib in the PRIMA/ENGOT-OV26/GOG-3012 trial","googleId":"PDS1Ci9Si98J","googleLink":"https://www.researchgate.net/profile/Lydia_Gaba2/publication/345369214_810MO_Patient-reported_outcomes_PROs_in_patients_pts_receiving_niraparib_in_the_PRIMAENGOT-OV26GOG-3012_trial/links/5fac2cfe45851507810c6247/810MO-Patient-reported-outcomes-PROs-in-patients-pts-receiving-niraparib-in-the-PRIMA-ENGOT-OV26-GOG-3012-trial.pdf","googleCitationCount":1,"googleAuthor":"F Heitz","statusesArray":[]},{"title":"LBA1 Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence","googleId":"1gtQRydSW8EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42361-0/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"973TiP LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell …","googleId":"UtiKVD5wyxkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41084-1/abstract","googleCitationCount":1,"googleAuthor":"LL Siu","statusesArray":[]},{"title":"LBA1 Interim results of a phase I/Ib study of LSZ102, an oral selective estrogen receptor degrader (SERD), in combination with ribociclib (RIB) or alpelisib (ALP) in …","googleId":"JwdSWsqQNjMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39305-4/abstract","googleCitationCount":4,"googleAuthor":"","statusesArray":[]},{"title":"915MO Long-term outcomes from KEYNOTE-048: Pembrolizumab (pembro) alone or with chemotherapy (pembro+ C) vs EXTREME (E) as first-line (1L) therapy for …","googleId":"2qUEWpUGcj4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41026-9/abstract","googleCitationCount":1,"googleAuthor":"R Greil","statusesArray":[]},{"title":"A phase III trial of capivasertib and fulvestrant versus placebo and fulvestrant in patients with HR+/HER2− breast cancer (CAPItello-291)","googleId":"qWpq2Vlgh7wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40448-X/abstract","googleCitationCount":1,"googleAuthor":"H Gomez","statusesArray":[]},{"title":"Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterogeneity to better understand their role in first line and adjuvant therapy","googleId":"kZ9RGUoZLvUJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753421001216","googleCitationCount":0,"googleAuthor":"EC Smyth","doi":"10.1016/j.annonc.2021.02.004","elsevierCitationCount":0,"altmetricAuthors":["E.C. Smyth","V. Gambardella","A. Cervantes","T. Fleitas"],"twitterCount":27,"altmetricId":100296528,"statusesArray":["1363806515547676682","1363480107118166020","1362884511990710285","1362564692011540481","1362233665959256070","1362232481898917893","1362223868237254662","1362223779687125003","1362210166439964672","1362193564319408128","1362164809865834498","1362154934972612615","1362148869858017281","1362148564944715779","1362060703243382789","1362048004744753156","1362033968695160841","1362031524569354241","1362017646909272067","1362011738955276288","1362010876811898882","1362000629695143936","1361995846745804800","1361986445171429381","1361966138972917764","1361946416386605060","1361941123359457282"]},{"title":"nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2-metastatic breast cancer","googleId":"6gZitA8fgOcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40371-0/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations","googleId":"bhmE0KVSISwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41603-5/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"SO-3 Maintenance olaparib in patients aged≥ 65 years with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial","googleId":"8Yv2sJvT6dsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39317-0/pdf","googleCitationCount":1,"googleAuthor":"P Hammel","statusesArray":[]},{"title":"O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or …","googleId":"nVo1n8hbzWQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39364-9/pdf","googleCitationCount":1,"googleAuthor":"M Özgüroğlu","statusesArray":[]},{"title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.","googleId":"67zBGPfQwbgJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420429801","googleCitationCount":0,"googleAuthor":"M Schmitt","doi":"10.1016/j.annonc.2020.10.478","elsevierAuthor":"Schubert M.L.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["M.-L. Schubert","M. Schmitt","L. Wang","C.A. Ramos","K. Jordan","C. Müller-Tidow","P. Dreger"],"twitterCount":14,"altmetricId":93771700,"statusesArray":["1324655640166436865","1324625153607815168","1324598528547659781","1324592978141339648","1324578417891835905","1324547043071807489","1324480940693807106","1324460554434482177","1324443497512857600","1324431191982829568","1324410921100431360","1324409725757345793","1324409403521589250","1324405477879533569"]},{"title":"The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers","googleId":"StuV43LM6-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)43225-0/abstract","googleCitationCount":1,"googleAuthor":"JC Soria","statusesArray":[]},{"title":"Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331","googleId":"jKX7GUineWEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753421000995","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2021.01.071","elsevierCitationCount":0,"altmetricAuthors":["D.R. Spigel","D. Vicente","T.E. Ciuleanu","S. Gettinger","S. Peters","L. Horn","C. Audigier-Valette","N. Pardo Aranda","O. Juan-Vidal","Y. Cheng","H. Zhang","M. Shi","A. Luft","J. Wolf","S. Antonia","K. Nakagawa","J. Fairchild","C. Baudelet","D. Pandya","P. Doshi","H. Chang","M. Reck"],"twitterCount":28,"altmetricId":99279857,"statusesArray":["1364248902728355841","1359937603374612480","1359390598109814786","1359266920541941765","1359255086736760835","1359246121273602052","1359238821213327368","1359232807680245761","1359225044266700801","1359215184917708801","1359210642100600842","1359206154757431298","1359196627911790599","1359195402084433920","1359194058657300481","1359193798480437254","1359193745506328580","1359192647349506050","1359192408219598849","1359192407582117890","1359192265286107138","1359191943021027404","1359187745613176837","1359187480017330176","1358034482150977537","1357661007070384134","1357645662515466240","1357132357782933506","1356542762657669121"]},{"title":"cfDNA analysis from phase I/II study of lerociclib (G1T38), a continuously dosed oral CDK4/6 inhibitor, with fulvestrant in HR+/HER2-advanced breast cancer patients","googleId":"oy-99SWGxfYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40376-X/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"LBA-7 Encorafenib plus cetuximab with or without binimetinib for BRAFV600E metastatic colorectal cancer (mCRC): Relationship between carcinoembryonic …","googleId":"wKjH-Apta5MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39901-4/pdf","googleCitationCount":1,"googleAuthor":"A Grothey","statusesArray":[]},{"title":"1986P MDM2 amplification and hyperprogression following treatment with immune checkpoint inhibitors in advanced non-small cell lung cancer","googleId":"65ykF2K6ZpgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41288-8/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma","googleId":"xer-T65hrJkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)53227-6/abstract","googleCitationCount":1,"googleAuthor":"M Jamal-Hanjani","statusesArray":[]},{"title":"The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers","googleId":"iOb76j34dhEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420429862","googleCitationCount":0,"googleAuthor":"F Lopes","doi":"10.1016/j.annonc.2020.10.483","elsevierAuthor":"Saturno G.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["G. Saturno","F. Lopes","I. Niculescu-Duvaz","D. Niculescu-Duvaz","A. Zambon","L. Davies","L. Johnson","N. Preece","R. Lee","A. Viros","D. Holovanchuk","M. Pedersen","R. McLeary","P. Lorigan","N. Dhomen","C. Fisher","U. Banerji","E. Dean","M.G. Krebs","M. Gore","J. Larkin","R. Marais","C. Springer"],"twitterCount":0,"altmetricId":97330957,"statusesArray":[]},{"title":"Final analysis of the randomized trial on imatinib as an adjuvant in localized gastrointestinal stromal tumors (GIST) from the EORTC Soft Tissue and Bone Sarcoma …","googleId":"M6szgLOiSSsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753421000120","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2021.01.004","elsevierCitationCount":0,"altmetricAuthors":["P.G. Casali","A. Le Cesne","A. Poveda Velasco","D. Kotasek","P. Rutkowski","P. Hohenberger","E. Fumagalli","I.R. Judson","A. Italiano","H. Gelderblom","N. Penel","J.T. Hartmann","F. Duffaud","D. Goldstein","J. Martin Broto","A. Gronchi","E. Wardelmann","S. Marréaud","J.R. Zalcberg","S. Litière","J.-Y. Blay"],"twitterCount":3,"altmetricId":98023573,"statusesArray":["1362683275014201345","1362445822944804865","1352961437531058177","1351832157682081793"]},{"title":"Patients should be the tipping point of individualizing breast cancer surgery: Commentary on 'Eliminating the breast cancer surgery paradigm after neoadjuvant …","googleId":"ULCB3jPL9iUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39844-6/fulltext","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"SO-5 Efficacy of second-line chemotherapy in patients with advanced or metastatic cholangiocarcinoma and FGFR2 fusions: A retrospective analysis","googleId":"Z_pafHY7GMAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39319-4/pdf","googleCitationCount":1,"googleAuthor":"S Roychowdhury","statusesArray":[]},{"title":"Treatment compliance in early-stage anal cancer","googleId":"NqMJpWbtFlgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39941-5/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"3O Mutation analysis of circulating tumour DNA from baseline and study discontinuation samples in SANDPIPER, a phase III study of taselisib or placebo with …","googleId":"OUd4oL6qsqwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36218-9/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancer","googleId":"gKnxvFJ3ChQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40456-9/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"1686P The impact of the COVID-19 crisis on perceived changes in care and wellbeing of cancer patients and norm participants: Results of the PROFILES registry","googleId":"We0CRr7hCNMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506350/","googleCitationCount":1,"googleAuthor":"LV Van de Poll-Franse","doi":"10.1016/j.annonc.2020.08.1750","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1761P Universal screening of SARS-CoV-2 of oncology healthcare workers—a Brazilian experience","googleId":"Pqbx6qaEleoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41821-6/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"CN5 Video consultations with older patients in the oncology nursing outpatient clinic","googleId":"-_HRuKob9zEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42173-8/abstract","googleCitationCount":1,"googleAuthor":"KB Dieperink","statusesArray":[]},{"title":"Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine","googleId":"E6PI733lPH4J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431680","googleCitationCount":0,"googleAuthor":"G Malleo","doi":"10.1016/j.annonc.2020.11.013","elsevierAuthor":"Casolino R.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-02-01","elsevierCoverDisplayDate":"February 2021","elsevierCitationCount":"0","altmetricAuthors":["R. Casolino","C. Braconi","G. Malleo","S. Paiella","C. Bassi","M. Milella","S.B. Dreyer","F.E.M. Froeling","D.K. Chang","A.V. Biankin","T. Golan"],"twitterCount":3,"altmetricId":95129617,"statusesArray":["1333739390024245249","1333573330398564357","1333004810333765632"]},{"title":"O-16 Relative impact of T4 and N2 on the efficacy of 3 versus 6 months of adjuvant CAPOX for high-risk stage II and stage III colon cancer: ACHIEVE and …","googleId":"OdXen-7HWm0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39368-6/pdf","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"FOLFOXIRI versus FOLFOX or FOLFIRI with targeted therapy in patients with mutant BRAF metastatic colorectal cancer: A systematic review and meta-analysis","googleId":"lHaRMqGuDzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40573-3/abstract","googleCitationCount":3,"googleAuthor":"","statusesArray":[]},{"title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or …","googleId":"6Kqwi3HYcAsJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753421000934","googleCitationCount":0,"googleAuthor":"A Brufsky","doi":"10.1016/j.annonc.2021.01.065","elsevierCitationCount":0,"altmetricAuthors":["A. Brufsky","S.B. Kim","Ž. Zvirbule","A. Eniu","J. Mebis","J.H. Sohn","M. Wongchenko","S. Chohan","R. Amin","Y. Yan","V. McNally","D. Miles","S. Loi"],"twitterCount":3,"altmetricId":99272002,"statusesArray":["1357647305134903297","1356602458911481860","1356543219098615811"]},{"title":"SO-20 Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the …","googleId":"gvMOfy8USTMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39334-0/pdf","googleCitationCount":1,"googleAuthor":"E Fontana","statusesArray":[]},{"title":"From astrology to prostate cancer: what is the role of subgroup analyses?","googleId":"kZfkia4YjDEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(19)40700-X/abstract","googleCitationCount":1,"googleAuthor":"C Cattrini","statusesArray":[]},{"title":"1061P TCR and HLA analysis of patients in a phase I/IIa trial of a therapeutic CMV vaccine against recurrent glioblastoma (GBM)","googleId":"t-v6NdueLaIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41177-9/abstract","googleCitationCount":1,"googleAuthor":"DE Anderson","statusesArray":[]},{"title":"Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.","googleId":"upjjLXRaBBIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753421001289","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2021.02.011","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1880P Two thousand consecutive parallel evaluations of Karnofsky and ECOG performance status: looking for a correct comparison","googleId":"QLEyvLxmvE8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41523-6/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor","googleId":"9QCOzUf91I0J","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431709","googleCitationCount":3,"googleAuthor":"","doi":"10.1016/j.annonc.2020.11.015","elsevierAuthor":"El Sharouni M.A.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"2","altmetricAuthors":["M.-A. El Sharouni","M.D. Stodell","T. Ahmed","K.P.M. Suijkerbuijk","A.E. Cust","A.J. Witkamp","V. Sigurdsson","P.J. van Diest","R.A. Scolyer","J.F. Thompson","C.H. van Gils","S.N. Lo"],"twitterCount":6,"altmetricId":95256758,"statusesArray":["1335620998469718018","1335581532904427521","1335513580792377345","1335509907588583424","1335509233492664321","1333729846824878083"]},{"title":"1422MO Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-low, advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results of the …","googleId":"72zpEF70Ye8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41924-6/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"CN37 Monitoring immuno-oncologically treated patients in cancer nursing: A collaborative project","googleId":"srXg3eAts7gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42211-2/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy","googleId":"gVG4FpevHewJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420432247","googleCitationCount":0,"googleAuthor":"C Denkert","doi":"10.1016/j.annonc.2020.12.016","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma","googleId":"sSJ-zTfdk4UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399920","googleCitationCount":0,"googleAuthor":"S Lo","doi":"10.1016/j.annonc.2020.07.016","elsevierAuthor":"Tetzlaff M.T.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["M.T. Tetzlaff","C. Adhikari","S. Lo","R.V. Rawson","R.N. Amaria","A.M. Menzies","J.S. Wilmott","P.M. Ferguson","M.I. Ross","A.J. Spillane","K.A. Vu","J. Ma","J. Ning","L.E. Haydu","R.P.M. Saw","J.A. Wargo","H.A. Tawbi","J.E. Gershenwald","G.V. Long","M.A. Davies","R.A. Scolyer"],"twitterCount":11,"altmetricId":87113805,"statusesArray":["1298061479598600193","1298055869070893056","1297937284617175040","1297936795791958016","1297935831513083904","1297925984193323008","1297871476033380352","1297822882748174341","1297819622981304321","1297816620161593344","1297816170934935552","1290484633247707138"]},{"title":"SO-9 Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs …","googleId":"Z3NhC-ZZ8oUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39323-6/pdf","googleCitationCount":1,"googleAuthor":"T Meyer","statusesArray":[]},{"title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized …","googleId":"8qQvIxMV_pMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753421000089","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.12.018","elsevierAuthor":"Wu X.H.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["X.H. Wu","J.Q. Zhu","R.T. Yin","J.X. Yang","J.H. Liu","J. Wang","L.Y. Wu","Z.L. Liu","Y.N. Gao","D.B. Wang","G. Lou","H.Y. Yang","Q. Zhou","B.H. Kong","Y. Huang","L.P. Chen","G.L. Li","R.F. An","K. Wang","Y. Zhang","X.J. Yan","X. Lu","W.G. Lu","M. Hao","L. Wang","H. Cui","Q.H. Chen","G. Abulizi","X.H. Huang","X.F. Tian","H. Wen","C. Zhang","J.M. Hou","M.R. Mirza"],"twitterCount":1,"altmetricId":97660496,"statusesArray":["1349681000188674048"]},{"title":"Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT","googleId":"bAwZDHJsRAoJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431746","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.11.019","elsevierAuthor":"Cottereau A.S.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"0","altmetricAuthors":["A.-S. Cottereau","M. Meignan","C. Nioche","N. Capobianco","J. Clerc","L. Chartier","L. Vercellino","O. Casasnovas","C. Thieblemont","I. Buvat"],"twitterCount":17,"altmetricId":95522905,"statusesArray":["1364256910384517125","1364181026587758594","1364121491516887040","1363950548668600322","1363913493028741125","1363903755960397825","1363903234310631424","1335951857471066115","1335903900935839745","1335861697115017216","1335819336213176321","1335624987454136322","1335621338577440768","1335606543027466244","1335579723838214145","1335579601691611137","1335540388841414658"]},{"title":"1907P Application of anti-PD1 drugs before or during thoracic radiotherapy increases the incidence of radiation pneumonia compared to the application after …","googleId":"HbLhuA8NzE8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41446-2/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the …","googleId":"xdkDNB4C0BwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41201-3/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): An open-label phase 1/2 trial","googleId":"0OxZ3a_MyosJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420432156","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.12.009","elsevierAuthor":"Yhim H.Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["H.-Y. Yhim","T. Kim","S.J. Kim","H.-J. Shin","Y. Koh","J.S. Kim","J. Park","G.S. Park","W.S. Kim","J.H. Moon","D.-H. Yang"],"twitterCount":7,"altmetricId":96538949,"statusesArray":["1343112871052533760","1342902245797621762","1342866879535337478","1342861421416247297","1342022260484415488","1341817609855983616","1341700477650530310"]},{"title":"Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial","googleId":"j-LWkRc4ZOMJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420429771","googleCitationCount":0,"googleAuthor":"S Haider","doi":"10.1016/j.annonc.2020.10.475","elsevierAuthor":"Sipos O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["O. Sipos","H. Tovey","J. Quist","S. Haider","S. Nowinski","P. Gazinska","S. Kernaghan","C. Toms","S. Maguire","N. Orr","S.C. Linn","J. Owen","C. Gillett","S.E. Pinder","J.M. Bliss","A. Tutt","M.C.U. Cheang","A. Grigoriadis"],"twitterCount":9,"altmetricId":92799517,"statusesArray":["1319740879331074050","1319740637428801537","1319310039828582402","1319262129422323720","1319187539387949064","1319037806015090688","1319037707960635401","1318994531816214528","1318868099278512128"]},{"title":"Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil","googleId":"-L196lui5HQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36409-7/pdf","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"1O Neratinib+ capecitabine vs lapatinib+ capecitabine in HER2+ metastatic breast cancer previously treated with≥ 2 HER2-directed regimens: Exploratory biomarker …","googleId":"Z3alskFNBIEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36216-5/abstract","googleCitationCount":1,"googleAuthor":"H Wildiers","statusesArray":[]},{"title":"P-344 The role of postoperative prognostic nutritional index as a prognostic factor and its association to systemic inflammatory response markers in stage III …","googleId":"N0fam-mBFCAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39725-8/pdf","googleCitationCount":1,"googleAuthor":"I Costa","statusesArray":[]},{"title":"25P Development of new therapeutic drugs for pancreatic cancer targeting choline transporter-like protein 1 (CTL1/SLC44A1)","googleId":"Qsx588Q-PBEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35977-9/abstract","googleCitationCount":1,"googleAuthor":"K Hirai","statusesArray":[]},{"title":"P-172 Prognostic factors in metastatic gastric cancer patients","googleId":"Udry2-13LVsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39553-3/pdf","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"1691P Evaluation of practice variation for cancer patients care in a French cancer center during the COVID-19 outbreak","googleId":"3bCU1IwIjLgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41751-X/abstract","googleCitationCount":0,"googleAuthor":"J Gal","statusesArray":[]},{"title":"1679P Determinants of mortality from SARS-CoV-2 infection in European cancer patients","googleId":"MU0VThtux60J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506408/","googleCitationCount":0,"googleAuthor":"DJ Pinato","doi":"10.1016/j.annonc.2020.08.1743","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research","googleId":"-rRX5-sitHkJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431977","googleCitationCount":0,"googleAuthor":"N Normanno","doi":"10.1016/j.annonc.2020.11.021","elsevierAuthor":"Belli C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"0","altmetricAuthors":["C. Belli","F. Penault-Llorca","M. Ladanyi","N. Normanno","J.-Y. Scoazec","L. Lacroix","J.S. Reis-Filho","V. Subbiah","J.F. Gainor","V. Endris","M. Repetto","A. Drilon","A. Scarpa","F. André","J.-Y. Douillard","G. Curigliano"],"twitterCount":62,"altmetricId":97666921,"statusesArray":["1352614914276225024","1352394234616307712","1352387894237818881","1352386786945884161","1352256231176630272","1352248459630436354","1352240135648251904","1352213473766338561","1352212817194192898","1352209588683157506","1352186750995673088","1352186675963813889","1351790791530852357","1351508460647669764","1351500298460798978","1351482039573348352","1351470049379438592","1351469491482488832","1351417815870410753","1351416782620418049","1350566819417960453","1350517576665862145","1350245138564603908","1350229999396257794","1350156383182876675","1350146417826750467","1350128247074402308","1350112637057720321","1350047422907613186","1350037059256397824","1350028005041721346","1349998193518456833","1349969859107549184","1349967928079376384","1349905599572504579","1349904846011334657","1349876038877253637","1349866607934386176","1349856596604674054","1349849480577728512","1349847645355958276","1349843717813899267","1349843346261495817","1349838360177762313","1349828510693650432","1349828458868826114","1349822102883467265","1349819776760217603","1349819012360900615","1349811633913290762","1349806558184673287","1349806479088484356","1349796013150785557","1349795953734258688","1349794021879803907","1349791256302465026","1349791077360918530","1349788357023432712","1349775819749654534","1349770346786861061","1349769232674906114","1349769146943287296","1349769129629257729","1349767807181991941","1349767066967007232","1349766798426693632","1349766467487727619","1349765509705854976","1349763395692724225","1349763305733300226","1349763167115767812","1349762996264984576","1349758106776072197","1349749151219773440","1349746733518102531","1349743010511249415","1349729766635577348","1349724502398124032","1349716514186911746","1349713887927693314","1349708658855186434","1349699408728887296","1349698870478053378","1349698738596569089"]},{"title":"SO-19 S-1 is a cost-effective alternative to capecitabine in metastatic colorectal cancer","googleId":"LoXrYxkBYckJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39333-9/pdf","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"P-322 Nutritional intervention impact on body mass index and toxicities related to 1st-line metastatic colorectal cancer treatment with targeted therapy","googleId":"CaGQoNh-BTkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39703-9/pdf","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆","googleId":"ei2k2EdQv5MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43157-6/abstract","googleCitationCount":0,"googleAuthor":"PA Gerber","statusesArray":[]},{"title":"PD-1 blockade in Japanese patients with acral lentiginous melanoma","googleId":"la4pSSvwr-kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39902-6/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"The influence of polypharmacy on outcome in real life non-small cell lung cancer (NSCLC) patients treated with immunotherapy","googleId":"SpkJoMCGhJkJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/the-influence-of-polypharmacy-on-outcome-in-real-life-non-small-c","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1647","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Trifluridine/tipiracil in earlier lines of chemotherapy for advanced colorectal cancer","googleId":"NgJDSUWHjvIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39872-0/abstract","googleCitationCount":1,"googleAuthor":"S Roselló","statusesArray":[]},{"title":"604TiP ON-TRK: A non-interventional study of larotrectinib in patients with TRK fusion cancer","googleId":"VY8-B2p-8mQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40714-8/abstract","googleCitationCount":0,"googleAuthor":"G Castro","statusesArray":[]},{"title":"1930O Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT)","googleId":"ssh5wInxl2kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41319-5/abstract","googleCitationCount":0,"googleAuthor":"L Mezquita","statusesArray":[]},{"title":"Data protection and research in the European Union: a major step forward, with a step back","googleId":"OB1_2Jj3LPwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42964-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer","googleId":"th6Cx-moljUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41343-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX vs EOX alone for first-line treatment of advanced CLDN18. 2 positive gastric and gastro …","googleId":"pYGKl4fPBCIJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753421001228","googleCitationCount":0,"googleAuthor":"U Sahin","doi":"10.1016/j.annonc.2021.02.005","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Imaging-based prostate cancer screening among BRCA mutation carriers—results from the first round of screening","googleId":"EVThvgFiFooJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420399373","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.06.025","elsevierAuthor":"Segal N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-11-01","elsevierCoverDisplayDate":"November 2020","elsevierCitationCount":"0","altmetricAuthors":["N. Segal","Y. Ber","O. Benjaminov","S. Tamir","M. Yakimov","I. Kedar","E. Rosenbaum","S. Sela","R. Ozalvo","L. Shavit-Grievink","D. Keder","J. Baniel","D. Margel"],"twitterCount":3,"altmetricId":90783975,"statusesArray":["1320183590731141121","1309853555881320454","1308736860500496384","1307754698502479874"]},{"title":"Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆","googleId":"cI0qC4GZmbQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(21)00011-9/abstract","googleCitationCount":0,"googleAuthor":"M Caplin","statusesArray":[]},{"title":"1682P Outcomes of cancer patients undergoing radiotherapy during the COVID-19 outbreak in Wuhan, China","googleId":"ZxzDjrh3bisJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506312/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1746","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"The ESMO-EANO clinical practice guidelines for neurological and vascular complications of primary and secondary brain tumours: a valuable tool for clinicians","googleId":"KBu3dzrwaAsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43204-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up","googleId":"YsqgXp-KQJgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43210-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"LBA78 A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden","googleId":"dCLRt__mCooJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506428/","googleCitationCount":1,"googleAuthor":"P Van Mol","doi":"10.1016/j.annonc.2020.08.2319","elsevierCitationCount":0,"altmetricAuthors":["P. Van Mol","A. Franken","C. Dooms","J. Yserbyt","D. Testelmans","P. Meersseman","G. Hermans","J. Wauters","J. Gunst","K. Nackaerts","J. Vansteenkiste","A. Garg","D. Lambrechts","E. Wauters"],"twitterCount":2,"altmetricId":93616484,"statusesArray":["1323364628571869186","1323350692694732805"]},{"title":"1703P UK Coronavirus Cancer Monitoring Project (UKCCMP): A national reporting network for real time data of the COVID-19 pandemic","googleId":"HCklgf44sfAJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506390/","googleCitationCount":0,"googleAuthor":"DJ Hughes","doi":"10.1016/j.annonc.2020.08.1767","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial","googleId":"JrMaQ4acgIYJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420429837","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.10.480","elsevierAuthor":"Yamazaki K.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"January 2021","elsevierCitationCount":"0","altmetricAuthors":["K. Yamazaki","T. Yamanaka","M. Shiozawa","D. Manaka","M. Kotaka","M. Gamoh","A. Shiomi","A. Makiyama","Y. Munemoto","T. Rikiyama","M. Fukunaga","T. Ueki","K. Shitara","H. Shinkai","N. Tanida","E. Oki","E. Sunami","A. Ohtsu","Y. Maehara","T. Yoshino"],"twitterCount":4,"altmetricId":93805582,"statusesArray":["1345166266269503489","1345145070962364417","1345046849476939776","1324665426815705088"]},{"title":"TOSCA—a delicious Swedish almond cake, an Italian opera and an Italian trial with important new data","googleId":"kHWxXy4hWDcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43126-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"6P The importance of biomarker expression in addition to lymph node status in the ESMO risk stratification of endometrial cancer","googleId":"Gyt3QC8P7r0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42230-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"SOLAR1s: alpelisib returns to earth?","googleId":"Un1a7FlVOnMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43202-8/abstract","googleCitationCount":0,"googleAuthor":"A Matikas","statusesArray":[]},{"title":"Patient selection biomarker strategies for PARP inhibitor therapy","googleId":"fWblDfgTJJQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42467-6/abstract","googleCitationCount":0,"googleAuthor":"PG Pilié","statusesArray":[]},{"title":"LBA69 Impact of the COVID-19 pandemic on management of medical cancer treatments and psychological consequence for the patients","googleId":"5KScla9udJ4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506429/","googleCitationCount":2,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2310","elsevierCitationCount":0,"altmetricAuthors":["F. Joly","A. Leconte","J-M. Grellard","J. Lequesne","G. Binarelli","M. Lange","L. Tron","F. Gernier","C. Rieux","M. Fernette","E. Bastien","A. Morel","B. Legrand","D. Richard","A. Faveyrial","R. Travers","L-F. Pépin","O. Rigal","F. Jardin","B. Clarisse"],"twitterCount":0,"altmetricId":94214675,"statusesArray":[]},{"title":"1716P Vigil plasmid (VP), a dual bi-shRNA-furin/GMCSF construct from cancer to SARS-CoV-2","googleId":"zQ1WnhIa33oJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506394/","googleCitationCount":0,"googleAuthor":"L Stanbery","doi":"10.1016/j.annonc.2020.08.1780","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1681P First results of the COCO study: COVID-19 outcomes in patients with cancer","googleId":"49MzbS-pEm4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506441/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1745","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1677MO COVID-19 mortality in hospitalized cancer patients is not significantly affected by chemotherapy or other anti-cancer treatments","googleId":"HeoxqYAu1nwJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506400/","googleCitationCount":0,"googleAuthor":"T Starkey","doi":"10.1016/j.annonc.2020.08.1742","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Conceptual and clinical interpretation of 2007 WCRF/AICR score in relation to cancer-related health outcomes","googleId":"lk0NcVV5NaEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39993-2/abstract","googleCitationCount":1,"googleAuthor":"R Jayaraj","statusesArray":[]},{"title":"Nintedanib (BIBF1120) after first line therapy in progressive medullary thyroid cancer: A multicenter EORTC prospective randomized double-blind phase II study …","googleId":"RFvIv1ZN7MgJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/nintedanib-bibf1120-after-first-line-therapy-in-progressive-medul","googleCitationCount":0,"googleAuthor":"B Hasan","doi":"10.1016/j.annonc.2020.08.1407","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial","googleId":"GG6qwfGEspEJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753420431564","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.11.004","elsevierAuthor":"de Steur W.O.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-03-01","elsevierCoverDisplayDate":"March 2021","elsevierCitationCount":"1","altmetricAuthors":["W.O. de Steur","R.M. van Amelsfoort","H.H. Hartgrink","H. Putter","E. Meershoek-Klein Kranenbarg","N.C.T. van Grieken","J.W. van Sandick","Y.H.M. Claassen","J.P.B.M. Braak","E.P.M. Jansen","K. Sikorska","H. van Tinteren","I. Walraven","P. Lind","M. Nordsmark","M.I. van Berge Henegouwen","H.W.M. van Laarhoven","A. Cats","M. Verheij","C.J.H. van de Velde"],"twitterCount":7,"altmetricId":97424197,"statusesArray":["1353742398371803139","1348650135505559552","1348641796155461638","1348539053839364096","1348518011775422467","1348454073943654408","1348436261435011072"]},{"title":"First-line nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) for the treatment of unresectable malignant pleural mesothelioma (MPM): Patient …","googleId":"LYN_30IR9y4J","googleLink":"https://research-repository.uwa.edu.au/en/publications/first-line-nivolumab-nivo-plus-ipilimumab-ipi-versus-chemotherapy","googleCitationCount":0,"googleAuthor":"S Antonia","doi":"10.1016/j.annonc.2020.10.603","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"P-348 A multi-institutional retrospective study of stage I-IV transverse colon cancer: Diagnosis, treatment and outcome analyses","googleId":"cFcEVKGApkUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39729-5/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER plus) …","googleId":"5vYcdudTJXUJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/a-randomised-double-blind-placebo-controlled-phase-ii-trial-of-pa","googleCitationCount":1,"googleAuthor":"MR Mirza","doi":"10.1016/j.annonc.2020.08.2258","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Reply to the Letter to the Editor 'Aspirin to prevent gastrointestinal cancer–but recent trial data don't fit'by Jacobsen and colleagues","googleId":"XTg_6ZaJG8EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39867-7/pdf","googleCitationCount":0,"googleAuthor":"C Bosetti","statusesArray":[]},{"title":"1473P Parameters of complete blood count might predict the prognosis of patients with advanced gastric cancer","googleId":"mkddjeyTTa0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41975-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Health-related quality of life (HRQoL) in patients (pts) with newly diagnosed stage III or IV ovarian cancer treated with veliparib (vel)+ chemotherapy followed by vel …","googleId":"e_Hq38Lb1GwJ","googleLink":"https://portal.findresearcher.sdu.dk/en/publications/health-related-quality-of-life-hrqol-in-patients-pts-with-newly-d","googleCitationCount":0,"googleAuthor":"D Cella","doi":"10.1016/annonc/annonc276;","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Osimertinib in CNS-progressive EGFR-mutant lung cancer: do we need to detect T790M?","googleId":"o0QaWY3hMOEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42060-5/abstract","googleCitationCount":1,"googleAuthor":"A Leonetti","statusesArray":[]},{"title":"TRKing PTC patients: NTRK gene fusion frequency and clinical characteristics of a Finnish papillary thyroid cancer cohort","googleId":"2bUOKHhKqA8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40249-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1692P SARS-CoV-2 RNA testing in cancer patients treated at a Department of Medical Oncology in Vienna, Austria","googleId":"iCLKE66CkF4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506345/","googleCitationCount":0,"googleAuthor":"M Gansterer","doi":"10.1016/j.annonc.2020.08.1756","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Commentary: SARS-CoV-2 vaccines and cancer patients","googleId":"U-FmoQnnOFoJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831848/","googleCitationCount":0,"googleAuthor":"C Corti","doi":"10.1016/j.annonc.2020.12.019","elsevierAuthor":"Corti C.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["C. Corti","G. Curigliano"],"twitterCount":6,"altmetricId":97656583,"statusesArray":["1349913053408575491","1349789227794518017","1349773177031950337","1349766825307942913","1349764920884273154","1349729809807536132","1349660552755339264","1349660076622176256"]},{"title":"Expected medium and long term impact of the COVID-19 outbreak in oncology","googleId":"nFjSutUmzpYJ","googleLink":"https://orbi.uliege.be/handle/2268/253771","googleCitationCount":0,"googleAuthor":"CE ONESTI","statusesArray":[]},{"title":"Germline-somatic fluidity in guiding patient care","googleId":"389TfcrxoF0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39789-1/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"91P Macrophage-lineage transcriptome networking reveals SMAD3 as a novel regulator for cancer-associated fibroblasts formation in NSCLC","googleId":"PQ5rk142jMkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43092-3/abstract","googleCitationCount":0,"googleAuthor":"KF To","statusesArray":[]},{"title":"1735P SARS-CoV-2 infection induces EMT-like molecular changes, including ZEB1-mediated repression of the viral receptor ACE2, in lung cancer models","googleId":"_JijqlZmsbUJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506457/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1799","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1272P Three-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer …","googleId":"3R_xkRFB_18J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41582-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"An analysis of cancer patients with asymptomatic infection of SARS-CoV-2 in a cancer center in Wuhan, China","googleId":"WxKHRL88NgYJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375965/","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.07.008","elsevierAuthor":"Yin P.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-10-01","elsevierCoverDisplayDate":"October 2020","elsevierCitationCount":"1","altmetricAuthors":["P. Yin","R. Zeng","Y.R. Duan","Y. Zhang","X.N. Kuang","H.F. Zhang","S.Z. Wei"],"twitterCount":0,"altmetricId":87084331,"statusesArray":[]},{"title":"1745P SARS-CoV-2 infects metabolically-primed epithelial cells in lung cancer models","googleId":"uDtdZMtU7EIJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506319/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1809","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1723P Organizational challenges and oncological activity volumes during the SARS-CoV-2 epidemic peak in Verona, Italy","googleId":"yLJVPJsa5LcJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506492/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1787","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1712P Risk of SARS-CoV-2 infection and outcome after infection: Experience from the day-care unit at CHU Liège in Belgium","googleId":"rkIYxh1EfbIJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506494/","googleCitationCount":0,"googleAuthor":"CE Onesti","doi":"10.1016/j.annonc.2020.08.1776","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"894P Diffuse large B-cell testicular lymphomas (DLBCL-TL): Survival outcomes over 20 years","googleId":"HzyUihN7UOMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40008-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1260MO Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (ICI): Step 1 results of …","googleId":"CFXbgmQeegAJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506388/","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1574","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA81 Keeping exhausted T-cells in check in COVID-19","googleId":"S_scR4GtkukJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506446/","googleCitationCount":0,"googleAuthor":"P Van Mol","doi":"10.1016/j.annonc.2020.08.2322","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1725P Development and validation of telematic follow-up for cancer patients during the COVID-19 outbreak","googleId":"HDnaVDc1eyAJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506391/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1789","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"The ESMO Call to Action on COVID-19 vaccinations and patients with cancer: Vaccinate. Monitor. Educate","googleId":"CcZXx6UajDQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(21)00096-X/abstract","googleCitationCount":0,"googleAuthor":"MC Garassino","statusesArray":[]},{"title":"319O The systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection","googleId":"Hlb0eMjyN9IJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680629/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.10.313","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1702P COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: The COVINT study","googleId":"vb1RnHoO-TkJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506452/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1766","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1671MO Provision of palliative care for patients with cancer and SARS-CoV-2 infection","googleId":"l4K-WsiweNMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506333/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1736","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Insulin-like growth factor-1 (IGF-1), insulin-like growth factor-binding protein-3 (IGFBP-3) and breast cancer risk: Observational and Mendelian randomization analyses …","googleId":"auH0WWYh4tgJ","googleLink":"https://ora.ox.ac.uk/objects/uuid:07449cdd-1ad7-407d-a2ae-5a1aa01e327a","googleCitationCount":0,"googleAuthor":"RM Martin","doi":"10.1016/j.annonc.2020.01.066","elsevierAuthor":"Murphy N.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-05-01","elsevierCoverDisplayDate":"May 2020","elsevierCitationCount":"10","altmetricAuthors":["N. Murphy","A. Knuppel","N. Papadimitriou","R.M. Martin","K.K. Tsilidis","K. Smith-Byrne","G. Fensom","A. Perez-Cornago","R.C. Travis","T.J. Key","M.J. Gunter"],"twitterCount":14,"altmetricId":77320430,"statusesArray":["1239543072217858051","1239250037730926594","1239182948831604738","1239155207575089153","1237712019190689793","1237698636240297986","1237690948328488960","1237683453233172480","1237681272161525760","1237681230319104001","1237680037240938496","1237679852590968832","1237679814854746115","1237679456686419969","1237678994369150977","1237665899592679424","1237665318966788096","1237664546854244352","1237663977955561472"]},{"title":"1710P International multicentric evaluation of breast cancer patients' satisfaction and experience with oncology telemedicine visits (TV) during the COVID-19 outbreak","googleId":"Q4m3wanekzsJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506409/","googleCitationCount":0,"googleAuthor":"M Karimi","doi":"10.1016/j.annonc.2020.08.1774","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1777P Launching local treatment guidelines for stage IV cancer during COVID-19 pandemic using ESMO MCBS","googleId":"zf4pWUWjBUEJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506433/","googleCitationCount":0,"googleAuthor":"A Mohamed","doi":"10.1016/j.annonc.2020.08.1841","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA80 Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)","googleId":"TO9aN1y3b5EJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506361/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2321","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Incidence of influenza-like illness (ILI) in cancer patients during COVID-19: The ONCOVID prospective observational study","googleId":"zMSyXIsZdkwJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506302/","googleCitationCount":0,"googleAuthor":"M Ghidini","doi":"10.1016/j.annonc.2020.08.1760","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1713P Active smoking and severity of COVID-19 infection in cancer patients","googleId":"NgoqvF2zoIwJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506323/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1777","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"57P The efficacy and safety of pembrolizumab in advanced cervical cancer: A real-world treatment study","googleId":"PjQ6XHz6EHgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43057-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1719P Clinical characteristics and 28-day mortality among patients with solid cancers and COVID-19 in a tertiary hospital","googleId":"6xIhFTATe3gJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506311/","googleCitationCount":0,"googleAuthor":"JC Tapia","doi":"10.1016/j.annonc.2020.08.1783","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1062P EGFR-XPAT, a novel pro-drug T-cell engager (TCEs) engineered to address on-target, off-tumour toxicity and an orthogonal approach for cancer …","googleId":"RmJ4Rq8v8gEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41178-0/abstract","googleCitationCount":0,"googleAuthor":"B Irving","statusesArray":[]},{"title":"Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential …","googleId":"6a0Yk1TCogQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40279-0/fulltext","googleCitationCount":1,"googleAuthor":"D Drubay","statusesArray":[]},{"title":"Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2+ metastatic breast cancer (MBC) with and without brain metastases (BM)","googleId":"ylpvhj35bBsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40373-4/abstract","googleCitationCount":1,"googleAuthor":"V Mueller","statusesArray":[]},{"title":"1714P Change of circulating pro-inflammatory markers between pre-COVID-19 condition and COVID-19 diagnosis predicts early death in cancer patients: The FLARE …","googleId":"FxVUKenWIsYJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506416/","googleCitationCount":0,"googleAuthor":"D Casadevall","doi":"10.1016/j.annonc.2020.08.1778","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"804TiP CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)","googleId":"-3x4smPcPasJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506430/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2075","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"379MO Durvalumab (D)±tremelimumab (T)+ platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden …","googleId":"YX6EtSBfSdwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42864-9/abstract","googleCitationCount":0,"googleAuthor":"MC Garassino","statusesArray":[]},{"title":"1228P Integrated analysis of gene expression and chromosomal aberrations to determine the global patterns of DNA methylation heterogeneity in the TRACERx lung …","googleId":"eDtoB12V7_4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41426-7/abstract","googleCitationCount":0,"googleAuthor":"EL Cadieux","statusesArray":[]},{"title":"1732P Prognostic indicators for COVID-19 related deaths in patients with cancer","googleId":"Rm-7C0m-kzUJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506451/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1796","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1680P SARS-CoV-2 infections in outpatients with cancer: Most infected patients are asymptomatic carriers without impact on chemotherapy","googleId":"38v-qwKBFuwJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506367/","googleCitationCount":1,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1744","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1705P SARS-CoV-2 infection among cancer patients receiving antitumor treatment in Italy: A nationwide observational study (CIPOMO ONCO COVID-19)","googleId":"G6g9w4Go544J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506478/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1769","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe","googleId":"ao9Dm_1dn5sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42984-9/abstract","googleCitationCount":0,"googleAuthor":"N Agarwal","statusesArray":[]},{"title":"1740P Assessing the impact of COVID-19 outbreak on the attitudes and practice of Italian oncologists towards breast cancer care and related research activities","googleId":"Np4I0oDCfQwJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506486/","googleCitationCount":0,"googleAuthor":"M Tagliamento","doi":"10.1016/j.annonc.2020.08.1804","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1733P Real-world data: Cancer and SARS-CoV-2 infection","googleId":"iZfbtoJEXYwJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506436/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1797","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1300P Intracranial efficacy of brigatinib (BRG) vs crizotinib (CRZ): Updated results from the ALTA-1L trial","googleId":"OutvQouvq8UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41610-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Leveraging existing data to contextualize phase II clinical trial findings in oncology","googleId":"o3kLyF_4upcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42458-5/abstract","googleCitationCount":0,"googleAuthor":"LA Carey","statusesArray":[]},{"title":"71P A phase II study of ADU-S100 in combination with pembrolizumab in adult patients with PD-L1+ recurrent or metastatic HNSCC: Preliminary safety, efficacy and …","googleId":"9uXpTWzk34gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43072-8/abstract","googleCitationCount":0,"googleAuthor":"R Ferris","statusesArray":[]},{"title":"843P Association of gene expression signatures and TMB with response to pembrolizumab (pembro) in patients (pts) with recurrent ovarian cancer (ROC) enrolled in …","googleId":"kevEhb-07VAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40978-0/abstract","googleCitationCount":0,"googleAuthor":"JA Ledermann","statusesArray":[]},{"title":"Selinexor in combination with carboplatin and paclitaxel in patients with advanced or metastatic solid tumours: Results of an open label, single-center, multi-arm …","googleId":"jOfcXOc2Vd0J","googleLink":"https://www.karyopharm.com/wp-content/uploads/2020/09/554P-Selinexor-carboplatin-paclitaxel-combo.pdf","googleCitationCount":0,"googleAuthor":"KZ Thein","statusesArray":[]},{"title":"31P Integrated safety analysis of anti-programmed cell death-1 (PD-1) antibody penpulimab in advanced solid tumour or lymphoma","googleId":"JBJz04aI0CkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43031-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"24P L1CAM as a candidate therapeutic target in small-cell neuroendocrine prostate cancer","googleId":"SfEVjGnDpy4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35976-7/abstract","googleCitationCount":0,"googleAuthor":"I Coleman","statusesArray":[]},{"title":"Osimertinib in central nervous system progressive EGFR-mutant lung cancer: do we need to detect T790M?","googleId":"DhaI5Bfe41YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42316-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1601P Estimated years of potential life lost due to absence of pembrolizumab in SUS","googleId":"6LRpVxhsOvQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41906-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1739P Clinical features and prognostic factors on admission of a prospective cohort of COVID-19 positive cancer patients in a third-level hospital in Madrid, Spain","googleId":"ruzeeLz0CjYJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506418/","googleCitationCount":0,"googleAuthor":"M PAZ","doi":"10.1016/j.annonc.2020.08.1803","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"82P Novel analysis of F. nucleatum subspecies in human CRC tissue and engineering of therapeutic F. nucleatum phage","googleId":"HRzvIrd_UrAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43082-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data","googleId":"d_8QgYhBs1IJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S092375342043220X","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.12.012","elsevierAuthor":"Di Filippo Y.","publicationName":"Annals of Oncology","elsevierCoverDate":"2021-01-01","elsevierCoverDisplayDate":"2021","elsevierCitationCount":"0","altmetricAuthors":["Y. Di Filippo","S. Dalle","L. Mortier","O. Dereure","S. Dalac","C. Dutriaux","M.-T. Leccia","D. Legoupil","P. Saiag","F. Brunet-Possenti","J.-P. Arnnault","E. Maubec","F. Granel-Brocard","J. De Quatrebarbes","F. Aubin","T. Lesimple","M. Beylot-Barry","P.-E. Stoebner","A. Dupuy","A. Stephan","J.-J. Grob","W. Lefevre","B. Oriano","C. Allayous","C. Lebbé","H. Montaudié"],"twitterCount":3,"altmetricId":96970281,"statusesArray":["1347137547454078978","1345324876651876352","1345097579340689414"]},{"title":"1155TiP Pan-tumour study CheckMate 8TT for long-term follow-up of cancer survivors who have participated in trials investigating nivolumab","googleId":"Q16lU_OPE7IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41274-8/abstract","googleCitationCount":0,"googleAuthor":"C Denlinger","statusesArray":[]},{"title":"28P Helping the killers: Innovative cancer immunotherapy harnessing quasi-universal tumour antigen-specific CD4 T cells","googleId":"kx9Hypjty5kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43027-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"89P Dissecting tumour-immune interactions in mesothelioma for identifying responders to immune checkpoint blockade","googleId":"QTGOBr2OY2EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43090-X/abstract","googleCitationCount":0,"googleAuthor":"V Addala","statusesArray":[]},{"title":"1100P Restricted mean survival time (RMST) and cure-rate modeling in estimating survival benefit with adjuvant dabrafenib (D) plus trametinib (T) treatment in …","googleId":"vlKdyg3mukYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41219-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: Results from the phase II innovaTV 204/GOG-3023/ENGOT-cx6 study","googleId":"jG2fXQUAB_oJ","googleLink":"https://vbn.aau.dk/en/publications/tisotumab-vedotin-in-previously-treated-recurrent-or-metastatic-c","googleCitationCount":2,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2262","elsevierCitationCount":0,"altmetricAuthors":["R.L. Coleman","D. Lorusso","C. Gennigens","A. González-Martín","L. Randall","D. Cibula","B. Lund","L. Woelber","S. Pignata","F. Forget","A. Redondo","R. Rangwala","S.D. Vindeløv","M. Chen","J.R. Harris","L. Nicacio","M.S.L. Teng","M. Smith","B.J. Monk","I.B. Vergote"],"twitterCount":0,"altmetricId":99927338,"statusesArray":[]},{"title":"1764P Prevalence, severity and evolution of Coronavirus disease 19 (COVID-19) infection in cancer patients from Mediterranean population","googleId":"ga5EDihygJ0J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506463/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1828","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"582P Preclinical development of AT1412, a patient derived CD9 antibody that does not induce thrombosis for treatment of precursor B ALL","googleId":"TNNq6dE9zAUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40692-1/abstract","googleCitationCount":1,"googleAuthor":"J Villaudy","statusesArray":[]},{"title":"1684P Scientia Potentia Est: How the Italian world of oncology changes in the COVID-19 pandemic","googleId":"ds1eilK4HpIJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506397/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1748","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1105P Estimating long-term survivorship in patients with advanced melanoma treated with immune-checkpoint inhibitors: Analyses from the phase III …","googleId":"Yp_4iabHfw0J","googleLink":"https://www.researchgate.net/profile/Yasir_Khan55/publication/344455869_1106P_International_experience_of_ipilimumab_and_nivolumab_in_patients_with_advanced_melanoma/links/5f77a32a92851c14bca9e11b/1106P-International-experience-of-ipilimumab-and-nivolumab-in-patients-with-advanced-melanoma.pdf","googleCitationCount":0,"googleAuthor":"J Larkin","statusesArray":[]},{"title":"1104P Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO+ IPI) in advanced melanoma patients with brain metastases: Real-world …","googleId":"KR8_EUglB-IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41223-2/abstract","googleCitationCount":0,"googleAuthor":"T Eigentler","statusesArray":[]},{"title":"688TiP Genetic information to inform treatment and screening (GIFTS) study for prostate cancer: Characterizing germline DNA alterations in men with metastatic …","googleId":"x4WpCIpdS7cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42079-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"839P A phase Ib/II study of rebastinib and paclitaxel in advanced or metastatic platinum-resistant ovarian cancer","googleId":"OJoy3UnEQkwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40974-3/abstract","googleCitationCount":0,"googleAuthor":"S Goel","statusesArray":[]},{"title":"1055P Updated results of subcutaneous (SC) anti-programmed cell death 1 (PD-1) receptor antibody PF-06801591 for locally advanced or metastatic non-small cell …","googleId":"I_ZgpOqHXewJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41171-8/abstract","googleCitationCount":0,"googleAuthor":"KD Penkov","statusesArray":[]},{"title":"747P Association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): Results from KEYNOTE-045 and KEYNOTE …","googleId":"BFCqeBPkDPEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40815-4/abstract","googleCitationCount":0,"googleAuthor":"J Bellmunt","statusesArray":[]},{"title":"598TiP A phase I/Ib dose-escalation study of intravenously administered SB 11285 alone and in combination with nivolumab in patients with advanced solid tumours","googleId":"nG1pEVnh6ZkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40708-2/abstract","googleCitationCount":0,"googleAuthor":"JJ Luke","statusesArray":[]},{"title":"1746P Impact of PD-1/PD-L1 blockade therapy in COVID-19 infected cancer patients (pts) hospitalization: Results of an Italian study in the province of Modena and …","googleId":"2S9wBnCBHygJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506484/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1810","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"858P Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR …","googleId":"c0OpjkBqlTEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40993-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1393P Risk of SARS-CoV2-related mortality in non-small cell lung cancer patients treated with first-line immune-oncology alone or in combination with chemotherapy","googleId":"8P8ayIHNMTsJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506387/","googleCitationCount":0,"googleAuthor":"GL Banna","doi":"10.1016/j.annonc.2020.08.1707","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"367P Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer …","googleId":"HDRh2b0qGtoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42851-0/abstract","googleCitationCount":0,"googleAuthor":"KWC Lee","statusesArray":[]},{"title":"713P Treatment-free survival, with and without toxicity, after immuno-oncology vs targeted therapy for advanced renal cell carcinoma (aRCC): 42-month results of …","googleId":"_OKDyacYY5UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40781-1/abstract","googleCitationCount":0,"googleAuthor":"M Regan","statusesArray":[]},{"title":"384P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC","googleId":"NdWrkG2NjdAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42869-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1707P CureCancer digital tool in the routine clinical oncology practice facilitates PROs, communicating with HCPs, treatment adherence and “distancing interventions” …","googleId":"EzN5eU0Udm8J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506405/","googleCitationCount":0,"googleAuthor":"A Karampeazis","doi":"10.1016/j.annonc.2020.08.1771","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1201P The role of a mini tumour mutational burden (TMB) score generated with a customized NGS panel to predict benefit from immunotherapy","googleId":"9agZ7OQWoqwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40091-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"79O Clinical performance of Immunoscore® in early colon cancer in the Asian population","googleId":"zi3-BA8BFRkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42590-6/abstract","googleCitationCount":0,"googleAuthor":"Y Kawakami","statusesArray":[]},{"title":"CN26 Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland: A qualitative study","googleId":"5iEDKc0u7DoJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506483/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2134","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1097P 4-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo) adjuvant ipilimumab (IPI)+ nivolumab (NIVO) in macroscopic stage III …","googleId":"UNxeRTR8hqIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41217-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1709P Cancer patients' perspectives on the real-world impact of COVID-19 pandemic: A multidisciplinary survey","googleId":"Tpwls1oLgCwJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506366/","googleCitationCount":0,"googleAuthor":"KM Cheung","doi":"10.1016/j.annonc.2020.08.1773","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1414TiP Evaluating telisotuzumab vedotin in combination with osimertinib in patients with advanced non-small cell lung cancer: A phase I/Ib study cohort","googleId":"nfE2dXik8moJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41724-7/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"1756P Cancer patients infected with COVID-19 at La Princesa Hospital: Real-world data study","googleId":"d1wBxtSH0BgJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506427/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1820","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"838P TRIOC-A randomised phase II trial to examine MVA-5T4 vaccine in patients with relapsed asymptomatic epithelial ovarian, fallopian tube or primary peritoneal …","googleId":"HAhokRlKJ4YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40973-1/abstract","googleCitationCount":0,"googleAuthor":"I McNeish","statusesArray":[]},{"title":"1075TiP MEDI1191, a novel IL-12 mRNA therapy for intratumoral (IT) injection for advanced solid tumours","googleId":"XOUPcs6zyQQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41191-3/abstract","googleCitationCount":0,"googleAuthor":"V Subbiah","statusesArray":[]},{"title":"Clinical relevance of MIR27A rs895819 polymorphism and its interaction with DPYD variants for predicting grade 4-5 fluoropyrimidine (FP) toxicity (tox) in the FUSAFE …","googleId":"Rn-C-TPMZloJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40511-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1307P Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison …","googleId":"ttSfWrtlYWQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41617-5/abstract","googleCitationCount":0,"googleAuthor":"X Li","statusesArray":[]},{"title":"1694P Discovery of circulating biomarkers in COVID-19 patients undergoing anti-IL6R immunotherapy","googleId":"VrtNgJTwiN8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41754-5/abstract","googleCitationCount":0,"googleAuthor":"JM Michot","statusesArray":[]},{"title":"1896MO Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma","googleId":"8zDKGxgqcLIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41435-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Androgen deprivation therapy in unlikely to be effective for treatment of COVID-19","googleId":"qIWj1ss0_gIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42464-0/abstract","googleCitationCount":0,"googleAuthor":"ME O'Callaghan","statusesArray":[]},{"title":"1266P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line …","googleId":"nQgQXU7_FPkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41576-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"64MO A phase (ph) II, multi-center study of the safety and efficacy of tebentafusp (tebe)(IMCgp100) in patients (pts) with metastatic uveal melanoma (mUM)","googleId":"-DEt2wRbaKIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43065-0/abstract","googleCitationCount":0,"googleAuthor":"R Carvajal","statusesArray":[]},{"title":"1021O Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to …","googleId":"IwElzS5cDOIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41137-8/abstract","googleCitationCount":0,"googleAuthor":"A Prawira","statusesArray":[]},{"title":"LBA10 Critical role of eosinophils during response to immune checkpoint blockade in breast cancer and other cancer types","googleId":"ln7PZno2CiQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42319-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Genomic evolution of metastatic tumours under therapeutic pressure","googleId":"oYIvSIloifgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40199-1/abstract","googleCitationCount":0,"googleAuthor":"J Van De Haar","statusesArray":[]},{"title":"1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC","googleId":"EA5jI_2tIIIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41606-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report","googleId":"XofvT41pB-UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36039-7/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"1748P Real-world outcomes in thoracic cancer patients (pts) with severe acute respiratory syndrome coronavirus 2 (COVID-19): Single UK institution experience","googleId":"52BW4ydP5PYJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506368/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1812","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"12P The correlation between non-coding RNA and response rate to immune-checkpoint inhibitors","googleId":"hTh6JSRXg6wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43010-8/abstract","googleCitationCount":0,"googleAuthor":"SA Read","statusesArray":[]},{"title":"1497TiP REACTION–a phase Ib pilot study of nivolumab or nivolumab in combination with relatlimab after targeted radiation in patients with advanced …","googleId":"gj31zdfWku0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41999-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"567P Exposure-response analyses of dabrafenib and trametinib in melanoma patients","googleId":"aMfO6FOGsWUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40677-5/abstract","googleCitationCount":0,"googleAuthor":"JM Janssen","statusesArray":[]},{"title":"P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in …","googleId":"PbgjwxTQhT8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39488-6/pdf","googleCitationCount":2,"googleAuthor":"S Ogasawara","statusesArray":[]},{"title":"1019O Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)","googleId":"FnFvuhdGcZcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41135-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"813MO Efficacy of subsequent chemotherapy for patients with BRCA1/2 mutated platinum-sensitive recurrent epithelial ovarian cancer (EOC) progressing on …","googleId":"Y7OA1hr5JbgJ","googleLink":"https://www.clearityfoundation.org/wp-content/uploads/2020/10/MEDIOLA-ESMO-2020.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"44P The hematologic toxicities of chemo-immunotherapy compared to chemotherapy alone: A systematic review and meta-analysis","googleId":"R9jdfz0SSEYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43044-3/abstract","googleCitationCount":0,"googleAuthor":"D Eiger","statusesArray":[]},{"title":"1633P Explorative model of imatinib resistant wild type GIST and potential immunotherapy strategies","googleId":"Hp3UpjhAc1oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41855-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma","googleId":"2Dq5QrVWk0UJ","googleLink":"https://www.sciencedirect.com/science/article/pii/S0923753419360818","googleCitationCount":0,"googleAuthor":"W Xu","doi":"10.1016/j.annonc.2019.10.024","elsevierAuthor":"Lukovic J.","publicationName":"Annals of Oncology","elsevierCoverDate":"2020-02-01","elsevierCoverDisplayDate":"February 2020","elsevierCitationCount":"0","altmetricAuthors":["J. Lukovic","F.A. Alfaraj","M.L. Mierzwa","G.N. Marta","W. Xu","J. Su","F.Y. Moraes","S.H. Huang","S.V. Bratman","B. O’Sullivan","J.J. Kim","J.G. Ringash","J. Waldron","J.R. de Almeida","D.P. Goldstein","K.A. Casper","A.J. Rosko","M.E. Spector","L.P. Kowalski","A. Hope","A. Hosni"],"twitterCount":5,"altmetricId":77000020,"statusesArray":["1260704602283966464","1259964694275620864","1259893201328103426","1259888922177437698","1259885199476822019","1259838428730064897"]},{"title":"13P PD-L1 prevalence in advanced urothelial carcinoma by demographic and clinical characteristics","googleId":"1mOw2Ny-d3MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43011-X/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"55P Evaluation of MDM2-p53 antagonists, nutlin-3 and RG7388, combined with the PARPi rucaparib in primary cultures of ovarian cancer","googleId":"mY1fdkHz0a8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42279-3/abstract","googleCitationCount":1,"googleAuthor":"NJ Curtin","statusesArray":[]},{"title":"Genetic and hormonal influence on SARS-CoV-2-infection susceptibility: Re: The potential influence of human Y-chromosome haplogroup on COVID-19 prevalence …","googleId":"-oO4O-516a4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42101-5/abstract","googleCitationCount":1,"googleAuthor":"M Rugge","statusesArray":[]},{"title":"1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline","googleId":"7nf5xT2ZwtUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41598-4/abstract","googleCitationCount":0,"googleAuthor":"S Siena","statusesArray":[]},{"title":"Tislelizumab Plus Chemotherapy as First-line Treatment for Lung Cancer in Chinese Patients","googleId":"pb1I9bkVMWIJ","googleLink":"https://www.beigenemedical.com/CongressDocuments/Wang%20BGB-A317%20206%20ESMO%20IO%20Abstract%202020.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid …","googleId":"sR6-jHdRfH0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40643-X/abstract","googleCitationCount":1,"googleAuthor":"DW Kim","statusesArray":[]},{"title":"Melatonin reverses the Warburg-dependent effect in ovarian cancer cell by binding to the MT1 and MT2 receptors","googleId":"XR2XCBh3c9wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40185-1/abstract","googleCitationCount":0,"googleAuthor":"LG Chuffa","statusesArray":[]},{"title":"1821P A multicentre analysis of toxicity in 6 weekly vs 3 weekly pembrolizumab dosing","googleId":"Ywtt3Rw3BPUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41464-4/abstract","googleCitationCount":0,"googleAuthor":"MP Rowe","statusesArray":[]},{"title":"1727P COVID-19 pandemic: Impact on doctors in training","googleId":"jUHmLr9gQTQJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506402/","googleCitationCount":0,"googleAuthor":"AR Farooq","doi":"10.1016/j.annonc.2020.08.1791","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Last but not least: antibody–drug conjugates in hormone receptor-positive metastatic breast cancer","googleId":"01goAPquHXwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42492-5/abstract","googleCitationCount":0,"googleAuthor":"SR Stecklein","statusesArray":[]},{"title":"1122P Real-world analysis of dabrafenib plus trametinib in patients with BRAFV600-mutated melanoma brain metastases","googleId":"S75W5EDU-3cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41241-4/abstract","googleCitationCount":0,"googleAuthor":"D Schadendorf","statusesArray":[]},{"title":"1131P C-reactive protein as biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting","googleId":"E28xYNVDpSkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41250-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"690TiP A phase III, randomized, double-blind trial of nivolumab or placebo combined with docetaxel for metastatic castration-resistant prostate cancer (mCRPC; …","googleId":"gw1ea8PWLqwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42081-2/abstract","googleCitationCount":0,"googleAuthor":"F Saad","statusesArray":[]},{"title":"PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy","googleId":"LZ1D5SdpFq8J","googleLink":"https://vbn.aau.dk/en/publications/pd-l1-tumor-mutational-burden-and-overall-survival-among-patients","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1122","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1420TiP A phase I/II trial of radium-223 (Ra-223) in combination with pembrolizumab in patients (pts) with stage IV non-small cell lung cancer (NSCLC)","googleId":"opj37X-MhesJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41730-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1415TiP INSIGHT 2: Tepotinib+ osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification …","googleId":"bRskAl6j5IUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41725-9/abstract","googleCitationCount":0,"googleAuthor":"EF Smit","statusesArray":[]},{"title":"1673MO The GCO-002 CACOVID-19 cohort: A French nationwide multicenter study of COVID-19 infected cancer patients and consequences on cancer management","googleId":"YGVIeznzX_AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41734-X/abstract","googleCitationCount":0,"googleAuthor":"IL Ray-Coquard","statusesArray":[]},{"title":"1077MO PD1 blockade with pembrolizumab in classic and endemic Kaposi sarcoma: A multicenter phase II study","googleId":"5fU_D7dhVIMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41197-4/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"157P Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers","googleId":"cHRxVHCHdlIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42669-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1087P Time to clinically meaningful changes in pain in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab in a phase II clinical trial","googleId":"8_gZQ5LXaQIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41207-4/abstract","googleCitationCount":0,"googleAuthor":"D Rischin","statusesArray":[]},{"title":"1507P A retrospective study of angiotensin-converting enzyme inhibitors or beta-blockers to prevent trastuzumab-induced cardiotoxicity","googleId":"4gWOBrqskEMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40129-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1717P Behavioral practices of cancer patients during COVID-19 pandemic: A Middle East and North Africa Study","googleId":"K4se25T-LPIJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506422/","googleCitationCount":0,"googleAuthor":"AR Jazieh","doi":"10.1016/j.annonc.2020.08.1781","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Cautionary tails","googleId":"d4VTi56Yn9gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42961-8/abstract","googleCitationCount":0,"googleAuthor":"IF Tannock","statusesArray":[]},{"title":"1130P BRAF and MEK inhibition in CDKN2A germline carriers and BRAF mutant melanoma","googleId":"gzmOEjcBXOIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41249-9/abstract","googleCitationCount":0,"googleAuthor":"F Spagnolo","statusesArray":[]},{"title":"1706P Implementing oncology virtual clinics (VC) in response to COVID-19 pandemic: A transformation driven by a crisis","googleId":"vBfa3pfXXTcJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506300/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1770","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"682P Results from ADVANCE: A phase I/II open-label non-randomised safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 (VTP-800) vaccine in …","googleId":"KcyqiiqYy00J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42073-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously …","googleId":"oBi8HEITN1MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42944-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1683P SARS-CoV-2 infection and lung cancer management in Europe","googleId":"4VlE7-1__w4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506443/","googleCitationCount":0,"googleAuthor":"A Addeo","doi":"10.1016/j.annonc.2020.08.1747","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"234O Maintenance olaparib for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): 5-year (y) follow-up (f/u) from …","googleId":"87YZplZgFJIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42719-X/abstract","googleCitationCount":0,"googleAuthor":"N Colombo","statusesArray":[]},{"title":"Annotating MammaPrint and BluePrint gene profile to the Hallmarks of cancer and understanding the biology of MammaPrint extreme risk groups","googleId":"NaaRWZ3fwhIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40338-2/abstract","googleCitationCount":0,"googleAuthor":"R Bhaskaran","statusesArray":[]},{"title":"1889P Information access and use: A Grounded theory of how patients and their friends and family use information to navigate the cancer journey","googleId":"k-pqPz8WsHoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41532-7/abstract","googleCitationCount":0,"googleAuthor":"S Sinclair","statusesArray":[]},{"title":"1060P HER2-XPAT, a novel protease-activatable pro-drug T-cell engager (TCE), engineered to address on-target, off tumour toxicity and provide large predicted …","googleId":"AAUzB5a5w5cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41176-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"975TiP Phase Ib trial of ABBV-368+ tilsotolimod in combination with nab-paclitaxel and/or budigalimab (ABBV-181) in patients with recurrent/metastatic head and …","googleId":"vQL_Og2woKkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41086-5/abstract","googleCitationCount":0,"googleAuthor":"X Le","statusesArray":[]},{"title":"1726P Expanding the role of medical oncologist in the management of COVID-19","googleId":"lRAerrdgEK8J","googleLink":"https://www.researchgate.net/profile/Teresa_Gorria/publication/345371665_1726P_Expanding_the_role_of_medical_oncologist_in_the_management_of_COVID-19/links/5fb4c67a299bf10c3689c63f/1726P-Expanding-the-role-of-medical-oncologist-in-the-management-of-COVID-19.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP)+ nab-paclitaxel (nab-PTX) in advanced triple-negative breast …","googleId":"pMSKDH2CMSQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40447-8/abstract","googleCitationCount":0,"googleAuthor":"S Loi","statusesArray":[]},{"title":"594P The Drug Rediscovery Protocol (DRUP): Results of the first 500 treated patients","googleId":"_5g2LFBRlWwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40704-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"A holistic perspective on plasma proteome changes associated with response to anti-PD-1 treatment in NSCLC patients","googleId":"uDwydGtPGAoJ","googleLink":"https://biognosys.com/media.ashx/4045esmo2020622curiefinal.pdf","googleCitationCount":0,"googleAuthor":"S Lopez-Lastra","statusesArray":[]},{"title":"566P A multicenter, open-label, dose-escalation, first-in-man study of MetAP2 inhibitor M8891 in patients with advanced solid tumours","googleId":"rXy3FRYAtUUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40676-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1285P Capmatinib in patients with METex14-mutated advanced non-small cell lung cancer who received prior immunotherapy: The phase II GEOMETRY mono-1 …","googleId":"j9murY24peEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41595-9/abstract","googleCitationCount":0,"googleAuthor":"EF Smit","statusesArray":[]},{"title":"226P Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)","googleId":"fVcRRPOMh0QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42937-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"High TLR3 expression predicts improved survival in patients with clear cell renal cell carcinoma","googleId":"vXXorWuWs8EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40273-X/abstract","googleCitationCount":0,"googleAuthor":"C Verschraegen","statusesArray":[]},{"title":"Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III …","googleId":"GBV1R2QoK5wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40394-1/abstract","googleCitationCount":0,"googleAuthor":"LA Emens","statusesArray":[]},{"title":"1413TiP LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)","googleId":"md3iylE9Zu4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41723-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1078MO MIND-DC: A randomized phase III trial to assess the efficacy of adjuvant dendritic cell vaccination in comparison to placebo in stage IIIB and IIIC melanoma …","googleId":"fdASJKoEmZYJ","googleLink":"https://www.groupgem.es/wp-content/uploads/2020/09/Informe-8_-Mini-Sesiones-orales-Melanoma-4.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"74P Pivotal trial 201 data on outpatient administration of naxitamab (Hu3F8), a humanized GD2 targeted immunotherapy for the treatment of refractory/relapsed (R/R) …","googleId":"9cPuoJ_AzNsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43075-3/abstract","googleCitationCount":0,"googleAuthor":"DA Morgenstern","statusesArray":[]},{"title":"200O Pembrolizumab plus axitinib (pembro+ axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern …","googleId":"46vvvgaZspMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42703-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1043P A review of meta-analyses on the impact of antibiotics on the efficacy of immune checkpoint inhibitors and cancer patients' survival","googleId":"0nQ7GCfntFwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41159-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) …","googleId":"KHVwz1t5qzYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40365-5/abstract","googleCitationCount":0,"googleAuthor":"S Loibl","statusesArray":[]},{"title":"4MO MET exon 14 screening strategy: How not to miss large deletions","googleId":"iyIRWEn6c-sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42228-8/abstract","googleCitationCount":0,"googleAuthor":"R Loyaux","statusesArray":[]},{"title":"Engineering and expression of constitutive activators of the PD-1 and LAG-3 signaling pathways","googleId":"NiXb7vDpM4MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40166-8/abstract","googleCitationCount":0,"googleAuthor":"L Chocarro","statusesArray":[]},{"title":"709P Cabozantinib (C) in combination with atezolizumab (A) in non-clear cell renal cell carcinoma (nccRCC): Results from cohort 10 of the COSMIC-021 study","googleId":"vEkhSqR67UgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40777-X/abstract","googleCitationCount":1,"googleAuthor":"N Agarwal","statusesArray":[]},{"title":"Androgen deprivation therapy and SARS-CoV-2 in men with prostate cancer: findings from the University of California Health System registry","googleId":"9pPIOvXkUnMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(21)00095-8/abstract","googleCitationCount":0,"googleAuthor":"DH Kwon","statusesArray":[]},{"title":"225P Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort","googleId":"1UQzLeqLQ9MJ","googleLink":"https://www.researchgate.net/profile/Arun_Azad/publication/347100360_225P_Prostate_cancer_treatments_and_outcomes_in_the_elderly_A_retrospective_analysis_of_an_Australian_real-world_cohort/links/5fe1cb3592851c13feada01d/225P-Prostate-cancer-treatments-and-outcomes-in-the-elderly-A-retrospective-analysis-of-an-Australian-real-world-cohort.pdf","googleCitationCount":0,"googleAuthor":"J Shapiro","statusesArray":[]},{"title":"Reduced risk of second primary cancer in patients treated with immune checkpoint inhibitors for a first cancer","googleId":"J7ND1h6aM-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42429-9/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"81P Monalizumab in combination with cetuximab post platinum and anti-PD-(L) 1 in patients with recurrent/metastatic squamous cell carcinoma of the head and neck …","googleId":"bAC_gdf0nIMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43081-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"GEP-NET: Knowledge gaps in the recent ESMO Guidelines","googleId":"N7A2l-77HNIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39801-X/abstract","googleCitationCount":0,"googleAuthor":"D Yip","statusesArray":[]},{"title":"927P Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2nd line treatment for PD-L1 unselected …","googleId":"m2y1W-7xC5AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41038-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer","googleId":"8aobD9_g5yoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40047-X/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"54P Impact of comorbidity and venous thromboembolism on outcome in real-life non-small cell lung cancer (NSCLC) patients treated with immune checkpoint …","googleId":"GLNiwjdreLwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43054-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"PI3K pathway biomarkers and clinical response in a phase I/Ib study of GDC-0077 in hormone receptor-positive/HER2-negative breast cancer (HR+/HER2–BC)","googleId":"G1VswiwXbC8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40434-X/abstract","googleCitationCount":0,"googleAuthor":"A Cervantes","statusesArray":[]},{"title":"1570P The emotional impact of COVID-19 outbreak on cancer out-patients and their caregivers: Impressions from the heart of the Italian pandemic","googleId":"yg282uRgIfMJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506410/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2053","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & …","googleId":"vHLCS3cZvHoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42376-2/abstract","googleCitationCount":2,"googleAuthor":"LC Villaruz","statusesArray":[]},{"title":"Beneficial effects of exercise in oncology-MoviS:'Movement and Health Beyond Care'","googleId":"sSttjVTeJFsJ","googleLink":"https://www.researchgate.net/profile/Valentina_Natalucci/publication/345371704_238P_Beneficial_effects_of_exercise_in_oncology_-_MoviS_'Movement_and_Health_Beyond_Care'/links/5fabdce792851cf7dd0df659/238P-Beneficial-effects-of-exercise-in-oncology-MoviS-Movement-and-Health-Beyond-Care.pdf","googleCitationCount":0,"googleAuthor":"F Lucertini","statusesArray":[]},{"title":"Real-world survival in advanced gastro-oesophagealadenocarcinoma with best supportive care","googleId":"0pvXNBko2A4J","googleLink":"https://discovery.dundee.ac.uk/en/publications/real-world-survival-in-advanced-gastro-oesophagealadenocarcinoma-","googleCitationCount":0,"googleAuthor":"M Baxter","doi":"10.1016/j.annonc.2020.08.1963","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"135TiP GELATO-trial: Assessing the efficacy of carboplatin and atezolizumab in metastatic lobular breast cancer","googleId":"LDrXUNEh5DkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36316-X/abstract","googleCitationCount":1,"googleAuthor":"HM Horlings","statusesArray":[]},{"title":"714P Time to deterioration in quality of life in previously untreated patients with advanced renal cell carcinoma (aRCC) in CheckMate 214","googleId":"4SgBHLc2U48J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40782-3/abstract","googleCitationCount":0,"googleAuthor":"D Cella","statusesArray":[]},{"title":"1573P Anxiety and depression in cancer patients during the COVID-19 pandemic: A single-centre study","googleId":"-77RZuU6VIYJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506327/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.2056","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"886MO Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab …","googleId":"jDIMlaRugr8J","googleLink":"https://www.researchgate.net/profile/Ewa_Paszkiewicz-Kozik/publication/345365950_886MO_Health-related_quality_of_life_HRQoL_from_KEYNOTE-204_A_phase_III_randomized_open-label_study_of_pembrolizumab_pembro_vs_brentuximab_vedotin_BV_in_relapsed_or_refractory_classical_Hodgkin_lympho/links/5fcf7fe745851568d149e18d/886MO-Health-related-quality-of-life-HRQoL-from-KEYNOTE-204-A-phase-III-randomized-open-label-study-of-pembrolizumab-pembro-vs-brentuximab-vedotin-BV-in-relapsed-or-refractory-classical-Hodgkin-lymp.pdf","googleCitationCount":0,"googleAuthor":"PL Zinzani","statusesArray":[]},{"title":"LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial …","googleId":"syHLy6ncWDsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42347-6/abstract","googleCitationCount":0,"googleAuthor":"PA Konstantinopoulos","statusesArray":[]},{"title":"Abnormal breast detection by an improved AlexNet model","googleId":"IOdQ3WleadwJ","googleLink":"https://www.researchgate.net/profile/Yu_Dong_Zhang/publication/344747342_Abnormal_breast_detection_by_an_improved_AlexNet_model/links/5f8d6af1a6fdccfd7b6c10f6/Abnormal-breast-detection-by-an-improved-AlexNet-model.pdf","googleCitationCount":0,"googleAuthor":"Y Zhang","statusesArray":[]},{"title":"SO-32 Biomarker analysis of the phase III IMblaze370 trial of atezolizumab plus cobimetinib or atezolizumab monotherapy vs regorafenib in third-line CRC","googleId":"jI78bMamBCIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39346-7/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1268P JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung …","googleId":"wcSWvX_-cKMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41578-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"299MO Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC","googleId":"MT8GiBrx67EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42784-X/abstract","googleCitationCount":0,"googleAuthor":"DSW Tan","statusesArray":[]},{"title":"254TiP ENGOT-cx11/KEYNOTE-A18: A phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally …","googleId":"qjNVspbGjjsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42739-5/abstract","googleCitationCount":0,"googleAuthor":"N Colombo","statusesArray":[]},{"title":"258O A germline variant rs2736098 in the TERT gene is a novel predisposition allele associated with JAK2V617F-positive myeloproliferative neoplasms","googleId":"4LusPu_fc28J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42743-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"LBA73 The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A* 01: 01","googleId":"-kDYtvPMIDcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42396-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"73P αGalCer/antibody complex targeting EGFR-tumor-associated iNKT to restore the immune response","googleId":"EotP3qwOTq8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43074-1/abstract","googleCitationCount":0,"googleAuthor":"J Le Pendu","statusesArray":[]},{"title":"43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo)+ chemotherapy (chemo) for previously untreated locally recurrent inoperable …","googleId":"fuOjm31MkA4J","googleLink":"https://www.researchgate.net/profile/Mastura_Md_Yusof2/publication/346525959_Phase_III_KEYNOTE-355_study_of_pembrolizumab_pembro_vs_placebo_pbo_chemotherapy_chemo_for_previously_untreated_locally_recurrent_inoperable_or_metastatic_triplenegative_breast_cancer_TNBC_Results_for_/links/5fc6253d4585152e9be8bbca/Phase-III-KEYNOTE-355-study-of-pembrolizumab-pembro-vs-placebo-pbo-chemotherapy-chemo-for-previously-untreated-locally-recurrent-inoperable-or-metastatic-triplenegative-breast-cancer-TNBC-Results-fo.pdf","googleCitationCount":0,"googleAuthor":"DW Cescon","statusesArray":[]},{"title":"102P TNFa and IL-2 armed adenovirus promotes abscopal effect in mice treated with anti-PD-1 immunotherapy","googleId":"jZ7wCavIX48J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43104-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"976TiP SPEARHEAD-2 trial design: A phase II pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck …","googleId":"Med4qDldSuwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41087-7/abstract","googleCitationCount":0,"googleAuthor":"EE Cohen","statusesArray":[]},{"title":"Perioperative pembrolizumab+ platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study …","googleId":"FL1qm8Bic58J","googleLink":"http://merck.creative.studios.s3.amazonaws.com/ESMO_2020/Tsuboi_KN671_TiP_ESMO_2020_poster_presented.pdf","googleCitationCount":0,"googleAuthor":"T Kato","statusesArray":[]},{"title":"782P Real-world evidence of the impact of prior autoimmune disease on immune checkpoint inhibitor outcomes in patients with metastatic urothelial cancer","googleId":"c9M59Sg4RU0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40850-6/abstract","googleCitationCount":0,"googleAuthor":"S Abou Alaiwi","statusesArray":[]},{"title":"1927TiP LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naïve RET-mutant medullary thyroid cancer (MTC)","googleId":"9qfIwjlxw8EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41411-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"3MO Mutational signatures in the perspective of tumour mutational burden in patients with non-small cell lung cancer","googleId":"PsR9HfyZUxMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42227-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pamiparib in combination with …","googleId":"VnZRITHs3_0J","googleLink":"https://www.beigenemedical.com/CongressDocuments/Stradella%20BGB-290%20103%20ESMO%20Abstract%202020.pdf","googleCitationCount":0,"googleAuthor":"S Goel","statusesArray":[]},{"title":"772P Phase Ib/II study of durvalumab plus guadecitabine in advanced clear cell renal cell cancer (ccRCC)","googleId":"OixUi146y1MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40840-3/abstract","googleCitationCount":0,"googleAuthor":"R Garje","statusesArray":[]},{"title":"Phase III study of GDC-0077 or placebo (pbo) with palbociclib (P)+ fulvestrant (F) in patients (pts) with PIK3CA-mutant/hormone receptor-positive/HER2-negative …","googleId":"aktggodX200J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40453-3/abstract","googleCitationCount":0,"googleAuthor":"S Loibl","statusesArray":[]},{"title":"687TiP ARC-6: A phase Ib/II, open-label, randomized platform study evaluating the efficacy and safety of AB928-based treatment combinations in patients with …","googleId":"rjIN7DaWRwIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42078-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"885TiP LIO-1: A phase II study of lucitanib+ nivolumab in patients (pts) with gynaecological tumours (CO-3810-101; NCT04042116; ENGOT-GYN3/AGO/LIO)","googleId":"qVg7WcdP6rYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42088-5/abstract","googleCitationCount":0,"googleAuthor":"I Vergote","statusesArray":[]},{"title":"1416TiP CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS (G12C) inhibitor, versus docetaxel in patients with previously treated advanced …","googleId":"tah5JpKU64YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41726-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"O-17 A TNM-Immune (TNM-I) classification staging system for predicting survival in colon cancer in a multicenter international SITC study","googleId":"FwfP9E0A4_cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39369-8/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro)+ olaparib (ola) vs pembro+ chemotherapy after induction with first-line …","googleId":"SIWrjYBG1jIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42579-7/abstract","googleCitationCount":0,"googleAuthor":"F Andre","statusesArray":[]},{"title":"1776P Analysis of potencial drug interactions in oncologic patients diagnosed with COVID-19","googleId":"_3bmBPHe6QYJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506444/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1840","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"VHIO immune gene-expression signature (VIGex) to enrich patient selection in immunotherapy (IT) phase I clinical trials","googleId":"92TUpGd7AocJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40641-6/abstract","googleCitationCount":0,"googleAuthor":"FM Mancuso","statusesArray":[]},{"title":"P-49 A study of first-line treatments for patients with BRAFV600E mutant metastatic colorectal cancer in a real-life setting: CAPSTAN study","googleId":"Wj8luChUwvkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39430-8/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"50P Update of systematic reviews and meta-analyses studying the association between antibiotic use and clinical outcomes of cancer patients treated with immune …","googleId":"4eRVcoc18QIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43050-9/abstract","googleCitationCount":0,"googleAuthor":"G Zalcman","statusesArray":[]},{"title":"1074TiP SGNTGT-001: A phase I study of SGN-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies","googleId":"DBt3vigUXTcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41190-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"400P Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study","googleId":"VOYR-dmc-64J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42885-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"The legacy of Professor Aron Goldhirsch","googleId":"7BZcYuFetUsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36375-4/abstract","googleCitationCount":0,"googleAuthor":"RD Gelber","statusesArray":[]},{"title":"1594P Harmonising patient-access programmes","googleId":"a4Zmd73-VfYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41899-X/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Undergraduate education in Medical Oncology lags behind in Greek Universities.","googleId":"M02ggrKsbxIJ","googleLink":"https://www.researchgate.net/profile/Dimitrios_Ragias/publication/344771916_Undergraduate_education_in_Medical_Oncology_lags_behind_in_Greek_Universities/links/5f8ec93da6fdccfd7b6eb014/Undergraduate-education-in-Medical-Oncology-lags-behind-in-Greek-Universities.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"5P Uncovering the evolution of glioblastoma proteome landscape from primary to the recurrent stage for development of novel diagnostic and predictive biomarkers","googleId":"zMeMTd9iP9MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43003-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"222P Tolerability and treatment response to darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) in the phase III …","googleId":"et_wvBWgYoYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42933-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1152P Influence of dietary and physical exercise habits on the melanoma risk: A case-control study","googleId":"mlT5FbUfKwMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41271-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Metastatic colorectal cancer derived organoids recapitulate genomic profile and treatment response of the original tumor","googleId":"IP6SWOfGVAAJ","googleLink":"https://www.researchgate.net/profile/Vincenza_Granata/publication/345368993_491P_Neoadjuvant_nivolumab_in_early_stage_colorectal_cancer/links/5fe9bf9ba6fdccdcb80d2dae/491P-Neoadjuvant-nivolumab-in-early-stage-colorectal-cancer.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1O Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy","googleId":"AzqP6mSU2dsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42999-0/abstract","googleCitationCount":0,"googleAuthor":"ZJ Assaf","statusesArray":[]},{"title":"822P Comparison of toxicities of PARP inhibitors used in gynaecological cancers observed at a large cancer centre","googleId":"WRUE06QEFLcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40957-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"812MO Maintenance olaparib+ bevacizumab (bev) in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): RECIST and/or CA-125 …","googleId":"C5-bvYuC2R8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40947-0/abstract","googleCitationCount":0,"googleAuthor":"N Colombo","statusesArray":[]},{"title":"1135P Plasma proteomics in patients with metastatic cutaneous melanoma treated with targeted therapy","googleId":"1xyWLOTRFooJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41254-2/abstract","googleCitationCount":0,"googleAuthor":"J Lehtiö","statusesArray":[]},{"title":"1153TiP A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable …","googleId":"t0Fkwu2TtDoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41272-4/abstract","googleCitationCount":0,"googleAuthor":"PA Ascierto","statusesArray":[]},{"title":"Germline mutation status and therapy response in patients with homologous recombination deficient, HER2-negative early breast cancer: Results of the GeparOLA …","googleId":"01hZQvASblIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40294-7/abstract","googleCitationCount":1,"googleAuthor":"C Ernst","statusesArray":[]},{"title":"1287P Efficacy and safety of entrectinib in locally advanced/metastatic ROS1 fusion-positive NSCLC: An updated integrated analysis","googleId":"JjjtItL3g-4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41597-2/abstract","googleCitationCount":0,"googleAuthor":"S Siena","statusesArray":[]},{"title":"P-184 A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal …","googleId":"uVw0CXnNv2kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39565-X/pdf","googleCitationCount":0,"googleAuthor":"J Shahidi","statusesArray":[]},{"title":"1724P Changes in the outpatient and inpatient clinic admissions during COVID-19 pandemic: Anticipating and mitigating risks for cancer patients","googleId":"r0f52vU88jAJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506310/","googleCitationCount":0,"googleAuthor":"DC Guven","doi":"10.1016/j.annonc.2020.08.1788","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Multicentre match-paired analysis of advanced biliary cancer (ABC) long-term survivors: The BILONG study","googleId":"_65neRP3uEUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40037-7/fulltext","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1073TiP A phase I, first-in-human, multicenter, open-label, dose-escalation study of IPH5201 as monotherapy or in combination with durvalumab±oleclumab in …","googleId":"aPIrB5fzXBwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41189-5/abstract","googleCitationCount":0,"googleAuthor":"BA Carneiro","statusesArray":[]},{"title":"76P Highly potent fully human anti-VISTA antibodies efficiently abrogate the interaction of this new target checkpoint inhibitor to its different putative receptors at …","googleId":"GPoQCHbWJsYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43077-7/abstract","googleCitationCount":0,"googleAuthor":"S Iadonato","statusesArray":[]},{"title":"705MO Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naïve, platinum-experienced patients (pts) …","googleId":"V4Tn09p6vQ0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40773-2/abstract","googleCitationCount":0,"googleAuthor":"P Msaouel","statusesArray":[]},{"title":"603TiP Phase II, open-label study of erdafitinib in adult and adolescent patients (pts) with advanced solid tumours harboring fibroblast growth factor receptor (FGFR) …","googleId":"C3vLqCPLY4IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40713-6/abstract","googleCitationCount":0,"googleAuthor":"C Massard","statusesArray":[]},{"title":"1015TiP Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha fetoprotein following a non-sorafenib based systemic therapy: An …","googleId":"l3qEBh6jOoIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41127-5/abstract","googleCitationCount":0,"googleAuthor":"PR Galle","statusesArray":[]},{"title":"1149P Validation of a model combining clinicopathologic risk factors and a gene expression profile to identify primary melanoma patients who can safely forgo …","googleId":"SHgtRp2MbXoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41268-2/abstract","googleCitationCount":0,"googleAuthor":"A Meves","statusesArray":[]},{"title":"Reply to the Letter to the Editor “Androgen deprivation therapy may constitute a more effective prophylactic than therapeutic strategy in COVID-19 patients” by N …","googleId":"hBSUDjbhlaAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42102-7/abstract","googleCitationCount":0,"googleAuthor":"M Rugge","statusesArray":[]},{"title":"1527P Assessing clinical benefit of olaparib maintenance treatment in subgroups of patients with germline BRCA mutation (gBRCAm) and metastatic pancreatic …","googleId":"rddMtTP4V0sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42006-X/abstract","googleCitationCount":0,"googleAuthor":"D Hochhauser","statusesArray":[]},{"title":"951P The relationship between overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in immune checkpoint inhibitor clinical trials …","googleId":"sWi0BbsysuQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41062-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"795TiP Phase III study of the programmed cell death protein 1 inhibitor PF-06801591 plus bacillus Calmette-Guérin for non-muscle invasive bladder cancer","googleId":"xfHDrxq-F9gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40863-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1017TiP KEYNOTE-937 trial in progress: adjuvant pembrolizumab in patients with hepatocellular carcinoma (HCC) and complete radiologic response after surgical …","googleId":"XkRWYKhgilIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41129-9/abstract","googleCitationCount":0,"googleAuthor":"T Yau","statusesArray":[]},{"title":"601TiP First-in-human phase I study of a novel oral Wee1 inhibitor (Debio 0123) in combination with carboplatin in patients with advanced solid tumours","googleId":"jcoET7-eTxUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40711-2/abstract","googleCitationCount":0,"googleAuthor":"H Gelderblom","statusesArray":[]},{"title":"O-13 Efficacy and safety of ripretinib as≥ 4th-line therapy for patients with gastrointestinal stromal tumor following crossover from placebo: Analyses from …","googleId":"OMTWrLMlwnIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39365-0/pdf","googleCitationCount":0,"googleAuthor":"M Heinrich","statusesArray":[]},{"title":"133TiP A phase II trial of nivolumab+ palbociclib+ anastrozole in postmenopausal women with ER+/HER2–primary breast cancer: CheckMate 7A8","googleId":"iLknP9A6BlEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36314-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"17P Effects of tumour mutation burden on the antigen presentation pathway","googleId":"-sfk-VApd3sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43015-7/abstract","googleCitationCount":0,"googleAuthor":"J Park","statusesArray":[]},{"title":"O-5 Efficacy and safety of nivolumab+ ipilimumab in Asian patients with advanced hepatocellular carcinoma: Subanalysis of the CheckMate 040 study","googleId":"RbrnsbXhNpEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39357-1/pdf","googleCitationCount":0,"googleAuthor":"T Yau","statusesArray":[]},{"title":"1674MO ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: Implications for …","googleId":"sz9Q_RlrY4gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41735-1/abstract","googleCitationCount":0,"googleAuthor":"R Bao","statusesArray":[]},{"title":"722P Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study","googleId":"XgKxZ6GPn-AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40790-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1085P Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only …","googleId":"uvymba9MgUYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41205-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1500TiP A phase Ib/II, multicenter, open-label, dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd; DS-8201) monotherapy and …","googleId":"cJb1C-hqXCkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42002-2/abstract","googleCitationCount":0,"googleAuthor":"YY Janjigian","statusesArray":[]},{"title":"1092P Non-progression with avelumab treatment in patients with metastatic Merkel cell carcinoma (mMCC) is associated with a clinically meaningful better health …","googleId":"4QWN6eyFfEwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41212-8/abstract","googleCitationCount":0,"googleAuthor":"M Bharmal","statusesArray":[]},{"title":"Long-term outcomes of patients with node-negative,≤ 3cm, HER2+ breast cancer (BC) enrolled in ALTTO","googleId":"zkSlEXbHU9sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40339-4/abstract","googleCitationCount":0,"googleAuthor":"D Eiger","statusesArray":[]},{"title":"356MO Osimertinib adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) NSCLC (ADAURA): Central nervous system (CNS) disease recurrence","googleId":"dsizqBIrRikJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42840-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"545P Preclinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer","googleId":"EQr0uPMqFK8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40655-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"P-38 KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or …","googleId":"JOWUEFuvH7EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39419-9/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1721P Prolonged positive SARS-CoV-2 RT-PCR in cancer outpatients requires specific reorganization of cancer centres","googleId":"Zo_wuGd71aMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41781-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1979MO Inhibition of fatty acid synthase (FASN) activity induces cytotoxicity on gefitinib-and osimertinib-resistant EGFR-mutated non-small cell lung cancer cells","googleId":"7MI5n92bbGgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41281-5/abstract","googleCitationCount":0,"googleAuthor":"J Bosch-Barrera","statusesArray":[]},{"title":"83MO AMG 510, a novel small molecule inhibitor of KRAS (G12C), for patients (pts) with advanced gastrointestinal (GI) cancers: Results from the CodeBreaK100 …","googleId":"CZLp4p4bmRQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42594-3/abstract","googleCitationCount":0,"googleAuthor":"M Fakih","statusesArray":[]},{"title":"732P Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study","googleId":"GfoMooNlzOEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40800-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"O-19 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors","googleId":"y1SE2AmCMT0J","googleLink":"https://www.researchgate.net/profile/Gabor_Liposits/publication/342777574_O-19_Feasibility_of_switching_to_S-1_upon_other_fluoropyrimidine-related_cardiotoxicity_during_chemotherapy_for_solid_tumors/links/5f3f47f2a6fdcccc43de7307/O-19-Feasibility-of-switching-to-S-1-upon-other-fluoropyrimidine-related-cardiotoxicity-during-chemotherapy-for-solid-tumors.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"798TiP Study EV-302: A 3-arm, open-label, randomized phase III study of enfortumab vedotin plus pembrolizumab and/or chemotherapy, versus chemotherapy alone …","googleId":"24GPr3hYO9cJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42066-6/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"322P Challenged faced by cancer patients during the COVID-19 pandemic","googleId":"dznFTYxK_oMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42807-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1412TiP Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)","googleId":"nOebhXKx0ZIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41722-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk …","googleId":"iZ2Y7sheeo8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42082-4/abstract","googleCitationCount":0,"googleAuthor":"U De Giorgi","statusesArray":[]},{"title":"596TiP Phase I first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumours","googleId":"IHLiaZ7yfekJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40706-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"852P Exploring the correlation between AXL expression and gene expression molecular subtyping (GEMS) in high grade serous ovarian cancer (HGSOC)","googleId":"o5Gh5AP7hOoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40987-1/abstract","googleCitationCount":0,"googleAuthor":"TZ Tan","statusesArray":[]},{"title":"597TiP A phase Ib study on a TRPV6-inhibitor, SORC13 in patients with advanced solid tumours","googleId":"iHSMPmvIppkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40707-0/abstract","googleCitationCount":0,"googleAuthor":"F Shaikh","statusesArray":[]},{"title":"1309P ARC-4: Efficacy and safety of AB928 plus carboplatin, pemetrexed and a PD-1 antibody in participants with metastatic non-small cell lung cancer (mNSCLC)","googleId":"pT6DpRHs_fUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41619-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1728P Evaluation of medical practices in oncology in a context of COVID-19 pandemic in France: Point of view of physicians, PRATICOVID study","googleId":"7CBXim5wugIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41788-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"559P Phase Ib study of CC-90011 plus etoposide and cisplatin (EP) in patients with first-line extensive-stage (ES) small cell lung cancer (SCLC)","googleId":"LWYHpOh-D78J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40669-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"301MO Genomic HLA as a predictive biomarker for survival among non-small cell lung cancer patient treated with single agent immunotherapy","googleId":"_r-ennh1AKYJ","googleLink":"https://researchrepository.murdoch.edu.au/id/eprint/59696/","googleCitationCount":0,"googleAuthor":"J Lo","doi":"10.1016/j.annonc.2020.10.295","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1298P RELAY, ramucirumab plus erlotinib (RAM+ ERL) versus placebo plus erlotinib (P+ ERL) in untreated EGFR mutated metastatic non-small cell lung cancer …","googleId":"sPrBZDWYG2UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41608-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Vemurafenib in non-melanoma V600 and non-V600 BRAF mutated cancers: Results of the AcSé basket trial","googleId":"Tx19qb7l9WsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40648-9/abstract","googleCitationCount":0,"googleAuthor":"J Mazieres","statusesArray":[]},{"title":"1056P Durvalumab (D) in combination with chemoradiotherapy (CRT) in solid tumours: Phase I CLOVER study","googleId":"b7nyr-tpD68J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41172-X/abstract","googleCitationCount":0,"googleAuthor":"SD Karam","statusesArray":[]},{"title":"1947P Single cell analysis reveals that CD8+ T cell clone size determines response to immune checkpoint blockade","googleId":"OL6jpTOwV-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41335-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1829P Are patient-reported symptoms and concerns affected by body mass index (BMI) and weight loss (WL) in patients with cancer cachexia?","googleId":"5lGviUgacYYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41472-3/abstract","googleCitationCount":0,"googleAuthor":"D Currow","statusesArray":[]},{"title":"777P Decrease in derived neutrophil-to-lymphocyte ratio (dNLR) related to immune checkpoint inhibitors (ICI) benefit in patients with metastatic urothelial …","googleId":"DftewNKISvoJ","googleLink":"https://www.researchgate.net/profile/Teresa_Gorria/publication/345365373_777P_Decrease_in_derived_neutrophil-to-lymphocyte_ratio_dNLR_related_to_immune_checkpoint_inhibitors_ICI_benefit_in_patients_with_metastatic_urothelial_carcinoma_mUC/links/5fb4c67992851cf24cdc3921/777P-Decrease-in-derived-neutrophil-to-lymphocyte-ratio-dNLR-related-to-immune-checkpoint-inhibitors-ICI-benefit-in-patients-with-metastatic-urothelial-carcinoma-mUC.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"879TiP Phase II study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in platinum-experienced advanced cervical cancer","googleId":"D6fPlMIXtJgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41014-2/abstract","googleCitationCount":0,"googleAuthor":"MJ Birrer","statusesArray":[]},{"title":"Optimal dose of eribulin as first line treatment in elderly patients≥ 70 years with advanced breast cancer: A multicenter phase II trial","googleId":"MOI6xkRE6fIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40443-0/fulltext","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1003P Baseline (BL) liver function and outcomes in patients (pts) with unresectable hepatocellular carcinoma (HCC) in KEYNOTE-240","googleId":"S9y-9iuEei4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41115-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"434P Pan-Canadian evidence-based, consensus-driven cancer treatment protocols/information for use at the point of care by medical oncologists? Is there a need?","googleId":"FRqeZR3CUAsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42917-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1586MO Pivotal trial endpoints of drugs for rare and non-rare cancers in the US and Europe","googleId":"ASEtyW4Haz0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42389-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"EPIK-B2: A phase III study of alpelisib (ALP) as maintenance therapy with trastuzumab (T) and pertuzumab (P) in patients (pts) with PIK3CA-mutated (mut) human …","googleId":"MSZIGIaRmzgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40450-8/abstract","googleCitationCount":0,"googleAuthor":"SKL Chia","statusesArray":[]},{"title":"387P Phase Ib study of savolitinib±osimertinib in Japanese patients (pts) with advanced solid malignancies & EGFRm NSCLC: TATTON part C","googleId":"GRbZLQGscRkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42872-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1784P Activity of lurbinectedin in second-line SCLC patients candidates for platinum re-challenge","googleId":"eWGHKWreEQMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41541-8/abstract","googleCitationCount":0,"googleAuthor":"V Subbiah","statusesArray":[]},{"title":"1480P M2 macrophages could promote an immunosuppressive phenotype in a prospective cohort of advanced gastric cancer patients","googleId":"SFkhUqSjQpgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41982-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"801TiP A phase II study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (ABATE)","googleId":"0I3OOpVT4vAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42069-1/abstract","googleCitationCount":0,"googleAuthor":"N Davis","statusesArray":[]},{"title":"1622MO Clinical benefit with ripretinib as≥ 4th line treatment in patients with advanced gastrointestinal stromal tumors (GIST): Update from the phase III INVICTUS …","googleId":"8PvcH53-gMsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41844-7/abstract","googleCitationCount":0,"googleAuthor":"JR Zalcberg","statusesArray":[]},{"title":"1305P Health-related quality of life (HRQoL) in a phase III study of first-line brigatinib (BRG) vs crizotinib (CRZ) in NSCLC: Updated results from ALTA-1L","googleId":"xWNBQQhxV5QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41615-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"27P Methodology for identification of clinically relevant targets for TCR-immunotherapy in hepatocellular carcinoma","googleId":"Bd05mf5zqDwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43026-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib+ dostarlimab in patients with platinum …","googleId":"ttzQesvVa28J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41018-X/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1931MO A HER3/DUSP6 loop determines sensitivity to HER2-targeted therapies in breast cancer","googleId":"_6kcy9s1oUcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41320-1/abstract","googleCitationCount":0,"googleAuthor":"M Momeny","statusesArray":[]},{"title":"138P TALAPRO-1: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer …","googleId":"-ZcARVSTD5wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40255-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1014TiP PROOF: A multicenter, open-label, randomized, phase III trial of infigratinib vs gemcitabine+ cisplatin in patients with advanced cholangiocarcinoma with …","googleId":"UTG7sR_6ek0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41126-3/abstract","googleCitationCount":0,"googleAuthor":"I Borbath","statusesArray":[]},{"title":"Treatment trends and clinical outcomes of left sided, RAS/RAF wild type metastatic colorectal cancer in the United States","googleId":"iC70rH2n3koJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40569-1/abstract","googleCitationCount":0,"googleAuthor":"CD Nevala-plagemann","statusesArray":[]},{"title":"67TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast …","googleId":"5FtT8OfTuYYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42578-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1749P COVID-19 impact and predictive factors for mortality in cancer patients","googleId":"tEm3YRxGMmIJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506432/","googleCitationCount":0,"googleAuthor":"ES Garcia","doi":"10.1016/j.annonc.2020.08.1813","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1313P Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro)+ chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC","googleId":"BwFxfBog9JIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41623-0/abstract","googleCitationCount":0,"googleAuthor":"N Peled","statusesArray":[]},{"title":"828P Expected versus observed response to platinum-based chemotherapy after poly (ADP-ribose) polymerase inhibitor treatment for relapsed ovarian cancer","googleId":"NaJieMtB8fgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40963-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"970P MEDINDUCTION: Phase I trial evaluating the safety of durvalumab in combination with docetaxel, cisplatin and 5-FU (DCF) as induction therapy for locally …","googleId":"6c51DXjAloIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41081-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Tumour mutation burden and response to immune checkpoint inhibitors in solid tumors: A systematic review and meta-analysis","googleId":"eoRPI5_Ywt0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40234-0/abstract","googleCitationCount":0,"googleAuthor":"K Choucair","statusesArray":[]},{"title":"1112P Intralesional therapy with talimogene laherparepvec for stage IIIB-IVM1a melanoma is able to achieve a high rate of complete and durable responses and is …","googleId":"o_4z77fzDZAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41231-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"924P SNS-301 added to pembrolizumab in patients (Pts) with ASPH+ advanced squamous cell carcinoma of the head & neck (SCCHN)","googleId":"ldeyV1ThPt4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41035-X/abstract","googleCitationCount":0,"googleAuthor":"AP Algazi","statusesArray":[]},{"title":"1020O A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART® molecule in patients with …","googleId":"1tvMSgFOEvEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41136-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1471P 3D patient-derived gastric cancer organoids as a tool for functional precision medicine for gastric cancer patients","googleId":"fPc1JQmOe6gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41973-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"816MO AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)","googleId":"eTHQtoYTDesJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40951-2/abstract","googleCitationCount":0,"googleAuthor":"A du Bois","statusesArray":[]},{"title":"1442P Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus …","googleId":"kzQ2pz3phHwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41944-1/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"Neoadjuvant nivolumab in early stage colorectal cancer","googleId":"jKr1Q9F-U6MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40598-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1052P Genetic modification of Iovance's TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancer","googleId":"L1XL5bvOC7kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41168-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"599TiP BT8009-100 phase I/II study of the safety, pharmacokinetics, & preliminary clinical activity of BT8009 in patients with Nectin-4 expressing advanced …","googleId":"E5F6O6WJs84J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40709-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"923P Immune alterations in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN)","googleId":"M7kDEdBp7EEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41034-8/abstract","googleCitationCount":0,"googleAuthor":"JM Curry","statusesArray":[]},{"title":"830P Subanalysis of a randomized phase III study comparing trabectedin and PLD vs PLD alone in patients with recurrent ovarian cancer (ROC)","googleId":"OSKOXWDPhPIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40965-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"69P TGFBI promoter methylation validation as an epigenetic biomarker for trastuzumab resistance in HER2+ breast cancer patients cohort","googleId":"i9Vj2W3nhc4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36282-7/abstract","googleCitationCount":0,"googleAuthor":"A Hernandez","statusesArray":[]},{"title":"Central nervous system recurrence in HER2-positive metastatic colorectal cancer","googleId":"YZc-9PapoKYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40613-1/abstract","googleCitationCount":0,"googleAuthor":"A Sartore-Bianchi","statusesArray":[]},{"title":"825P Olaparib maintenance therapy in routine clinical practice: Quality of life interim results of the non-interventional C-PATROL study in ovarian cancer patients in …","googleId":"DdrUm-7cXQgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40960-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"A new benchmark for designing phase II trials for advanced or metastatic leiomyosarcoma (LMS) patients using progression free survival (PFS) as primary endpoint …","googleId":"fU-O06CSqxAJ","googleLink":"https://leiomyosarcoma.info/wp-content/uploads/2020/09/Georgios_Kantidakis_Presentation_ESMO2020.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"266O Combination ipilimumab and nivolumab in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Updated efficacy and safety analysis of NCT03097939","googleId":"0RWU3w1FjL0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42751-6/abstract","googleCitationCount":0,"googleAuthor":"DSW Tan","statusesArray":[]},{"title":"1770P Clinical and epidemiologic aspects of patients with cancer and COVID-19 in a Brazilian cancer center","googleId":"xo_07ErPedUJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506322/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1834","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"SO-33 Clonal selection of RAS mutant metastatic colorectal cancer into RAS wild-type during first-line therapy","googleId":"ns8DqLLTgV8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39347-9/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Real-world clinical outcomes with pembrolizumab (pembro) for treatment of advanced melanoma: Evidence from the United States community oncology setting","googleId":"aQkn5Y0UhzwJ","googleLink":"http://merck.creative.studios.s3.amazonaws.com/ESMO_2020/Cowey_RW_outcomes_ESMO_2020_poster_presented.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"438P Real-world data of relapse after adjuvant treatment (Tx) in high-risk melanoma","googleId":"9jJ6BX60R2kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42921-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations","googleId":"IjfnwVxZ0t4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42375-0/abstract","googleCitationCount":1,"googleAuthor":"R Cornelissen","statusesArray":[]},{"title":"320P Psychometric interplay of the perception of the real-life impact of COVID-19 pandemic: A cross-sectional survey of patients with newly diagnosed malignancies","googleId":"lLCMcNL8MM4J","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680616/","googleCitationCount":0,"googleAuthor":"KM Cheung","doi":"10.1016/j.annonc.2020.10.314","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"607P Prognostic value of early total, free and bound to lipoprotein fractions plasma mitotane measurements in advanced adrenocortical carcinoma at the time of …","googleId":"NqOZ-nbDA5wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40463-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"302MO Development of a flow cytometry-based whole-blood prognostic immune signature in metastatic cancer patients treated with immune checkpoint inhibitors","googleId":"hSv2Fo9xzlUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42787-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"P-105 Defining novel regulators of inflammatory signaling in pancreatic cancer","googleId":"5gGcSJHLY10J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39486-2/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1812MO Effects of oncologic rehabilitation during adjuvant endocrine therapy in overweight or obese patients with breast cancer","googleId":"qddIujlkAwoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41455-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"141P Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple negative breast cancer","googleId":"8039qBCRDE8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36321-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Causes of mortality in elderly UICC stage III colon cancer (CC) patients (pts.)-Tumor related death and competing risks from the Colopredict Plus (CPP) registry","googleId":"CZhYLcIVQ6IJ","googleLink":"https://www.researchgate.net/profile/Frank_Hartmann3/publication/345366143_409P_Causes_of_mortality_in_elderly_UICC_stage_III_colon_cancer_CC_patients_pts_-_Tumor_related_death_and_competing_risks_from_the_Colopredict_Plus_CPP_registry/links/5fe1cb2e299bf140883370c9/409P-Causes-of-mortality-in-elderly-UICC-stage-III-colon-cancer-CC-patients-pts-Tumor-related-death-and-competing-risks-from-the-Colopredict-Plus-CPP-registry.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"188P Impact of HIV infection (HIV+) on baseline characteristics and survival of breast cancer (BC) patients (pts): A systematic review and meta-analysis","googleId":"jwjdOXk6t2wJ","googleLink":"https://www.researchgate.net/profile/Daniel_Eiger/publication/341613600_188P_Impact_of_HIV_infection_HIV_on_baseline_characteristics_and_survival_of_breast_cancer_BC_patients_pts_A_systematic_review_and_meta-analysis/links/5eda743e299bf1c67d41f37b/188P-Impact-of-HIV-infection-HIV-on-baseline-characteristics-and-survival-of-breast-cancer-BC-patients-pts-A-systematic-review-and-meta-analysis.pdf","googleCitationCount":0,"googleAuthor":"M Bruzzone","statusesArray":[]},{"title":"1350P Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer (mNSCLC)","googleId":"m80FxVCmIBMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41660-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1948P Characterising the peripheral myeloid response to immune checkpoint blockade","googleId":"ziWeLbyRnToJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41336-5/abstract","googleCitationCount":0,"googleAuthor":"C Taylor","statusesArray":[]},{"title":"1899P Autoimmune diseases in centrally reviewed thymic epithelial tumours (TET)","googleId":"D-datYQ4438J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41438-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"P-131 Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial","googleId":"MOR_VZ6yTGMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39512-0/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"26P Cellulose beads prepared in deep eutectic solvent function as carrier and cytoprotective encapsulation matrix for CAR-T cells in T-cell therapy against …","googleId":"ZkvX-4Y-_mAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43025-X/abstract","googleCitationCount":0,"googleAuthor":"S Vuoti","statusesArray":[]},{"title":"The use of Ki67 testing and scoring in HR+, HER2-early breast cancer","googleId":"ttoEO90gwn8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40299-6/fulltext","googleCitationCount":0,"googleAuthor":"D Schlauch","statusesArray":[]},{"title":"Identification of proteome and secretome signatures in primary colorectal cancer associated fibroblasts","googleId":"HZtXqOaqnEEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40589-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"881TiP A multi-centre, open-label phase II trial of the combination of VB10. 16 and atezolizumab in patients with advanced or recurrent, non-resectable HPV16 …","googleId":"2zIJaq6uYnsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41016-6/abstract","googleCitationCount":0,"googleAuthor":"JF Baurain","statusesArray":[]},{"title":"32P Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular …","googleId":"ZicloNiyQvcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43032-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"80O Patient (pt) preference and satisfaction with the subcutaneous fixed-dose combination of pertuzumab (P) and trastuzumab (H) in pts with HER2-positive …","googleId":"DtcNZXMuluIJ","googleLink":"https://www.researchgate.net/profile/Ljiljana_Stamatovic/publication/341613407_80O_Patient_pt_preference_and_satisfaction_with_the_subcutaneous_fixed-dose_combination_of_pertuzumab_P_and_trastuzumab_H_in_pts_with_HER2-positive_early_breast_cancer_HER2_eBC_Interim_analysis_of_the/links/5f733fb0299bf1b53efd9a67/80O-Patient-pt-preference-and-satisfaction-with-the-subcutaneous-fixed-dose-combination-of-pertuzumab-P-and-trastuzumab-H-in-pts-with-HER2-positive-early-breast-cancer-HER2-eBC-Interim-analysis-of-th.pdf","googleCitationCount":0,"googleAuthor":"J Cruz","statusesArray":[]},{"title":"1128P Germline variation in PDCD1 is associated with survival in metastatic melanoma after anti-PD-1 monotherapy","googleId":"H74v8WhGFxYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41247-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"999P Real-life clinical data of cabozantinib for unresectable hepatocellular carcinoma","googleId":"-HdwU7nVYoYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41111-1/abstract","googleCitationCount":0,"googleAuthor":"F Tovoli","statusesArray":[]},{"title":"221P Patient-reported sexual and urinary function in nonmetastatic castration-resistant prostate cancer (nmCRPC) when treated with apalutamide (APA) vs placebo …","googleId":"RTM7WcqlL0MJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42932-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1687P Oncologists knowledge, attitude and practice in COVID-19 pandemic and its negative impact on them: An international study","googleId":"83OQD6pxv9EJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506425/","googleCitationCount":0,"googleAuthor":"AR Jazieh","doi":"10.1016/j.annonc.2020.08.1751","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"669P Body composition and clinical outcomes in men with metastatic castration-resistant prostate cancer (mCRPC)","googleId":"eMGxK1biXcAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40924-X/abstract","googleCitationCount":0,"googleAuthor":"AW Hahn","statusesArray":[]},{"title":"1354P Detection of EGFR T790M in EGFR activating mutation-positive advanced non-small cell lung cancer (NSCLC): Comparison between two assays on circulating …","googleId":"SO5KOI05Jc0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41664-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"794P UK practices for treatment of relapse in seminoma testicular cancer","googleId":"4BrliQYZ3YYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40862-2/abstract","googleCitationCount":0,"googleAuthor":"JK Joffe","statusesArray":[]},{"title":"33P Immune analysis of lymph nodes in relation to the presence or absence of tumour infiltrating lymphocytes in triple negative breast cancers","googleId":"WO3fCmfbxq8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36246-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer according the trials within cohorts design: The MEDOCC-CrEATE trial","googleId":"qnt-ms5BXJkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40627-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"A study of sustained androgen signaling dependence in metastatic castrate resistant prostate cancer (mCRPC)","googleId":"HlLfHtbuEp8J","googleLink":"https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/en/covidwho-800781","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.895","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"764P Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: Longitudinal expression, transcriptome-level effects and modulation of …","googleId":"bGymjMgfgLsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40832-4/abstract","googleCitationCount":0,"googleAuthor":"B Nodin","statusesArray":[]},{"title":"1937P ERN GENTURIS guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes","googleId":"5IcAomukcKQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41326-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)","googleId":"6T9Lc90fM_wJ","googleLink":"https://hal.archives-ouvertes.fr/hal-03040225/","googleCitationCount":1,"googleAuthor":"M Meylan","doi":"10.1016/j.annonc.2020.08.772","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"799TiP PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma …","googleId":"jNCOye1vhBUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42067-8/abstract","googleCitationCount":0,"googleAuthor":"DM Somford","statusesArray":[]},{"title":"1217P Breathomics eNose technology as a non-invasive, inexpensive, point-of-care predictive test to detect early stage lung cancer in never or former light smokers","googleId":"jNq2SEBjDD4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41415-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"97TiP Identification of therapeutic targets in patients with squamous cell carcinoma of the head and neck who progress on or after anti-PD-(L) 1 therapy: An IMMUcan …","googleId":"8BJVhT_6DS0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43098-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1813MO Impact of systemic inflammation, intramuscular adipose tissue content, and EORTC-QLQ-CAX24 symptom scale on the prognosis of patients with advanced …","googleId":"Ddj5Xk_NOGQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41456-5/abstract","googleCitationCount":0,"googleAuthor":"G De Castro","statusesArray":[]},{"title":"1771P Do breast cancer patients with COVID-19 have a poor prognosis? Experience in a hospital in Madrid","googleId":"KsxGEbRTvjQJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506445/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1835","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"972TiP Phase II study of intratumoral MK-1454 plus pembrolizumab compared with pembrolizumab monotherapy as first-line treatment for metastatic or unresectable …","googleId":"eA7MIaNKFf0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41083-X/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Avoid systemic overtreatment of postmenopausal breast cancer patients with ultralow MammaPrint result","googleId":"4UlVyhCmQGoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40289-3/abstract","googleCitationCount":0,"googleAuthor":"M Opdam","statusesArray":[]},{"title":"P-228 SGNLVA-005: Open-label, phase 2 study of ladiratuzumab vedotin (LV) for aerodigestive tract malignancies","googleId":"1boRZx0ArZgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39609-5/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1235TiP Perioperative pembrolizumab+ platinum-based chemotherapy for resectable locally advanced non-small cell lung cancer: The phase III KEYNOTE-671 study","googleId":"u2QV-XSvzv8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41433-4/abstract","googleCitationCount":0,"googleAuthor":"T Kato","statusesArray":[]},{"title":"1960P Differential induction of gene expression may explain differences in reported adverse event profiles between the FGFR-inhibitors derazantinib and erdafitinib …","googleId":"DmKuGlIMxRAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41348-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"SO-4 phase Ib/II, open-label, randomised evaluation of atezolizumab plus RO6874281 vs control in MORPHEUS–pancreatic ductal adenocarcinoma","googleId":"LmmTq6T-3IAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39318-2/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Prospective validation of a radiomics signature for chemoradiotherapy lung cancer patients","googleId":"BAnS3uS-N-UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40154-1/abstract","googleCitationCount":0,"googleAuthor":"R Leijenaar","statusesArray":[]},{"title":"748P Prognostic factors related to post-platinum atezolizumab for relapsed metastatic urothelial cancer (mUC) from the SAUL study","googleId":"EPSeRz3rrtAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40816-6/abstract","googleCitationCount":0,"googleAuthor":"A Bamias","statusesArray":[]},{"title":"1374P Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence","googleId":"sUkzQfnkFawJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41684-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"555P Metronomic oral vinorelbine (MOV) combined with tremelimumab (T)+ durvalumab (D) in advanced solid tumours (AST): Dose finding results","googleId":"ISlEffkEz78J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40665-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1669TiP A non-randomized, open-label phase II trial evaluating efficacy and feasibility of combined treatment with trabectedin and nivolumab in patients with …","googleId":"zC1a-g37oNIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41890-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"195TiP GLOW: Phase III study of first-line zolbetuximab+ CAPOX versus placebo+ CAPOX in Claudin18. 2⁺/HER2⁻ advanced/metastatic gastric or gastroesophageal …","googleId":"ZPOWZ3KdmnMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42950-3/abstract","googleCitationCount":0,"googleAuthor":"SE Al-Batran","statusesArray":[]},{"title":"32P The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of CDK 4/6 inhibitors in women with hormone receptor-positive/HER2 …","googleId":"B1JRqmVlUXwJ","googleLink":"https://www.researchgate.net/profile/Emma_Zattarin/publication/341613877_32P_The_neutrophil-to-lymphocyte_and_platelet-to-lymphocyte_ratios_predict_efficacy_of_CDK_46_inhibitors_in_women_with_hormone_receptor-positiveHER2-negative_advanced_breast_cancer/links/5f118389a6fdcc3ed70e5441/32P-The-neutrophil-to-lymphocyte-and-platelet-to-lymphocyte-ratios-predict-efficacy-of-CDK-4-6-inhibitors-in-women-with-hormone-receptor-positive-HER2-negative-advanced-breast-cancer.pdf","googleCitationCount":0,"googleAuthor":"C Fabbroni","statusesArray":[]},{"title":"HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer","googleId":"N9bgMVAznLUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40451-X/abstract","googleCitationCount":2,"googleAuthor":"AC Wolff","statusesArray":[]},{"title":"198TiP SPOTLIGHT: Phase III study of zolbetuximab+ mFOLFOX6 versus placebo+ mFOLFOX6 in first-line Claudin18. 2⁺/HER2⁻ advanced or metastatic gastric or …","googleId":"W1tLcjlF4-sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42953-9/abstract","googleCitationCount":0,"googleAuthor":"K Shitara","statusesArray":[]},{"title":"1330P Discontinuation of ICIs above 18 months of treatment in real-life patients with NSCLC: A multicentric retrospective study","googleId":"bDUPryYthm0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41640-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1O Inducible T cell co-stimulatory (ICOS) receptor agonist, GSK3359609 (GSK609) alone and combination with pembrolizumab: Preliminary results from INDUCE-1 …","googleId":"bJm57-k82PoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35982-2/abstract","googleCitationCount":0,"googleAuthor":"D Rischin","statusesArray":[]},{"title":"80P Oncolytic adenovirus type 3 coding for CD40L facilitates dendritic cell therapy of prostate cancer in humanized mice and patient samples","googleId":"19DhxMg0V-0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43080-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"624P Tolerability of olaparib (OLA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene …","googleId":"zzPR2aY7JBkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40879-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"326P Management of diffuse large B cell lymphomas in the COVID-19 era","googleId":"E9VfZ01HSiQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42811-X/abstract","googleCitationCount":0,"googleAuthor":"SH Tan","statusesArray":[]},{"title":"421P A multicenter, randomized, double-blind, placebo (PBO)-controlled, phase III trial of lenvatinib (LEN) in patients (pts) with radioiodine-refractory differentiated …","googleId":"ndVzLmbGBb4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42904-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"KRAS Mutant Epithelial Ovarian Carcinomas (EOC) Represent Distinct Genomic Genotypes","googleId":"TPe7g4Nxz98J","googleLink":"https://www.carislifesciences.com/wp-content/uploads/2020/09/ESMO-2020-POA-CMI-KRAS-Mutant-Epithelial-Ovarian-Carcinomas-EOC-Represent-Distinct-Genomic-Genotypes.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"34P N-glycosylation status of membrane phosphate transporter NaPi2b is crucial for its epitope recognition by monoclonal antibody in tumour cells","googleId":"q2eHq4sfwc4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42258-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1334P Real word experience with first-line immunotherapy in advanced non-small cell lung cancer patients in a Danish nationwide cohort","googleId":"Ceb1P7-8TtsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41644-8/abstract","googleCitationCount":0,"googleAuthor":"M Poehl","statusesArray":[]},{"title":"Characteristics of patients with HER2-negative advanced/metastatic gBRCA-associated breast cancer who achieved durable response in the phase III BROCADE3 …","googleId":"XI9i0XW2UIoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40423-5/abstract","googleCitationCount":0,"googleAuthor":"H Wildiers","statusesArray":[]},{"title":"1234TiP SYMptom monitoring with patient-reported outcomes using a web application among lung cancer patients in the Netherlands (SYMPRO-Lung)","googleId":"dmMowJuHHXYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41432-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1031P Tilsotolimod engages the TLR9 pathway to promote antigen presentation and type I IFN signaling in solid tumours","googleId":"BCVoprL6RYAJ","googleLink":"https://www.researchgate.net/profile/Erkut_Borazanci/publication/345365523_1031P_Tilsotolimod_engages_the_TLR9_pathway_to_promote_antigen_presentation_and_type_I_IFN_signaling_in_solid_tumours/links/5fb28f4ca6fdcc9ae058f124/1031P-Tilsotolimod-engages-the-TLR9-pathway-to-promote-antigen-presentation-and-type-I-IFN-signaling-in-solid-tumours.pdf","googleCitationCount":0,"googleAuthor":"H Babiker","statusesArray":[]},{"title":"632P Health-related quality of life (HRQoL) at final analysis of the SPARTAN study of apalutamide (APA) vs placebo (PBO) in patients (pts) with non-metastatic …","googleId":"uGgBRV408yEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40887-7/abstract","googleCitationCount":0,"googleAuthor":"BA Hadaschik","statusesArray":[]},{"title":"Ribociclib (RIB) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) and resistance to prior endocrine therapy (ET) in the MONALEESA (ML)-3 and-7 …","googleId":"6OtYl_8Y11EJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40427-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"768P Prognostic score combining systemic inflammation index (SII) and PD-L1+/-LDH in advanced urinary tract carcinoma patients treated with atezolizumab …","googleId":"qdXHqNCd9f8J","googleLink":"https://www.researchgate.net/profile/Sara_Rebuzzi/publication/344477232_Prognostic_score_combining_systemic_in_fl_ammation_index_SII_and_PD-L1_-_LDH_in_advanced_urinary_tract_carcinoma_patients_treated_with_atezolizumab_Subanalysis_in_the_Italian_population_of_the_SAUL_st/links/5f7b30bb299bf1b53e0e5b7b/Prognostic-score-combining-systemic-in-fl-ammation-index-SII-and-PD-L1-LDH-in-advanced-urinary-tract-carcinoma-patients-treated-with-atezolizumab-Subanalysis-in-the-Italian-population-of-the-SAUL.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT)+ paclitaxel (PAC) for inoperable locally …","googleId":"q4S9_BJq_IIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36319-5/abstract","googleCitationCount":0,"googleAuthor":"R Dent","statusesArray":[]},{"title":"1446P Initial safety and efficacy findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer","googleId":"euCbsmOfjrYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41948-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"ESMO localised colon cancer guidelines:'can we improve on our surveillance protocols?'","googleId":"EtRRlDGBE_QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42463-9/abstract","googleCitationCount":0,"googleAuthor":"D Yip","statusesArray":[]},{"title":"Comparative effectiveness of ribociclib plus fulvestrant (RIB+ FUL) versus palbociclib plus letrozole (PAL+ LET) as first-line (1L) treatment (Tx) of HR+/HER2 …","googleId":"LO9X6ViDxLgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40428-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1629MO First-line chemotherapy (CT) in advanced well-differentiated/dedifferentiated liposarcoma (WD/DD LPS): An EORTC Soft Tissue and Bone Sarcoma Group …","googleId":"hwCD3Q3JtxwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41851-4/abstract","googleCitationCount":0,"googleAuthor":"W Van der Graaf","statusesArray":[]},{"title":"1314P Blood-based proteomic biomarkers for predicting response to immunotherapy in non-small cell lung cancer","googleId":"FGUdnfy181IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41624-2/abstract","googleCitationCount":0,"googleAuthor":"Y Shaked","statusesArray":[]},{"title":"40P Correlation of IL-1-β-serum concentration with the number of leukocytes in peripheral blood in patients with solid tumours before immune checkpoint inhibitors …","googleId":"l1U5RZlqPfkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42264-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1502TiP Paclitaxel+ ramucirumab versus paclitaxel alone in patients with squamous-cell carcinoma of the esophagus, refractory or intolerant to combination therapy …","googleId":"8Ho1Wry78ikJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42090-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"368P Real-world characteristics, treatment, and outcomes of stage III non-small cell lung cancer in Japan: SOLUTION study","googleId":"rq0p-WolwGYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42852-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"408P Integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutation","googleId":"LtU62tns4v4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42893-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1022MO Clinical potential of adoptive cell therapy with tumour infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma …","googleId":"D7ISbk2SSIQJ","googleLink":"https://www.researchgate.net/profile/Christina_Yap/publication/345371745_1024MO_A_phase_III_MATINS_trial_Part_1_pharmacokinetic_safety_and_efficacy_results_of_Clever-1_blockade_in_advanced_cancer/links/5fb661be299bf104cf5b0d4a/1024MO-A-phase-I-II-MATINS-trial-Part-1-pharmacokinetic-safety-and-efficacy-results-of-Clever-1-blockade-in-advanced-cancer.pdf","googleCitationCount":0,"googleAuthor":"C Chamberlain","statusesArray":[]},{"title":"1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations","googleId":"sWRCZYKkHooJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41575-3/abstract","googleCitationCount":0,"googleAuthor":"F Cappuzzo","statusesArray":[]},{"title":"962P Immunotherapeutic implications of mucin 1/16 expression in head and neck squamous cell carcinoma (HNSCC)","googleId":"wiUrSM34xMMJ","googleLink":"https://www.researchgate.net/profile/Theodoros_Rampias/publication/345365292_962P_Immunotherapeutic_implications_of_mucin_116_expression_in_head_and_neck_squamous_cell_carcinoma_HNSCC/links/5fc760f792851c00f8452ff9/962P-Immunotherapeutic-implications-of-mucin-1-16-expression-in-head-and-neck-squamous-cell-carcinoma-HNSCC.pdf","googleCitationCount":0,"googleAuthor":"T Rampias","statusesArray":[]},{"title":"Neoadjuvant and adjuvant chemotherapy (NACT/ACT) treatment (tx) patterns in a real-world cohort of US pts with early triple-negative breast cancer (eTNBC)","googleId":"j7uhVsIvmIEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40314-X/fulltext","googleCitationCount":0,"googleAuthor":"LA Emens","statusesArray":[]},{"title":"332MO Comparison of NEPA-based versus olanzapine/aprepitant-based antiemetic regimen for Chinese breast cancer patients undergoing highly emetogenic …","googleId":"IWBBbMUq4VYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42817-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"57P Benefit of CDK4/6 inhibitors beyond PIK3CA mutations in metastatic breast cancer patients","googleId":"NId7jUKn370J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36270-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"600TiP A first-in-human study of, NUC-7738, a 3'-dA phosphoramidate, in patients with advanced solid tumours (NuTide: 701)","googleId":"nA-_pr9irLkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40710-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Tumour-only sequencing led to inflated tumour mutational burden estimation especially in under-represented ethnic groups","googleId":"kQJQrOmkKSEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40201-7/abstract","googleCitationCount":0,"googleAuthor":"M Borad","statusesArray":[]},{"title":"P-68 Safety and tolerability of a novel combination regimen OXIRI and its immunomodulatory effect in Asian pancreatic ductal adenocarcinoma patients","googleId":"Q04UhRvMZ_4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39449-7/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"183O Use of physical activity (PA) and supportive care (SC) among patients (pts) with early breast cancer (BC) reporting cancer-related fatigue (CRF)","googleId":"6YUuf2nNegUJ","googleLink":"https://www.researchgate.net/profile/Agnes_Dumas/publication/341614152_183O_Use_of_physical_activity_PA_and_supportive_care_SC_among_patients_pts_with_early_breast_cancer_BC_reporting_cancer-related_fatigue_CRF/links/5ee90afe299bf1faac5c6475/183O-Use-of-physical-activity-PA-and-supportive-care-SC-among-patients-pts-with-early-breast-cancer-BC-reporting-cancer-related-fatigue-CRF.pdf","googleCitationCount":0,"googleAuthor":"A Di Meglio","statusesArray":[]},{"title":"Extent of lymph node (LN) resection and tumour sidedness in operable colon cancer (CC) stage and survival","googleId":"UUFGEs8hzr8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40517-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"SO-14 Baseline diffusion-weighted magnetic resonance imaging features to predict recurrence of anal squamous cell carcinoma following chemoradiotherapy","googleId":"F2Api7XwiaAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39328-5/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Re: Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer","googleId":"ci5sXSkiNLgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39826-4/pdf","googleCitationCount":0,"googleAuthor":"BA Mahal","statusesArray":[]},{"title":"Glucocorticoids mediate adverse events of deep androgen receptor axis inhibition in prostate cancer patients","googleId":"eYZp0tINUlIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35935-4/abstract","googleCitationCount":1,"googleAuthor":"N Mitsiades","statusesArray":[]},{"title":"SO-22 Atypical non-V600E BRAF (aBRAF) mutations as a prognostic and predictive factor in real-life metastatic colorectal cancer patients from the Nordic …","googleId":"-5VC2ks_IukJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39336-4/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"85MO Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC …","googleId":"KuDCq-vB7oQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42596-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Differences in the mutational profile between primary breast carcinomas and their cutaneous metastasis","googleId":"kmfrJYLl7NoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40396-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"629P Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with …","googleId":"LNhqxcYtd8kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40884-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"25P Improving efficacy and reducing toxicity of anti-PD-L1 treatment: T-cells as delivery vehicles for anti-PD-L1 blocking nanobodies","googleId":"-duBrPZ1Jk8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43024-8/abstract","googleCitationCount":0,"googleAuthor":"BJ van den Eynde","statusesArray":[]},{"title":"KEYNOTE-966 trial in progress: Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer","googleId":"kfkxiRR8xOkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40052-3/abstract","googleCitationCount":0,"googleAuthor":"J Edeline","statusesArray":[]},{"title":"1808TiP Atezolizumab (ATZ) in combination with carboplatin (Cb) and etoposide (Eto) in the treatment of patients with previously untreated extensive-stage small cell …","googleId":"_-BN5JNlZywJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41565-0/abstract","googleCitationCount":0,"googleAuthor":"MC Garassino","statusesArray":[]},{"title":"411P Impact of pre-treatment AXL expression on osimertinib efficacy in patients with non-small cell lung cancer with EGFR mutation","googleId":"Dl2UyACFk9AJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42896-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1499TiP FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for taxane-pretreated patients with advanced or metastatic adenocarcinoma of the stomach or …","googleId":"r8Cf2j6mmB4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42001-0/abstract","googleCitationCount":0,"googleAuthor":"SE Al-Batran","statusesArray":[]},{"title":"Link between PODXL and the EGFR axis in metastatic colorectal cancer and in vitro: Implications for improved treatment stratification","googleId":"eZ0__5i1z4QJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40592-7/abstract","googleCitationCount":0,"googleAuthor":"B Nodin","statusesArray":[]},{"title":"79P Statins and immunotherapy: Togetherness makes strength-the potential effect of statins on immunotherapy for NSCLC","googleId":"G_MhmxjkWA4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43079-0/abstract","googleCitationCount":0,"googleAuthor":"M Filetti","statusesArray":[]},{"title":"Avelumab (anti-PD-L1) in patients with platinum-refractory/ineligible recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) …","googleId":"lHRuG7Z_RAUJ","googleLink":"https://medical.emdserono.com/content/dam/web/health-care/biopharma/web/USMI/congress-presentations/Poster-2-Avelumab-anti-PD-L1-in-patients-Guigay_ESMO-2020_poster_Ph1b-cohort-avelumab-in-platinum-refreactory-RM-SCCHN.pdf","googleCitationCount":0,"googleAuthor":"J Guigay","statusesArray":[]},{"title":"731P The impact of proton pump inhibitors on pazopanib exposure","googleId":"AR5jKe3kEIMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40799-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"2MO Abemaciclib in high risk early breast cancer","googleId":"9Qc8zFj03YsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42514-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"P-297 Outcomes of combined modality treatment neoadjuvant chemo-radiotherapy and surgery in resectable esophageal carcinoma patients treated at a …","googleId":"lpQ_mpXVfFEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39678-2/pdf","googleCitationCount":0,"googleAuthor":"R Singh","statusesArray":[]},{"title":"P-23 Microwave ablation versus radiofrequency ablation in BCLC-A hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials","googleId":"wqWw7hpcfZwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39404-7/pdf","googleCitationCount":0,"googleAuthor":"S Tavolari","statusesArray":[]},{"title":"International phase III trial: Balixafortide (a CXCR4 antagonist)+ eribulin versus eribulin alone in patients with HER2-negative, locally recurrent or metastatic breast …","googleId":"It7ob5rrO54J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40457-0/abstract","googleCitationCount":0,"googleAuthor":"M Martin","statusesArray":[]},{"title":"151P The landscape of patients with metastatic breast cancer enrolled in phase I trials","googleId":"vxVH7AGpSaIJ","googleLink":"https://www.researchgate.net/profile/Antonio_Marra2/publication/341613843_151P_The_landscape_of_patients_with_metastatic_breast_cancer_enrolled_in_phase_I_trials/links/5ece73cb299bf1c67d209ffd/151P-The-landscape-of-patients-with-metastatic-breast-cancer-enrolled-in-phase-I-trials.pdf","googleCitationCount":0,"googleAuthor":"G Viale","statusesArray":[]},{"title":"1737P National approaches to managing cancer care: Responses of countries in the MENA region to COVID-19 pandemic","googleId":"2QfX3k4aMOsJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506337/","googleCitationCount":0,"googleAuthor":"B Al Bahrani","doi":"10.1016/j.annonc.2020.08.1801","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"Ribociclib (RIB)+ letrozole (LET) in subgroups of special clinical interest with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative …","googleId":"lalWXWuodbQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40431-4/abstract","googleCitationCount":0,"googleAuthor":"PH Cottu","statusesArray":[]},{"title":"Efficacy, safety and pharmacokinetics of a proposed trastuzumab biosimilar HLX02 compared with trastuzumab in metastatic breast cancer: A global phase III study","googleId":"3P1Mk6EzYigJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40385-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"867P Patterns of recurrence after minimally invasive and open abdominal radical hysterectomy for cervical cancer: A propensity-matched analysis","googleId":"JRPwmjf7anYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41002-6/abstract","googleCitationCount":0,"googleAuthor":"C Pinelli","statusesArray":[]},{"title":"1659P AI-based grading approach identifies FNCLCC grade 3 soft tissue sarcomas","googleId":"7U1n3VgxSs4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41881-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"919MO ACCURACY a phase II trial of AL101, a selective gamma secretase inhibitor, in subjects with recurrent/metastatic (R/M) adenoid cystic carcinoma (ACC) …","googleId":"yhkiu_Z66jUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41030-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"616MO Efficacy of BN-brachyury (BNVax)+ bintrafusp alfa (BA)+ N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick …","googleId":"XntbfDF7RlsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40871-3/abstract","googleCitationCount":0,"googleAuthor":"RA Madan","statusesArray":[]},{"title":"595P Abdominal events in targeted therapies: Report from the Drug Rediscovery Protocol (DRUP)","googleId":"_3vIFvdm0B0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40705-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"891MO Role of baseline PET SUVmax in predicting early progression in follicular lymphoma (FL): A single-center retrospective analysis","googleId":"BbjJW8az3DQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40005-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"SO-28 A randomized phase II trial of mFOLFOX6-based standard of care alone or in combination with Ad-CEA vaccine plus avelumab in patients with …","googleId":"wGLNW3AReggJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39342-X/pdf","googleCitationCount":0,"googleAuthor":"M Gatti-Mays","statusesArray":[]},{"title":"8P Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)","googleId":"1AIeU3lsBvEJ","googleLink":"https://www.researchgate.net/profile/Nuria_Chic/publication/341613409_8P_Characterization_of_immune_microenvironment_before_and_following_anti-HER2_neoadjuvant_therapy_NAT/links/5fbd8269458515b79769eb67/8P-Characterization-of-immune-microenvironment-before-and-following-anti-HER2-neoadjuvant-therapy-NAT.pdf","googleCitationCount":0,"googleAuthor":"T Pascual","statusesArray":[]},{"title":"15P The CelTIL score as an early predictor of anti-tumour response following neoadjuvant therapy (NAT): A SOLTI biomarker analysis","googleId":"mvUlX42G8hIJ","googleLink":"https://www.researchgate.net/profile/Bernardo_Rapoport/publication/341612171_17P_Dysregulation_of_immune_checkpoint_proteins_in_newly_diagnosed_early_breast_cancer_patients/links/5f16e92c299bf1720d56b388/17P-Dysregulation-of-immune-checkpoint-proteins-in-newly-diagnosed-early-breast-cancer-patients.pdf","googleCitationCount":0,"googleAuthor":"P Nuciforo","statusesArray":[]},{"title":"1277P An exosomal miRNA signature as predictor of benefit from immune checkpoint inhibitors in non-small cell lung cancer","googleId":"bBPJjMvEuBEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41587-X/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"1418TiP Randomized, placebo-controlled phase III study of 1L pembrolizumab (Pembro) plus carboplatin/taxane followed by pembro with or without maintenance …","googleId":"Q8v014QVrzoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41728-4/abstract","googleCitationCount":0,"googleAuthor":"TK Owonikoko","statusesArray":[]},{"title":"1051P Clinical experience of tabelecleucel in patients with EBV+ primary (PID) or acquired immunodeficiency (AID) associated lymphoproliferative disease","googleId":"WKlelH_mexkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41167-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"420TiP UpSwinG: Real-world study of TKI activity in patients with EGFR mutation-positive (EGFRm+) NSCLC with uncommon mutations, and sequencing of afatinib …","googleId":"e2eD6AWL5-wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42957-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Evaluation of the circulating stromal biomarker VICM reflecting M1-like macrophage activity in metastatic melanoma patients treated with anti-PD-1 therapy","googleId":"7wWBWJyCBXsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40217-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study","googleId":"y3NpIg4SetAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40372-2/abstract","googleCitationCount":0,"googleAuthor":"H Wildiers","statusesArray":[]},{"title":"1326P Liver metastasis but not bone metastasis impact overall survival of advanced non-small cell lung cancer (NSCLC) treated by nivolumab (GFPC 04-2016)","googleId":"a-4iqmKGfPgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41636-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"977TiP Role of microbiome as a biomarker in locoregionally-advanced oropharyngeal squamous cell carcinoma 2 (ROMA LA-OPSCC2)","googleId":"4r6_1FQdokYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41088-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"689TiP NRG Oncology's GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy …","googleId":"lOLniu590ZoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42080-0/abstract","googleCitationCount":0,"googleAuthor":"Z Zumsteg","statusesArray":[]},{"title":"Pancreatic cancer transcriptomes: molecular stratification in the adjuvant setting","googleId":"gXQRCXQh0NYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43167-9/abstract","googleCitationCount":0,"googleAuthor":"FX Real","statusesArray":[]},{"title":"182TiP Effectiveness of niraparib plus aromatase inhibitors (AI) for germinal BRCA1/2-mutated (gBRCAm) or homologous recombination deficient (HRD) …","googleId":"9cNXzJYfGxkJ","googleLink":"https://www.researchgate.net/profile/Jose_Enrique_Ales-Martinez/publication/341614532_182TiP_Effectiveness_of_niraparib_plus_aromatase_inhibitors_AI_for_germinal_BRCA12-mutated_gBRCAm_or_homologous_recombination_deficient_HRD_hormone_receptor_HRhuman_epidermal_growth_factor_receptor_2_/links/5ee0861f92851cf1386f55f4/182TiP-Effectiveness-of-niraparib-plus-aromatase-inhibitors-AI-for-germinal-BRCA1-2-mutated-gBRCAm-or-homologous-recombination-deficient-HRD-hormone-receptor-HR-human-epidermal-growth-factor-recepto.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"257O Intercontinental cooperative non-Hodgkin T-cell lymphoma prospective registry study in Asia: ICT study","googleId":"yYJzs1UZWmUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42742-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"605TiP Targeting anti-cancer drug resistance in gastro-intestinal cancer: Inhibition of the SRPK1 kinase and degradation of the ABCG2 drug efflux pump","googleId":"GEW7nq6JxMIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40715-X/abstract","googleCitationCount":0,"googleAuthor":"M Ladekarl","statusesArray":[]},{"title":"SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative …","googleId":"l7LywhexuOgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40455-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"78P Novel allogeneic cell immunotherapy for advanced cancers","googleId":"raXRcyW9ntoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42589-X/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"CN31 Oncology nurses' experience in German and French-speaking Switzerland during the COVID-19 pandemic","googleId":"7Bi70nWwNmgJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506352/","googleCitationCount":0,"googleAuthor":"M Eicher","doi":"10.1016/j.annonc.2020.08.2139","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"45O Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2","googleId":"oKcimUHDlKQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42556-6/abstract","googleCitationCount":0,"googleAuthor":"J Sohn","statusesArray":[]},{"title":"Patterns of care and outcomes in carcinoma of unknown primary: A SEER-Medicare study","googleId":"y1QdKoJKddQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40625-8/fulltext","googleCitationCount":0,"googleAuthor":"L Mileshkin","statusesArray":[]},{"title":"Patient-derived organoids as a tool for modelling localized colorectal cancer","googleId":"Zew1dqac84sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40595-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"849P Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer","googleId":"-H9r5iPmMWYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40984-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"159P The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts)","googleId":"SEz7gxW-EaQJ","googleLink":"https://www.researchgate.net/profile/Daniel_Eiger/publication/341612961_159P_The_clinical_landscape_of_central_nervous_system_CNS_involvement_in_metastatic_triple-negative_breast_cancer_TNBC_patients_pts/links/5efba7d492851c52d60c7e38/159P-The-clinical-landscape-of-central-nervous-system-CNS-involvement-in-metastatic-triple-negative-breast-cancer-TNBC-patients-pts.pdf","googleCitationCount":0,"googleAuthor":"D Eiger","statusesArray":[]},{"title":"Results of the phase Ib dose escalation study of MEN1611, a PI3K inhibitor, combined with trastuzumab (T)±fulvestrant (F) for HER2+/PIK3CA mutant (mut) advanced …","googleId":"cxbCk_4j74wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40445-4/abstract","googleCitationCount":0,"googleAuthor":"F Duhoux","statusesArray":[]},{"title":"9P The histopathologic profile of pregnancy associated breast cancer; a particularly aggressive breast cancer subtype. Analysis of the Dutch National Registry","googleId":"mUhO6gYg02oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36224-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"P-79 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing …","googleId":"Ygx7elhrs2IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39460-6/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"21P OX401, a new generation of PARP-interfering drug for cancer treatment","googleId":"Wbx7z0i_WYgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)35973-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"922P EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas","googleId":"m0nyaLOfiF8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41033-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"979TiP POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients with performance status 2 with recurrent or metastatic squamous …","googleId":"diq46FoXv3sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41090-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"68P Deciphering the interplay between nuclear RNA export factors and long non-coding RNAs in breast cancer metabolism","googleId":"Y0FRBgudCc8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36281-5/abstract","googleCitationCount":0,"googleAuthor":"B Gottschalk","statusesArray":[]},{"title":"Efficacy of the triple combination of Estrogen Receptor, CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer","googleId":"nsNYDeg1LwkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40152-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Acceptance of SARS-CoV-2 vaccination among French patients with cancer: a cross-sectional survey","googleId":"Zg3a6JRdl2oJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(21)00094-6/abstract","googleCitationCount":0,"googleAuthor":"J Gal","statusesArray":[]},{"title":"370P Bespoke circulating tumour DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients","googleId":"xG54sf9vHw0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43122-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1700P Perception and attitudes of Italian physicians towards the management of checkpoint inhibitors in oncology during COVID-19 outbreak: Results from a …","googleId":"IeuQvdHM3jQJ","googleLink":"https://www.researchgate.net/profile/Marco_Tagliamento/publication/345365405_1700P_Perception_and_attitudes_of_Italian_physicians_towards_the_management_of_checkpoint_inhibitors_in_oncology_during_COVID-19_outbreak_Results_from_a_national_survey/links/5fc6aa70a6fdcc697bd32d41/1700P-Perception-and-attitudes-of-Italian-physicians-towards-the-management-of-checkpoint-inhibitors-in-oncology-during-COVID-19-outbreak-Results-from-a-national-survey.pdf","googleCitationCount":0,"googleAuthor":"M Tagliamento","statusesArray":[]},{"title":"Comprehensive profiling of MDM2 amplified gastrointestinal (GI) cancers","googleId":"lITtZV4r9SQJ","googleLink":"https://www.carislifesciences.com/wp-content/uploads/2020/09/ESMO-2020-POA-CMI-2020-Comprehensive-profiling-of-MDM2-amplified-gastrointestinal-GI-cancers.pdf","googleCitationCount":0,"googleAuthor":"F Battaglin","statusesArray":[]},{"title":"A single arm, prospective, open-label study of injected temozolomide plus hypofractionated radiation therapy for metastatic brain tumours","googleId":"Q3BEprFcY6gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40500-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Reply to the letter to the editor 'Neutropenia in metastatic colorectal cancer receiving trifluridine/tipiracil'by Colloca et al.","googleId":"vonFSWmXml4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39311-X/abstract","googleCitationCount":0,"googleAuthor":"HJ Lenz","statusesArray":[]},{"title":"189P Recommendation for “a start to move” program: A 8-week program of incremental physical activity in sedentary breast cancer survivors","googleId":"ItSB2RyAybMJ","googleLink":"https://www.researchgate.net/profile/Davide_Radice2/publication/341614469_189P_Recommendation_for_a_start_to_move_program_A_8-week_program_of_incremental_physical_activity_in_sedentary_breast_cancer_survivors/links/5fcf9e99299bf188d403d856/189P-Recommendation-for-a-start-to-move-program-A-8-week-program-of-incremental-physical-activity-in-sedentary-breast-cancer-survivors.pdf","googleCitationCount":0,"googleAuthor":"K Mazzocco","statusesArray":[]},{"title":"Evaluation of the cardioprotective effects of l-carnitine and silymarin in cancer patients receiving anthracycline-containing chemotherapy","googleId":"-VedjyA70W0J","googleLink":"https://www.researchgate.net/profile/Hosny_Elewa2/publication/345368682_292P_Evaluation_of_the_cardioprotective_effects_of_l-carnitine_and_silymarin_in_cancer_patients_receiving_anthracycline-containing_chemotherapy/links/600009ae45851553a041948e/292P-Evaluation-of-the-cardioprotective-effects-of-l-carnitine-and-silymarin-in-cancer-patients-receiving-anthracycline-containing-chemotherapy.pdf","googleCitationCount":0,"googleAuthor":"M Abdel-Latif","statusesArray":[]},{"title":"1411TiP GFPC 06-2018: A multicenter non-randomized phase II study evaluating platinum-pemetrexed-atezolizumab (+/-bevacizumab) for patients with stage IIIB/IV …","googleId":"JtxLCeEG8KAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41721-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Association between the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and efficacy of CDK 4/6 inhibitors in advanced breast cancer: The observational …","googleId":"bTflr3oFLHgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40398-9/abstract","googleCitationCount":0,"googleAuthor":"C Fabbroni","statusesArray":[]},{"title":"Deep eutectic solvent mixture formed from 2-deoxy-D-glucose and metformin targets cancer cell metabolism and induces apoptosis in breast cancer cell line …","googleId":"g90094QKYNwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40168-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2− advanced breast cancer (ABC) in MONALEESA (ML)-3 and-7","googleId":"FYIJusbXIskJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40429-6/abstract","googleCitationCount":0,"googleAuthor":"M De Laurentiis","statusesArray":[]},{"title":"1873P Cancer-related fatigue: Are we evaluating it?","googleId":"0NvwWvBIdm0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41516-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1668TiP A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus …","googleId":"jVc1l1MUSXQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41889-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"A phase II/III, randomized, placebo-controlled study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer","googleId":"DILWMv3vGroJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40053-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1275P Extended follow-up of DURVAST trial: A phase II study evaluating durvalumab treatment in HIV-1-infected patients with solid tumours by the Spanish lung …","googleId":"NMfteu_9lZAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41585-6/abstract","googleCitationCount":0,"googleAuthor":"T Moran","statusesArray":[]},{"title":"1154TiP A randomized, prospective, multicenter study to assess the impact of early detection of asymptomatic brain metastases (mets) vs standard follow-up on …","googleId":"lQVheTDLk3UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41273-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1108P Real world (RW) sequencing outcomes with immunotherapy and targeted therapy (TT) in BRAF+ metastatic melanoma (The NOBLE study series)","googleId":"ZvvSTzIfmUcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41227-X/abstract","googleCitationCount":0,"googleAuthor":"AB Warner","statusesArray":[]},{"title":"674P Evaluation of cognitive function (CogF) in trials testing new-generation hormonal treatments (NGHT) in patients with prostate cancer (PC): A systematic review","googleId":"Xh-tWvtK08gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40929-9/abstract","googleCitationCount":0,"googleAuthor":"L Marandino","statusesArray":[]},{"title":"69TiP A pilot study of combined biomarker-based treatment strategies in patients with recurrent/metastatic squamous cell carcinoma of the cervix: RAIDS molecular …","googleId":"wQ3ofR6TNXkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42294-X/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"SO-35 Tumor infiltrating CD3 lymphocytes and CD68 macrophages are associated with long-time survival in metastatic colorectal cancer patients treated with …","googleId":"ITs9SGrX-ZIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39349-2/pdf","googleCitationCount":0,"googleAuthor":"J Bruun","statusesArray":[]},{"title":"Preliminary report on survival outcomes of BRCA mutation carriers with triple-negative breast cancer","googleId":"cp4Ne0nwgTEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40058-4/fulltext","googleCitationCount":0,"googleAuthor":"AS Ferrigno","statusesArray":[]},{"title":"Synergistic activity of PARP inhibitor and ATR inhibitor in melanoma cell lines may depend on BRAF-V600 mutation status","googleId":"kbGaogl3pTgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40162-0/abstract","googleCitationCount":0,"googleAuthor":"V Belli","statusesArray":[]},{"title":"94P New marker of tumour-associated macrophages IL-35 is negatively associated with lymphatic metastasis in colorectal cancer","googleId":"opZSGRsWcRUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43095-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"2D-echocardiography strain vs. cardiac MRI strain using deep learning: A prospective cohort study in HER2-positive breast cancer patients undergoing trastuzumab …","googleId":"V4hv3bZuwAoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40328-X/abstract","googleCitationCount":0,"googleAuthor":"MD Levin","statusesArray":[]},{"title":"LBA5_PR Abemaciclib in high risk early breast cancer","googleId":"jpgN1S82ZVgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42320-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1940P CALIBRATION: Can early changes in circulating tumour DNA (ctDNA) predict durable tumour responses in patients (pts) with advanced esophageal …","googleId":"OeVHfw8qGiAJ","googleLink":"https://www.researchgate.net/profile/Richard_Baird/publication/345365482_1940P_CALIBRATION_Can_early_changes_in_circulating_tumour_DNA_ctDNA_predict_durable_tumour_responses_in_patients_pts_with_advanced_esophageal_adenocarcinoma_EAC_receiving_anti_PD-L1_antibody_durvaluma/links/5fab1961a6fdcc331b944746/1940P-CALIBRATION-Can-early-changes-in-circulating-tumour-DNA-ctDNA-predict-durable-tumour-responses-in-patients-pts-with-advanced-esophageal-adenocarcinoma-EAC-receiving-anti-PD-L1-antibody-durvaluma.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"432P Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled …","googleId":"Za-z0FbvozkJ","googleLink":"http://orca.cf.ac.uk/id/eprint/138299","googleCitationCount":0,"googleAuthor":"D Papamichael","doi":"10.1016/j.annonc.2020.08.543","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"78P Cancer immunotherapy: Rejuvenation of anti-cancer response by immune checkpoint blockade using novel multifunctional nanoparticle to block CTLA-4 and …","googleId":"R3fImZBBm8sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43078-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"818P Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in …","googleId":"iy24EdoPow4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40953-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1788P Persistent sex-differences in lung cancer mortality between 2001 and 2017 in the US and EU","googleId":"c8zCL38rCDwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41545-5/abstract","googleCitationCount":0,"googleAuthor":"C Jani","statusesArray":[]},{"title":"65P The new mouse anti-nNav1. 5 monoclonal antibody","googleId":"5r3rJtdhcF0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42576-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"641P Real-world patterns of genomic testing in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC)","googleId":"W0n8WShdNC8J","googleLink":"https://www.researchgate.net/profile/Alicia_Gayle/publication/345365810_641P_Real-world_patterns_of_genomic_testing_in_patients_Pts_with_metastatic_castration-resistant_prostate_cancer_mCRPC/links/5fca1ee845851568d13a9636/641P-Real-world-patterns-of-genomic-testing-in-patients-Pts-with-metastatic-castration-resistant-prostate-cancer-mCRPC.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1111P Suboptimal real-world (RW) outcomes for BRAF+ metastatic melanoma (MM) patients in 2L therapy (The NOBLE study series)","googleId":"LNgxfI0Y8b8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41230-X/abstract","googleCitationCount":0,"googleAuthor":"AB Warner","statusesArray":[]},{"title":"1996P Clinical significance of ephrin receptor (EPH)-B1,-B2,-B4 and-B6 expression in thymic epithelial tumours","googleId":"Z0cL6-QxmNEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41298-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"50P Cardiosafe nano-formulation of doxorubicin allows coadministration with trastuzumab in neoadjuvant setting improving antitumor efficacy and preventing …","googleId":"Iv6RsA80bkgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36263-3/abstract","googleCitationCount":0,"googleAuthor":"F Andreata","statusesArray":[]},{"title":"134TiP A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2− primary breast cancer: CheckMate 7FL","googleId":"vXELBAX9USMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36315-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"P-76 A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE®) immune therapy, targeting MUC17 in patients with gastric and …","googleId":"UAIhXMkow6UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39457-6/pdf","googleCitationCount":0,"googleAuthor":"F Lordick","statusesArray":[]},{"title":"695TiP ORACULUM: A retrospective observational epidemiological study using artificial intelligence and natural language processing in electronic health records to …","googleId":"yEGB2AtTPjQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42086-1/abstract","googleCitationCount":0,"googleAuthor":"A Alcaraz","statusesArray":[]},{"title":"First in human study of ONO-4578, a PGE2-receptor EP4 antagonist, in monotherapy and combination with PD-1 checkpoint inhibitor nivolumab in patients with …","googleId":"2lK3mVxuwkoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40644-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Trends in breast cancer mortality between 2001 and 2017: An observational study in EU and UK","googleId":"c0QEQIztGZUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40413-2/abstract","googleCitationCount":0,"googleAuthor":"CT Jani","statusesArray":[]},{"title":"1192P Breast cancer induces a tolerogenic signalling pathway profile in CD4+ lymphocytes from a subset of primary breast cancer patients, characterized by …","googleId":"l73XXFseA4UJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40082-1/abstract","googleCitationCount":0,"googleAuthor":"Y Wesseling-Rozendaal","statusesArray":[]},{"title":"1624MO Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on …","googleId":"fKfER0znEnwJ","googleLink":"https://www.researchgate.net/profile/Antonio_Gutierrez13/publication/345368555_1624MO_Weekly_nab-paclitaxel_for_progressive_or_symptomatic_desmoid_tumors_A_multicenter_single_arm_phase_II_trial_from_the_Spanish_Group_for_Research_on_Sarcoma_GEIS/links/5fd7e3f7299bf140880f583a/1624MO-Weekly-nab-paclitaxel-for-progressive-or-symptomatic-desmoid-tumors-A-multicenter-single-arm-phase-II-trial-from-the-Spanish-Group-for-Research-on-Sarcoma-GEIS.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated …","googleId":"IzMJgZJSlU8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40543-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"569P Intratumoral injection of allogeneic pro-inflammatory dendritic cells (ilixadencel) in combination with anti-CTLA-4 treatment induce complete tumour responses …","googleId":"xf_yAC_bvXsJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40679-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"P-138 A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases","googleId":"N3a5kBY0iZMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39519-3/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1566TiP PRODIGE 65-UCGI 36-GEMPAX: A unicancer phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX …","googleId":"HqG6pp-HsgUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42045-9/abstract","googleCitationCount":0,"googleAuthor":"P Hammel","statusesArray":[]},{"title":"3MO IMpassion031: Results from a phase III study of neoadjuvant (neoadj) atezolizumab+ chemo in early triple-negative breast cancer (TNBC)","googleId":"2vsgJKA_IzIJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42515-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"716P Optimizing ipilimumab in metastatic renal cell carcinoma: SAKK 07/17 study","googleId":"cIUg1csm_nEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40784-7/abstract","googleCitationCount":0,"googleAuthor":"R Cathomas","statusesArray":[]},{"title":"Prognostic impact of progesterone receptor levels in luminal-like Her2-early breast cancer patients: A retrospective analysis","googleId":"4AXaT5Qp-nEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40291-1/abstract","googleCitationCount":0,"googleAuthor":"G Buono","statusesArray":[]},{"title":"Real-time PCR-based assessment of RAS/BRAF mutations in the plasma of metastatic colorectal cancer (mCRC) patients: A single institution experience","googleId":"fCSYzlh6C0oJ","googleLink":"https://www.researchgate.net/profile/Erika_Martinelli/publication/345371658_461P_Real-time_PCR-based_assessment_of_RASBRAF_mutations_in_the_plasma_of_metastatic_colorectal_cancer_mCRC_patients_A_single_institution_experience/links/5fef1a8e299bf140886131dc/461P-Real-time-PCR-based-assessment-of-RAS-BRAF-mutations-in-the-plasma-of-metastatic-colorectal-cancer-mCRC-patients-A-single-institution-experience.pdf","googleCitationCount":0,"googleAuthor":"V De Falco","statusesArray":[]},{"title":"Effective tumour growth control by combined vaccine-immune-checkpoint inhibition in MLH1-/-mice","googleId":"beNsbAxiDH0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40157-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving …","googleId":"BP6ZeBBdea0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39415-1/pdf","googleCitationCount":0,"googleAuthor":"J Bennouna","statusesArray":[]},{"title":"LBA37 A blinded, randomized, parallel group, comparative investigation of a novel device (Cooral) for cryoprevention of oral mucositis","googleId":"MbQQJOkkJgMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42349-X/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1343P Correlating osimertinib and erlotinib pharmacokinetics with efficacy and toxicity in EGFR-mutated NSCLC patients (START-TKI study)","googleId":"R6cVkkq1uGcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41653-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"99P Association of gut microbiome diversity and composition with pathological complete response (pCR) after neoadjuvant chemotherapy in triple negative …","googleId":"WKbdclTXmfUJ","googleLink":"https://www.researchgate.net/profile/Grazia_Vernaci/publication/341614235_99P_Association_of_gut_microbiome_diversity_and_composition_with_pathological_complete_response_pCR_after_neoadjuvant_chemotherapy_in_triple_negative_breast_cancer/links/5f204cb845851515ef505e08/99P-Association-of-gut-microbiome-diversity-and-composition-with-pathological-complete-response-pCR-after-neoadjuvant-chemotherapy-in-triple-negative-breast-cancer.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Personalized circulating tumour DNA assay for the detection of minimal residual disease in CRC patients after resection of metastases","googleId":"-0tGodTqnh8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40512-5/abstract","googleCitationCount":0,"googleAuthor":"F Loupakis","statusesArray":[]},{"title":"P-156 A phase Ib/II study of cetuximab and pembrolizumab in metastatic colorectal cancer","googleId":"ANgDI_euILYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39537-5/pdf","googleCitationCount":0,"googleAuthor":"S Mukherjee","statusesArray":[]},{"title":"635P ARCHES-The role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer …","googleId":"fSuikwa7GbwJ","googleLink":"https://www.researchgate.net/profile/Arun_Azad/publication/345368099_635P_ARCHES_-_The_role_of_androgen_deprivation_therapy_ADT_with_enzalutamide_ENZA_or_placebo_PBO_in_metastatic_hormone-sensitive_prostate_cancer_mHSPC_Post_hoc_analyses_of_efficacy_by_baseline_prostat/links/5fb25d2a92851cf24cd5b7d9/635P-ARCHES-The-role-of-androgen-deprivation-therapy-ADT-with-enzalutamide-ENZA-or-placebo-PBO-in-metastatic-hormone-sensitive-prostate-cancer-mHSPC-Post-hoc-analyses-of-efficacy-by-baseline-prostat.pdf","googleCitationCount":0,"googleAuthor":"A Alcaraz","statusesArray":[]},{"title":"863P A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in pts with selected FRα-positive solid tumours: Results in the endometrial cancer (EC …","googleId":"tQdDyPXgpaAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40998-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"267O Distinct phenotypes of locoregionally advanced (LA-NPC) harbor disparate survival outcomes and are associated with germline variants","googleId":"18_2hFK67DEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42752-8/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"83P Impact of treatment duration of extended adjuvant therapy with neratinib in early stage HER2+ HR+ breast cancer after trastuzumab-based therapy on patient …","googleId":"Di_vaYdrl7sJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36102-0/abstract","googleCitationCount":0,"googleAuthor":"B Ejlertsen","statusesArray":[]},{"title":"163P Population-adjusted comparison of SOLAR-1 and BOLERO-2: PFS with second-line alpelisib+ fulvestrant vs everolimus+ exemestane in postmenopausal pts …","googleId":"SaKqLVPBwTUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36342-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"LBA55 WJOG@ Be study: A phase II study of atezolizumab (atez) with bevacizumab (bev) for non-squamous (sq) non-small cell lung cancer (NSCLC) with high PD-L1 …","googleId":"v95j2edYXgEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42370-1/abstract","googleCitationCount":2,"googleAuthor":"","statusesArray":[]},{"title":"P-230 Intensifying peri-operative chemotherapy with radiotherapy in resectable gastro-esophageal junction (GEJ) and stomach cancer patients: Initial results of …","googleId":"8_CgiYCsB1wJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39611-3/pdf","googleCitationCount":0,"googleAuthor":"S Singh","statusesArray":[]},{"title":"181TiP Xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor …","googleId":"2gEXdOrnnC8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36360-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"41P A window-of-opportunity study with atezolizumab and the oncolityc virus pelareorep in early breast cancer (REO-027, AWARE-1)","googleId":"zWguu-GPhxEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36254-2/abstract","googleCitationCount":0,"googleAuthor":"N Chic","statusesArray":[]},{"title":"880TiP Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after …","googleId":"DlH1b38qnk8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41015-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1140P A digital companion for patients with BRAF-mutant advanced melanoma treated with targeted therapies: TAVIE skin app","googleId":"MrT09PcSUiYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41259-1/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1491P Bespoke circulating tumor DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients","googleId":"G4O3xqHdroEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41993-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1984P Tumour infiltrating lymphocytes in early breast cancer: High levels of CD3, CD8 cells and Immunoscore® are associated with pathological CR and time to …","googleId":"-U0JSp-w9vQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41286-4/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"MGMT status influences prognosis of patients with IDH wild type grade III gliomas","googleId":"eUoSKaSMtCsJ","googleLink":"https://www.researchgate.net/profile/Lidia_Gatto/publication/345369039_378P_MGMT_status_influences_prognosis_of_patients_with_IDH_wild_type_grade_III_gliomas/links/5fad7f5ea6fdcc9389b0b10b/378P-MGMT-status-influences-prognosis-of-patients-with-IDH-wild-type-grade-III-gliomas.pdf","googleCitationCount":0,"googleAuthor":"E Franceschi","statusesArray":[]},{"title":"PLK1 expression and KRAS mutations in colorectal cancer","googleId":"cm1h3Kx4wQoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40580-0/abstract","googleCitationCount":0,"googleAuthor":"P Jayachandran","statusesArray":[]},{"title":"O-9 Discordant prognostic significance of negative lymph node size in patients with oesophageal cancer treated with either surgery or neoadjuvant …","googleId":"gLr6OzbK3T0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39361-3/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Metronomic oral vinorelbine (MOV) combined with tremelimumab (T)+ durvalumab (D): Efficacy and safety preliminary results of the advanced breast cancer (ABC) …","googleId":"UwS0fc2nJQEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40441-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"P-115 PEMREC: A phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized microsatellite stable rectal …","googleId":"CnjYQSA_7jMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39496-5/pdf","googleCitationCount":0,"googleAuthor":"N Buchs","statusesArray":[]},{"title":"PREDIX HER2 trial: Event-free survival and pathologic complete response in clinical subgroups and stromal TILs levels","googleId":"J21ZTkD14MgJ","googleLink":"https://www.diva-portal.org/smash/record.jsf?pid=diva2:1457795","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.03.037","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"A plasma biomarker panel of microRNAs for early breast cancer diagnosis","googleId":"CTXYuUrhevAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40295-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"P-47 A phase I/II study of pembrolizumab in combination with ibrutinib for advanced, refractory microsatellite stable colorectal cancers","googleId":"4eiXDMTVf_IJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39428-X/pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program","googleId":"orAh1OwTGswJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41698-9/abstract","googleCitationCount":0,"googleAuthor":"GL Russo","statusesArray":[]},{"title":"2O ERBB3 mRNA expression in breast cancer (BC): A SOLTI biomarker discovery analysis","googleId":"f1fkT_YJIxcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36217-7/abstract","googleCitationCount":0,"googleAuthor":"T Pascual","statusesArray":[]},{"title":"1259O A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan …","googleId":"2lmQOfjm9AQJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41569-8/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"P-144 Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations …","googleId":"tX02NPFJ4P8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39525-9/pdf","googleCitationCount":0,"googleAuthor":"I Borbath","statusesArray":[]},{"title":"570P A first-in-human phase I study of the AXL inhibitor DS-1205c in combination with gefitinib in subjects with EGFR-mutant NSCLC","googleId":"llJZB1aS0VkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40680-5/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Recent eUpdate on cabozantinib and nivolumab for first-line clear cell renal cancer to the ESMO Clinical Practice Guidelines on Renal Cell Carcinoma","googleId":"jION2lonnyoJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)43171-0/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"Delivery and activity of SN-38 by sacituzumab govitecan in CNS tumours","googleId":"fv2X9EEVxY4J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40478-8/abstract","googleCitationCount":1,"googleAuthor":"AJ Brenner","statusesArray":[]},{"title":"306P Detection of anaplastic lymphoma kinase (ALK) mutations using circulating tumour DNA (ctDNA) in advanced non-squamous non-small cell lung cancer (non …","googleId":"R89iFxY2ZBYJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42791-7/abstract","googleCitationCount":0,"googleAuthor":"KWC Lee","statusesArray":[]},{"title":"1417TiP Immunotherapy, chemotherapy and stereotactic radiotherapy to metastases, followed by definitive surgery or radiotherapy to the primary tumour, in patients …","googleId":"WWAU9Ohdh3YJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41727-2/abstract","googleCitationCount":0,"googleAuthor":"M Guckenberger","statusesArray":[]},{"title":"MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer","googleId":"iH-ujn5KXW8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42063-0/abstract","googleCitationCount":0,"googleAuthor":"A Cercek","statusesArray":[]},{"title":"P-26 RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction …","googleId":"cdnscjaJhGMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39407-2/pdf","googleCitationCount":0,"googleAuthor":"C Denlinger","statusesArray":[]},{"title":"NTRK1/2/3 fusions in secretory versus non-secretory breast cancers","googleId":"wniNfKlX3nEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40248-0/abstract","googleCitationCount":1,"googleAuthor":"","statusesArray":[]},{"title":"1672MO\" DOMONCOVID PROJECT\": A homecare model for cancer patients during COVID-19","googleId":"E5IVnrp6vUcJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506313/","googleCitationCount":0,"googleAuthor":"","doi":"10.1016/j.annonc.2020.08.1737","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"1932MO Ki67 expression and CDK4/6i activity: An emerging role for PIK3CA mutations in metastatic breast cancer patients","googleId":"4oZKxr7LzjkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41321-3/abstract","googleCitationCount":0,"googleAuthor":"M Del Re","statusesArray":[]},{"title":"36P Eligibility and outcomes in phase I clinical trials testing targeted therapy, immunotherapy and combinations: A single-institution study","googleId":"46vBaPpykeAJ","googleLink":"https://www.researchgate.net/profile/Antonio_Marra2/publication/339911259_36P_Eligibility_and_outcomes_in_phase_I_clinical_trials_testing_targeted_therapy_immunotherapy_and_combinations_A_single-institution_study/links/5e788d05a6fdcccd62192478/36P-Eligibility-and-outcomes-in-phase-I-clinical-trials-testing-targeted-therapy-immunotherapy-and-combinations-A-single-institution-study.pdf","googleCitationCount":0,"googleAuthor":"A Marra","statusesArray":[]},{"title":"128P Clinical update with plasma and tumour-based genomic analyses in expansion part of phase I study of selective FGFR inhibitor E7090","googleId":"9pP2dsbeavkJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42640-7/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"160P Phase II study of sintilimab combined with FLOT regimen for neoadjuvant treatment of gastric or gastroesophageal junction (GEJ) adenocarcinoma","googleId":"LFpTSDGF_v0J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42672-9/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1216P A circulating exosomal miRNA-based risk score as a predictive biomarker of relapse in early stage non-small cell lung cancer","googleId":"7jHHvitXXNEJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41414-0/abstract","googleCitationCount":0,"googleAuthor":"G Chiorino","statusesArray":[]},{"title":"67P Digital analysis of distant and cancer-associated adipocytes in breast cancer","googleId":"aWZZdSQuUm8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)36280-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1833P Role of grip strength & the short physical performance battery in prediction of chemotherapy related outcomes in older adults with cancer","googleId":"2Aj93QuR93kJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41476-0/abstract","googleCitationCount":0,"googleAuthor":"N Timilshina","statusesArray":[]},{"title":"1958P Reflex screening of somatic BRCA1/2 identifies pathogenic mutations in non-ovarian and breast cancers","googleId":"z0OqwOEhjWcJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41346-8/abstract","googleCitationCount":0,"googleAuthor":"A Grinshpun","statusesArray":[]},{"title":"49P Targeting IGF1R in osteosarcoma","googleId":"7UlWIgmdNcMJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42273-2/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"In vivo persistence of Iovance tumor-infiltrating lymphocytes LN-145 in cervical cancer patients","googleId":"mNvDDuJOf2kJ","googleLink":"https://www.iovance.com/wp-content/uploads/IovanceBio-ESMO_Poster_2_2020.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1344P The impact of TP53 mutations on EGFR mt+ NSCLC IV patients treated with 3rd generation TKI on second-line or further line therapy: Real world data from the …","googleId":"ysERYOygn2gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41654-0/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1117P Immunotherapy in octogenarian and nonagenarian metastatic melanoma patients","googleId":"aiVqPiamsFEJ","googleLink":"https://www.researchgate.net/profile/Bozena_Cybulska-Stopa/publication/345371853_1117P_Immunotherapy_in_octogenarian_and_nonagenarian_metastatic_melanoma_patients/links/5fbd3c7392851c933f570d50/1117P-Immunotherapy-in-octogenarian-and-nonagenarian-metastatic-melanoma-patients.pdf","googleCitationCount":0,"googleAuthor":"B Cybulska-Stopa","statusesArray":[]},{"title":"90P Patient-reported outcomes among patients with HR+/HER2-early breast cancer: A systematic literature review","googleId":"rpH21O2v0vEJ","googleLink":"https://www.researchgate.net/profile/Jenilee_Cueto/publication/341613465_90P_Patient-reported_outcomes_among_patients_with_HRHER2-_early_breast_cancer_A_systematic_literature_review/links/5fec914e299bf140885c9d60/90P-Patient-reported-outcomes-among-patients-with-HR-HER2-early-breast-cancer-A-systematic-literature-review.pdf","googleCitationCount":0,"googleAuthor":"EH Law","statusesArray":[]},{"title":"Clinical outcomes of platinum-based polichemotherapy in patients with advanced breast cancer: A 10-year single institutional experience","googleId":"b4sPqmU49iAJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40442-9/abstract","googleCitationCount":0,"googleAuthor":"MA Franzoi","statusesArray":[]},{"title":"837P Phase II trial of oncolytic vaccinia virus primed immunochemotherapy in platinum-resistant/refractory ovarian cancer (PRROC)(NCT02759588)","googleId":"bFAQCcaWWaYJ","googleLink":"https://www.researchgate.net/profile/Sarfraz_Ahmad11/publication/345369122_837P_Phase_II_trial_of_oncolytic_vaccinia_virus_primed_immunochemotherapy_in_platinum-resistantrefractory_ovarian_cancer_PRROC_NCT02759588/links/5fc7091445851568d13238d9/837P-Phase-II-trial-of-oncolytic-vaccinia-virus-primed-immunochemotherapy-in-platinum-resistant-refractory-ovarian-cancer-PRROC-NCT02759588.pdf","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"Are we ready to accept intermediate outcome measures in clinical cancer trials?","googleId":"6hIRP5ETlogJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)39838-0/abstract","googleCitationCount":0,"googleAuthor":"E Calvo","statusesArray":[]},{"title":"1423MO End-of-study analysis from JACOB: A phase III study of pertuzumab (P)+ trastuzumab (H) and chemotherapy (CT) in HER2-positive metastatic gastric or …","googleId":"Jxren7iL174J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41925-8/abstract","googleCitationCount":1,"googleAuthor":"PM Hoff","statusesArray":[]},{"title":"Minimal residual disease (MRD) detection in colorectal cancer (CRC) using a plasma-only integrated genomic and epigenomic circulating tumor DNA (ctDNA) …","googleId":"Pn8PfSW3H1gJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40526-5/fulltext","googleCitationCount":0,"googleAuthor":"A Parikh","statusesArray":[]},{"title":"1978MO Tumour-infiltrating macrophages, PD-L1 and tumour/stroma ratio as independent prognostic factors in a well-defined European cohort of patients with oral …","googleId":"gk6IioBTgA8J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41280-3/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"1072P Beyond classical surrogate endpoints in trials of PD1/PD-L1 immune checkpoint inhibitors (ICI) plus chemotherapy (CT)","googleId":"VY4cvIuQI50J","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)41188-3/abstract","googleCitationCount":0,"googleAuthor":"GV Javierre","statusesArray":[]},{"title":"562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex","googleId":"dIaojxTqDNUJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40672-6/abstract","googleCitationCount":0,"googleAuthor":"","statusesArray":[]},{"title":"802TiP Immune tumor microenvironment (TME) in correlation with peripheral blood immune biomarkers as prognostic factor in metastatic renal cell carcinoma (mRCC …","googleId":"9ggcbY6eWzwJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)42070-8/abstract","googleCitationCount":0,"googleAuthor":"S Buti","statusesArray":[]},{"title":"1698P The presence of COVID-19 makes more cancer patients distressed and time perception may distinguish them","googleId":"O3maXRdXtdwJ","googleLink":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7506454/","googleCitationCount":0,"googleAuthor":"NV Conev","doi":"10.1016/j.annonc.2020.08.1762","elsevierCitationCount":0,"altmetricAuthors":[],"twitterCount":0,"statusesArray":[]},{"title":"MicroRNAs related to immune response as markers in the prognosis of metastatic breast cancer","googleId":"WoFUv2Y-LNgJ","googleLink":"https://www.annalsofoncology.org/article/S0923-7534(20)40397-7/abstract","googleCitationCount":0,"googleAuthor":"S Agelaki","statusesArray":[]}]